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Introduction
Blood contains a variety of short-living cells that are fundamental to the human body. These 
cells travel through miles of blood vessels to sustain the correct functioning of our organs. 
They carry out a myriad of vital activities, including transport of oxygen and nutrients to 
all tissues, protection against harmful pathogenic conditions and prevention of blood 
loss by repairing damaged blood vessels1. This functional diversity is to be attributed to 
the presence of different, highly specialized cell types that are generally categorized in 
a myeloid and a lymphoid compartment. While cells belonging to the myeloid lineage are 
implicated in the innate immune system (granulocytes, monocytes and macrophages), 
oxygen supply (red cells or erythrocytes) and maintenance of hemostasis (megakaryocytes 
and platelets), the lymphoid compartment comprises the remaining fraction of cells that 
participate in the innate immune response (natural killer cells) and cells that are fundamental 
to the adaptive immune system (dendritic, B- and T- cells). All these different types of cell 
originate from a rare population of cells, denominated the hematopoietic stem cells (HSCs), 
during a sophisticated and highly regulated developmental process called hematopoiesis2. 
Hematopoiesis
Current models of hematopoiesis
Hematopoietic ontology has traditionally been described in a hierarchical fashion 
where HSCs sit at the bottom of a ‘’tree’’, with branches representing the different 
lineages of maturation that culminate in the production of all blood cell types (Figure 1). 
To be at the foundation of the hematopoietic system, HSCs are long-lived and possess 
multipotency properties that permit them to differentiate towards more committed 
progenitors and precursors that, subsequently, will generate all mature blood cells. 
Very importantly, HSCs possess a unique self-renewal capacity, which guarantees 
the maintenance of a pool of ancestors that support the continuous production of blood cells 
throughout an entire life3,4. According to the classical model, HSCs give rise to multipotent 
progenitors (MPPs) that further differentiate into common myeloid progenitors (CMPs) or 
common lymphoid progenitors (CLPs)5. Through a series of lineage-restricted transitions, 
CMPs and CLPs generate terminally differentiated cells that constitute the myeloid and 
the lymphoid compartments, respectively. Accordingly, the multipotential capacity to 
generate other lineages is progressively lost alongside a particular differentiation route, 
resulting in a distinct separation between myeloid and lymphoid lineages6. However, 
the discovery of early progenitors, such as EPLMs (early progenitors with lymphoid and 
myeloid potential)7 and LMPPs (lymphoid-primed multi potent progenitors)8,9, that showed an 
unexpected flexibility to differentiate towards diverse lineages, suggests that hematopoietic 
differentiation is not constrained to a strict linear subdivision in compartments. Rather, 
this supports an alternative ontological model characterized by increased plasticity in cell 
lineage determination of hematopoietic progenitors, where the development of a specific 
cell type can occur through different maturation paths.
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Figure 1. Classic ontological model of hematopoiesis. In the classic model of hematopoiesis, 
there is a strict segregation during the formation of the myeloid and lymphoid compartments. 
HSCs, which sit at the top of the organizational hierarchy, give rise to common myeloid progenitors 
(CMPs) and common lymphoid progenitors (CLPs). CLPs differentiate further into mature 
lymphocytes (natural killer (NK-), B-lymphocytes and T-lymphocytes), while CMPs generate 
the megakaryocyte/erythroid progenitors, which give rise to megakaryocytes and erythrocytes, 
and the granulocyte/monocyte progenitors (GMPs), which give rise to granulocytes 
(neutrophils, basophils and eosinophils), monocytes and macrophages. Dendritic cells can 
originate either from CLPs or monocytes, while plasma cells originate from B-lymphocytes. Cell 
types equipped with self-renewal capacity are indicated by the circular arrows.
Regulation of hematopoiesis
The anatomical location of hematopoiesis is subjected to various transitions during 
development. In embryos, initial sites of hematopoietic production can be found in 
the yolk sac, placenta, the aorta-gonad-mesonephros region and the umbilical and vitelline 
arteries10. HSCs derive from the development of hemangioblasts, which are multipotent 
precursor cells capable to generate both the hematopoietic and the endothelial tissues11. 
These cells originate the haemogenic endothelium that lines the aortic floor in the late stages 
of embryonic development. Following an endothelial to hematopoietic transition (EHT), 
hemogenic cells lose their endothelial identity to subsequently give rise to hematopoietic 
progenitors12,13. Mice studies have shown that newly formed HSCs can migrate to 
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extramedullary locations, such as liver and spleen, to ultimately reach the intramedullary 
spaces of bones14. Definitive adult hematopoiesis takes place in the bone marrow, a cavity 
with complex architecture that provides a supportive and protective microenvironment 
wherein HSCs are regulated15,16. The bone marrow is organized in different niches that 
containing a variety of cell types including osteoblasts, endothelial cells, adipocytes and 
stromal cells, which act in concert to control HSCs survival, proliferation, migration and 
differentiation. The fate of HSCs and hematopoietic precursors is determined by direct 
interactions with surrounding cells and the stimulation of molecules that are secreted within 
the niche microenvironment15–17. Binding of hematopoietic growth factors and cytokines 
to their membrane receptors initiates a chain of consequential intracellular events that 
control the expression of specific responsive genes. The intracellular amplification of these 
signals is propagated by fine-tuned transduction machineries consisting of proteins that, 
via post-translational protein modifications, induce or inhibit downstream targets. The final 
receivers of this signaling cascade are generally transcriptional regulators, in particular 
transcription factors, which form complex networks that coordinate the expression 
of hematopoietic genes18–20. During hematopoietic differentiation, genes regulating 
self-renewal of progenitor cells are repressed while sets of genes that govern 
the differentiation are activated. The balance between self-renewal and differentiation 
is crucial to control the expansion of the different hematopoietic lineages and maintain 
tissue haemostasis. The lineage specificity is determined by a coordinated expression of 
cell type-specific transcription factors, which promote the differentiation towards a distinct 
lineage meanwhile impeding the generation of others21. Although the expression of some 
transcription factors is restricted to a particular cell type, many of them have overlapping 
functions in regulating the destiny of multiple lineages, thereby contributing to the high 
intricacy of the hematopoietic transcriptional regulatory system19-22.
Outlook of this thesis
As it will be discussed in this thesis, transcriptional regulation is fundamental to 
the development of blood cells. The function and identity of blood cells are determined by 
the sets of genes expressed in each cell. Acquired and inherited changes in hematopoietic 
transcription factors and their up-stream regulators can cause hematological disorders 
ranging from bleeding disorders to leukemia. These alterations disrupt the genome-wide 
control over gene expression resulting in the generation of pathogenic transcriptional 
programs that compromise proper blood cell development and function. In addition, 
these altered expression patterns significantly influence the biological characteristics of 
the various diseases they generate and therefore their clinical outcome. Because aberrant 
gene expression contributes to the etiology of hematological diseases, their development 
and their clinical responses, a better understanding of transcriptional regulation is required 
for the development of successful therapies. 
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Megakaryopoiesis and platelet production
Megakaryocytes and platelets
The integrity of the blood circulatory system is essential for survival. This is maintained 
through a physiological response, denominated haemostasis, which prevents significant 
blood loss following vascular injury. This process depends on an intricate series of events 
that primarily relies on the action of platelets, which are anucleate discoid cells that also 
play important functions in angiogenesis and innate immunity23–25. Present in the blood 
stream in a quiescent state, platelets store multiple types of granules which contain a variety 
of molecules that mediate coagulation. Upon stimulation, platelets release their granule 
content and form a physical barrier at the site of injury that impedes excessive bleeding. 
Generation of platelets, defined as thrombopoiesis, is orchestrated by a rare population 
of highly specialized cells, called megakaryocytes (MKs), which are among the largest 
hematopoietic cells residing in the bone marrow26. According to the most recent model 
of platelet formation, fully mature MKs infiltrate long branching membrane protrusions, 
called pro-platelets, into sinusoidal blood vessels, wherein these eventually shed and 
release functional platelets in circulation27,28. Although being present at low frequency 
(only 1 in 10000 nucleated cells), MKs sustain a massive production of approximately 1 x 1011 
platelets every day, thus providing an enormous reservoir that guarantees proper control on 
circulating platelet levels. 
Early events of megakaryopoiesis
The process underlying the formation of MKs is defined as megakaryopoiesis. According 
to this model, MKs derive from megakaryocyte/eythroid progenitors (MEPs) following 
various highly regulated developmental stages29. These multipotent cells were generally 
thought to be produced by CMPs, however, recent studies have proposed that MEPs 
can arise directly from HSCs without the CMP intermediate8,30. Differentiation along the 
megakaryocytic lineage begins in the osteoblastic niche where it is mainly accompanied by 
nuclear polyploidization26,31. This is achieved through endomitosis, which is an alternative 
form of mitosis consisting of repeated replications of the DNA in the absence of cytoplasmic 
divisions32,33. As a consequence of this, MKs accumulate genomic material resulting in the 
formation of their characteristic polyploid and multilobulated nuclei, with a total DNA 
content that can reach up to 128N. Although the precise biological consequence of this 
process is unclear, it is theorized that an increase in gene copy number would ensure MKs to 
produce large amounts of mRNA and proteins that are usually packed into platelet granules, 
while retaining the ability to properly perform cellular functions. 
Late events of megakaryopoiesis
Following polyploidization, MK precursors migrate to the endothelial niche where they 
undergo maturation to ultimately generate pro-platelets34. During this stage of development, 
which requires an impressive rearrangement of the cytoskeleton, the cytoplasm of MKs 
increases in size as a result of an intense production of granules and the progressive formation 
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of a unique and elaborate pool of membranes denominated invaginated membrane system 
(IMS)26. The latter, also referred to as demarcation membrane system (DMS), is contiguous 
with the plasma membrane, permeates the cytoplasm of MKs and retains contact with 
the extracellular environment35,36. The IMS was believed to demarcate the cytoplasm in small 
territories from where platelets were originally thought to be formed37, however, refined 
models support a function for the IMS as a membrane reservoir for the formation and 
extension of pro-platelets38,39. Granules are essential mediators of platelet function. Upon 
formation in the MK body, all the different types of granules are individually transported 
along microtubules to the MK periphery, where they are eventually captured at the tips 
of forming pro-platelets40. The multitude of roles that is attributed to platelets in various 
physiological processes like inflammation, angiogenesis, microbial response, malignancy 
and wound healing mostly derives from the heterogeneous and distinct cargo transported 
in their granules. Each granule population can be distinguished based on the role played 
by the released constituents26,41,42. Dense (δ-) granules, for example, contain membrane 
transporters and small bioactive molecules like adenosine nucleotides and calcium that 
stimulate platelet aggregation. α-granules, the most abundant platelet organelles, transport 
large adhesive and healing proteins including crucial hemostatic factors such as fibrinogen, 
PF4 (platelet factor 4), BTG (beta thromboglobulin) and VWF (von Willebrand factor), that 
mediate blood coagulation and tissue repair26. As proteins present in α-granules can 
have opposing functions, this indicates that platelets release different sub-populations of 
α-granules in a regulated manner, depending on the type of activity to perform. In addition, 
platelet granules also include lysosomes, which contain degradative enzymes that eliminate 
circuIating platelet aggregates, and the newly identified t-granules41, whose function is 
still unknown.
Pro-platelet formation and platelet release
Maturation of MKs culminates with the formation of pro-platelets. These are long, thin 
extensions of the megakaryocyte cytoplasm that serve as assembly lines for the production 
of platelets. As platelet release occurs in circulation, MKs migrate to the bone marrow sinuses 
to infiltrate and extend pro-platelets into the underlying blood vessels27,28. Pro-platelet 
production begins with the formation of a primitive membrane structure, called pseudopod. 
Powered by the essential activity of microtubules, this pro-platelet precursor elongates 
further to ultimately became a pro-platelet and reach the bloodstream43,44. Subsequently, 
this process continues until the complete MK, with the exception of the MK cell body, is 
transformed in pro-platelets. At this stage, the characteristic multilobulated nucleus is 
excluded from the MK cell body and degraded26. In parallel, all the granules and organelles 
have been concentrated within pro-platelet tips, ready to be distributed and packed 
into nascent platelets. Recent evidence suggests that pro-platelets are first released into 
the circulation to undergo additional fragmentation into platelets43, however, the exact 
location and mechanisms of the final steps of thrombopoiesis are still controversial. 
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Transcription factors in megakaryopoiesis
As previously mentioned, mature MKs derive from MEPs, which constitute a bipotent 
population of hematopoietic progenitors from which both the megakaryocytic and 
erythroid lineages arise29. During MK commitment, MEPs undergo radical changes that result 
in the acquisition of nuclear polyploidy, a vast cellular enlargement and the assembly of 
peculiar membranous structures in the cytoplasm. These profound transformations require 
the prevention of erythroid differentiation and the simultaneous activation of MK-related 
gene expression programs. In MEPs and more committed megakaryocytic cells, these are 
obtained through the coordinated activity of both MK- and erythoid-specific as well as 
widely expressed transcription factors20,45–47. While some of these transcription factors 
are expressed throughout the entire MK differentiation, others are activated only during 
specific developmental stages. Many of them interact with each other and other co-factors, 
forming protein complexes that regulate transcriptional activity. The lineage-speciﬁcity and 
spatio-temporal regulation of gene expression are controlled by combinatorial binding of 
multiple transcription factors to gene promoters48. Although many studies have proven this 
complexity in regulating MK gene expression, the mechanism by which these regulators 
collaborate to constitute fully mature MKs capable to produce platelets remains elusive. 
Nevertheless, precious insights have been gained from the identification of genetic 
alterations that cause hereditary thrombocytopenias (Table 1)49,50. As these pathologies are 
generally caused by the effect of a single mutation, they can unequivocally reveal which gene 
is required for proper control of megakaryopoiesis and platelet production. In combination 
with mouse studies, these investigations have uncovered important transcription factors 
involved in human megakaryopoiesis, such as GATA1, RUNX1, and FLI1, which will be 
individually discussed below. 
Table 1. Summary of inherited thrombocytopenias based on the underlying mechanisms 
of defective platelet production. (Adapted from 49)
Disease (OMIM entry) Inheritance
Gene  
(chromosome location)
Platelet 
features
Defective megakaryocytic 
differentiation
Congenital amegakaryocytic 
thrombocytopenia (604498)
AR MPL (1p34) Normal-
sized 
platelets
Thrombocytopenia with absent 
radii (274000)
AR RBM8A (1q21.1) Normal-
sized 
platelets
Congenital thrombocytopenia with 
radio-ulnar synostosis (605432)
AD HOXA11 (7p15-14) Normal 
sized 
platelets
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Table 1. (continued)
Disease (OMIM entry) Inheritance
Gene  
(chromosome location)
Platelet 
features
Defective megakaryocyte 
maturation
Familial platelet disorder and 
predisposition to acute  
myeloid leukemia (601399)
AD CBFA2, RUNX1 (21q22) Normal-
sized 
platelets
Paris-Trousseau  
thrombocytopenia (600588), 
Jacobsen syndrome (147791)
AD Large deletion (11q-ter ), 
including FLI1
Large 
platelets
GATA1-related diseases: 
Dyserythropoietic anemia with 
thrombocytopenia (300367) 
X-linked thrombocytopenia with 
thalassemia (314050)
XL GATA1 (Xp 11) Large 
platelets
ANKRD26-related thrombocytopenia 
(313900)
AD ANKRD26 (10p2) Normal-
sized 
platelets
Gray platelet syndrome AR NBEAL2 (3p21.1) Giant gray 
platelets
Defective pro-platelet formation 
and platelet release
MYH9-related disease (nd) AD MYH9 (22q12-13) Giant 
platelets
ACTN1-related thrombocytopenia (nd) AD ACTN1 (14q24) Large 
platelets
FLNA-related thrombocytopenia (nd) XL FLNA (Xq28) Large 
platelets
Wiskott-Aldrich syndrome (301000) XL WAS (Xp11) Small 
platelets
X-linked  
thrombocytopenia (313900)
Small 
platelets
Bernard-Soulier syndrome  
(231200): Biallelic
AR GP1BA (17P13) 
GP1BB(22q11) GP9(3q21)
Giant 
platelets
Monoallelic AD GP1BA (17P13) Large 
platelets
ITGA2B/ITGB3-related 
thrombocytopenia (nd)
AD ITGA2B (17q21.31)
ITGB3 (17q21.32)
Large 
platelets
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GATA1
GATA-binding factor 1 (GATA1) belongs to a family of zinc finger transcription factors that 
recognize and bind to specific WGATAR consensus sequences on gene promoters51,52. 
This family is composed of six different GATA-paralogues that are differentially expressed in 
human tissues, with GATA1 and GATA2 being the major GATA proteins to be broadly expressed 
during hematopoiesis53. GATA1 expression gradually increases during differentiation of both 
erythoid and megakaryocytic lineage. Either disruption or overexpression of GATA1 in mice 
leads to embryonic lethalilty due to the failure of erythroid maturation54–56. In addition, 
a tissue-specific lack of GATA1 in the megakaryocytic lineage has been shown to dramatically 
reduce nuclear polyploidization and impair cytoplasmatic maturation of MKs, indicating 
that the activity of GATA1 is essential for the development of both the erythoid and 
the megakaryocytic lineages57. The importance of GATA1 in the regulation of MK development 
is also underscored by the presence of GATA consensus sequences in MK-specific gene 
promoters58. The binding to the DNA can be mediated by two highly conserved zinc finger 
domains, the N- and C-fingers, which also mediate protein-protein interactions59. Despite 
the fact that these structures share sequence similarities, it has been shown that the C-finger 
primarily contributes to DNA-binding while the N-finger is implicated in the binding with 
its crucial co-regulator friend of GATA1 (FOG-1)60–62. Also this transcription factor is essential 
for MK development. Mouse studies have shown that FOG-1 deficiency completely inhibits 
the formation of the megakaryocytic lineage63. In addition, the expression of GATA1 mutants 
that are unable to interact with FOG-1 results in a similar phenotype as that caused by GATA1 
deficiency64. This suggests that although GATA1 and FOG-1 do not always have overlapping 
functions, their interaction is indispensable for proper MK development. GATA1 mutations 
are found in a variety of hematological diseases including anemia and thrombocytopenia65,66. 
Depending on their location along the gene, GATA1 mutations induce distinct biochemical 
dys-functions on the resulting mutated proteins that are associated with distinct clinical 
phenotypes. Specific loss-of-function mutations abrogating the ability of GATA1 to bind to 
specific DNA sequences or disrupting the interaction with its co-factor FOG1, for example, 
are found in patients with thrombocytopenia67,68. Furthermore, while mutations affecting 
Table 1. (continued)
Disease (OMIM entry) Inheritance
Gene  
(chromosome location)
Platelet 
features
TUBB1-related thrombocytopenia (nd) AD TUBB1 (6p21.3) Giant 
platelets
CYCS-related  
thrombocytopenia (612004)
AD CYSC (7p15.3) Normal-
sized 
platelets
OMIM, Online Mendelian Inheritance in Man; AD, autosomal dominant; AR, autosomal recessive; 
XL, linked to chromosome X; MDS, myelodysplastic syndrome; nd, not defined.
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DNA binding have a mild effect on the development of the erythroid compartment, those 
affecting FOG1-interaction severely impact erythroid maturation causing anemia, as 
observed in X-linked thrombocytopenia with thalassemia and dyserythropoietic anemia 
with thrombocytopenia, respectively69–71. Commonly in these diseases, patients display 
prolonged bleeding time, enlarged platelets that have an abnormal spherical shape rather 
than discoid, and an elevated number of MKs in their bone marrow. MKs are usually small 
with an immature cytoplasm that contains a substantially reduced number of platelet 
granules and a highly disorganized membrane system, indicating that the platelet defects 
induced by these types of GATA1 mutations derive from aberrant MK development. Of 
note, GATA1 is frequently mutated in acute megakaryoblastic leukemia (AMKL), which is 
characterized by an uncontrolled proliferation of megakaryocytic precursor cells72,73.  In this 
disease, specific GATA1 mutations that are located outside the DNA- or the FOG1-binding 
domains, result in the expression of a truncated GATA1 form, GATA1s, that lacks the first 83 
amino acids74. GATA1s allows the commitment towards the MK lineage, but it prevents MK 
maturation, resulting in an expansion and accumulation of immature MK cells in the bone 
marrow75. Overall, the abovementioned phenotypes underscore the broad role of GATA1 in 
the regulation of fundamental processes underlying proper MK development.
RUNX1
The core binding factor (CBF) family of transcription factors comprises three homologous 
DNA binding proteins (RUNX1-3), of which RUNX1 covers a fundamental function in blood 
cell development76,77. Normally, RUNX1 acts by forming a heterodimer with its non-DNA 
binding regulatory subunit CBFβ, which confers increased stability and DNA binding affinity 
to the complex76,78,79. The importance of these transcription factors is emphasized by the fact 
that homozygous deficiency of either RUNX1 or CBFβ impairs the establishment of definitive 
hematopoiesis in mice, thus causing embryonic lethality80–83. These animals completely lack 
cells of the myeloid, erythroid and megakaryocytic lineage, indicating that the RUNX1- CBFβ 
complex is fundamental for the emergence of hematopoiesis82–86. These transcription factors 
are highly expressed in hematopoietic stem and progenitor cells where they coordinate 
the expression of crucial genes involved in proliferation, differentiation and self-renewal. 
In addition, RUNX1 expression is found in MEPs and retained during the differentiation along 
the megakaryocytic, but not the erythroid lineage87,88. Consistently, conditional disruption 
of RUNX1 after birth rapidly causes thrombocytopenia in mice, with minimal consequences 
on erythropoiesis89–91. Similarly to GATA1 deficiency, MKs from these mice fail to undergo 
maturation showing defective polyploidization and impaired cytoplasmatic development. 
Important insights into the biological functions of RUNX1 in megakaryopoiesis have 
been gained through investigations on patients affected by familial platelet disorder with 
predisposition to acute myeloid leukemia (FPD/AML)47,49,50,92–98. In this disease, germline 
heterozygous RUNX1 mutations lead to thrombocytopenia, which is associated with a higher 
risk to develop AML, as seen in roughly 40% of the cases. RUNX1 is a common mutational 
target in AML77 and the increased incidence of this disease among FPD/AML cases is likely 
to reflect its important role in balancing the homeostasis of HSCs between proliferation and 
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differentiation99. FPD/AML patients show an increased number of morphologically abnormal 
micromegakaryocytes in their BM biopsies95,98. Consistently with the phenotypes observed in 
knockout studies89, these cells display a poorly developed cytoplasm and a reduced nuclear 
lobulation49,76,92,93. Platelets show a marked reduction of dense granules and significant 
defects in aggregation response95,98, indicating that thrombocytopenia in FPD/AML is also 
associated with platelet dys-functions. In combination with the fact that MKs of FPD/AML 
patients fail to assemble and extend proplatelets, these findings imply an important role 
for RUNX1 in the final stages of MK maturation98,100. Most of FPD/AML cases exhibit similar 
clinical manifestations. Although recent studies have raised the possibility that some of 
these congenital RUNX1 mutations may act in a dominant-negative manner96,101, many of 
them results in haploinsufficiency, indicating that the defects observed in FPD/AML patients 
derives from a RUNX1 dosage effect.  
FLI1
DNA binding sites for the ETS family of winged helix-turn-helix transcription factors are 
over-represented in promoters of many MK-specific genes102. Components of this family 
contain a highly conserved DNA interaction domain that binds to genomic sequences 
harboring a core GGA(A/T) consensus motif103, which often flank GATA recognition sites104. 
An important member of this family is Friend leukemia virus integration 1 (FLI1), which 
has been shown to play a central role in MK development and platelet biogenesis102,105,106. 
This gene is located on a particular region on chromosome 11107 which is partially deleted in 
patients affected by Paris-Trousseau thrombocytopenia (TCPT) and the more severe Jacobsen 
syndrome (JBS)106,108,109. These disorders are associated with physical and developmental 
defects and mental retardation, the severity of which depends on the size of the deleted 
region.  An increased bleeding tendency, associated to a mild thrombocytopenia, is also 
observed in these pathologies109. FLI1 has been found to be deleted in almost all TCPT/JBS 
cases affected by bleeding complications106,108. The majority of circulating platelets in these 
patients exhibit a normal morphology, but a small subset of the whole population (roughly 
15%) includes abnormally enlarged platelets with a solitary giant α-granule originated by 
fusion110. Bone marrow examination of TCPT/JBS patients revealed the presence of subsets 
of immature micromegakaryocytes with small and poorly developed α-granules, mono-
lobulated nuclei and abnormally distributed internal membranes109. As FLI1 gene expression 
undergoes mono-allelic inactivation in early stages of differentiation, hemizygous loss of 
FLI1 may result in the absence of FLI1 expression, thus causing dys-megakaryopoiesis and 
explaining the existence of discrete populations of normal and abnormal MKs. Lentiviral 
overexpression of FLI1 in HSCs from TCPT patients rescued many of these abnormalities in 
vitro, proving that FLI1 plays an important role at multiple levels in megakaryopoiesis110. 
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The gray platelet syndrome
Defective production or secretion of platelet granules is causative for a number of bleeding 
disorders that can be clinically classified as storage-pool diseases (SPDs)111–113. The gray platelet 
syndrome (GPS) is a rare inherited SPD with a variable degree of severity that was originally 
described by Raccuglia et al. in 1971114. This disease is characterized by a mild to moderate, 
occasionally severe, thrombocytopenia, splenomegaly and the presence of enlarged 
platelets that, upon morphological staining, appear gray under light microscopy111–120. 
This typical appearance is caused by a paucity of α-granules and their constituents in 
platelets121. As previously mentioned, α-granules are intracellular storage pools that contain 
hundreds of different proteins which are secreted to mediate adhesion and aggregation 
of platelets at the site of vessel damage. The biogenesis of α-granules is a complex and 
still poorly understood process. α-granules develop following the fusion of multivesicular 
bodies, which are formed upon maturation of budding vesicles in the Golgi apparatus, with 
endocytic vesicles, and are transported to the pro-platelet protrusions122. In GPS, proteins 
that are endogenously synthetized or endocytosed by MKs fail to be incorporated into 
functional α-granules123. Consequentially, it has been hypothesized that these proteins may 
be released in the extracellular marrow, where they may stimulate the formation of fibers and 
contribute to the frequently observed myelofibrosis of GPS patients114,119,120. MKs are highly 
vacuolated, with large cytoplasmatic areas devoid of cell organelles, and are often present in 
normal number119,123. In contrast to α-granules, other platelet organelles such as lysosomes 
and dense granules develop normally123. A curious phenotype that is associated to the MKs 
of GPS patients is emperipolesis, which is defined as the active penetration by one cell into 
and through larger cells117,119. In fact, more than one neuthophil can be seen embedded 
within the cytoplasm of a single GPS MK. Because engulfed neutrophils can degranulate and 
release molecules that promote fibrogenesis124, emperipolesis is also thought to contribute 
to the still unclear etiology of myelofibrosis in GPS.
Both autosomal dominant and autosomal recessive forms of the disease have been 
reported. However, the majority of GPS cases exhibit an autosomal recessive inheritance119. 
Recently, more than 35 different NBEAL2 (neurobeachin-like-2) homozygous or compound 
heterozygous alterations have been identified in patients with autosomal-recessive GPS125–
127. Although NBEAL2 has been shown to localize within the endoplasmic reticulum125, where 
it may be required for the sorting or packing of granule components, the precise molecular 
functions carried out by NBEAL2 in MKs and platelets remain elusive. The types of mutations 
found and their zygosity have been associated with heterogeneous clinical manifestation 
of the disease, ranging from moderate to severe macrothrombocytopenia with complete 
absence of α-granules in almost all platelets128. Interestingly, as individuals with the same 
NBEAL2 mutation may have divergent clinical phenotypes, additional factors are likely 
to contribute to differences in bleeding severity of NBEAL2-related GPS. Because NBEAL2 
genetic variations are found in many, but not all, GPS cases, further efforts are required to 
identify new genes that are responsible for the pathological mechanisms underlying GPS. 
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Growth factor independence transcription factors 
The Growth Factor Independence (GFI) family of transcription factors includes 
the transcriptional repressors GFI1 and its paralogue GFI1B129–132. Ablation of both genes 
is incompatible with HSC biology133 and deletion of either GFI1 or GFI1b in mice results 
in defective hematopoiesis with different lineages being affected134–141. Whereas GFI1 is 
important for proper formation and function of cells from the adaptive and innate immune 
system135,136, GFI1B is important for MK and red blood cell development137,138,140. Besides these 
complementary functions, both proteins regulate proliferation and survival of HSCs134,139,140. 
However, while loss of GFI1 results in reduced HSC self-renewal capacity139, this phenotype 
is not observed upon loss of GFI1B140. Finally, it has been recently shown that together with 
other transcription factors GFI1B is able to program hemogenesis in fibroblasts142, further 
highlighting the broad and essential role of GFI proteins in blood cell development. 
Expression, structure, regulation and function of GFI1 and GFI1B
The distinct non-overlapping hematological functions of GFI1 and GFI1B reflect the mostly 
mutually exclusive and tissue-specific expression of these genes143,144. In many hematopoietic 
lineages, GFI1 and GFI1B have been shown to directly cross-repress each other’s expression 
or to coordinate their own expression by auto-regulatory feedback loops143,145–149. However, 
in the cellular compartments where both GFI1 and GFI1B are co-expressed, additional 
regulatory mechanisms are likely to be implicated. In fact, several transcription factors 
such as GATA1, NF-Y, Oct1, Ebf1 and HMGB2, for GFI1B146,148,150, and Ikaros151 and Ajuba152, 
for GFI1, have been reported to co-regulate the expression of GFI-genes. Additionally, also 
microRNAs153 and the ubiquitin proteasome-degradation system154,155 have been implicated 
in the regulation of GFI protein expression and stability, indicating that GFI1 and GFI1B levels 
are tightly controlled at multiple levels.
The introduction of the GFI1B gene in the GFI1 locus has been shown to rescue nearly all 
the hematopoietic phenotypes observed in GFI1-deficient mice156, suggesting that both GFI 
proteins perform similar activities at the molecular level in hematopoiesis. Consistently, the 
protein structure of GFI proteins is largely identical and well conserved among vertebrates, 
with a SNAG (Snail/GFI1) domain at the N-terminal region, a central intermediate region 
and six zinc finger domains at the C-terminal region129–132. Found in other transcriptional 
repressors, the SNAG domain is a conserved 20 amino-acid long region, which is essential 
for the recruitment of histone modifying proteins157. At the other side of the protein, six C2-H2 
zinc fingers mediate protein-protein interactions and also the binding to the DNA, which is 
exclusively dependent on the integrity of zinc fingers 3 through 5129,158,159. In contrast to the 
SNAG and the zinc finger domains, which are 89% identical at protein level, the intermediate 
part shows only 39% similarity between GFI1 and GFI1B. Recently, it has been proposed that 
PIAS3-mediated sumoylation of a SUMO-consensus motif present within this region induces 
GFI1 degradation160. As this modification seems to be antagonized by the interaction with 
Notch1 intracellular domain N1-ICD161, these findings suggest that the GFI intermediate 
region is likely to provide a binding platform for the interaction with specific co-factors and 
to function as a regulatory domain. Remarkably, the same SUMO-consensus site is absent 
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in GFI1B. This implies that although both GFI1 and GFI1B function in a similar biochemical 
manner, their activity is differentially modulated at the post-translational level, possibly 
depending on the cellular and molecular context and through the interaction with specific 
binding partners. 
GFI1 and GFI1B genes encode for 422 and 330 amino acid transcription factors, 
respectively, that recognize specific ”AATC” containing consensus-sequences within 
the promoters of target genes and inhibit their expression129,130,132. This is achieved by 
remodeling chromatin through the recruitment of proteins that modify histones157. Upon 
binding to the DNA, GFI proteins form a complex with deacetylases and (de)methylases which, 
in turn, apply epigenetic marks on histones that render chromatin structure inaccessible for 
gene transcription. Furthermore, this process is facilitated by the engagement of a variety 
of other co-repressor molecules that enhance the repressive activity of the GFI-complex. 
Although the molecular events are largely unknown, it has recently been shown, at least 
for GFI1, that the p150 subunit of the chaperon Caf-1 (chomatin assembly factor 1) bridges 
the repressive complex to histones, enabling possible co-factors like HDACs 1-2 (histone 
deacetylases)162, LSD1 (lysine specific demethylase 1), CoREST/Rcor1 (Rest co-repressor) 
and the major histone methyltransferases G9A162–164 and SUV39H1164, to be recruited and 
contribute to gene repression. Interestingly, it has been reported that GFI proteins can 
also function as positive regulators of gene transcription164,165, although the underlying 
molecular mechanisms remain to be elucidated. Moreover, GFI proteins were shown to 
physically interact with and reciprocally influence the activity of other transcription factors. 
For example, GFI1B controls the activity of GATA1 upon binding on erythrocytic gene 
promoters148,166, while GFI1 can co-regulate gene expression upon DNA-dependent binding 
to ETS1167 and DNA-independent binding to Miz-1168 and Pu.1169, indicating that GFI proteins 
can exert their transcriptional functions through different modes of action. Besides gene 
expression, GFI1 has been also shown to regulate alternative splicing170 and protein post-
translational modifications160. However, these latter molecular activities have not been 
reported for GFI1B as yet.
Biological and molecular activities of GFI1B during hematopoiesis
GFI1B is expressed in HSCs and highly expressed in MEPs and cells of the erythroid and 
megakaryocytic lineage144. Germline deletion of a single GFI1B allele in mice does not have 
apparent effects on hematopoiesis137. However, ablation of both GFI1B loci is lethal during 
embryogenesis due to the failure of erythrocyte precursors to produce fully differentiated 
red blood cells137. Conditional knockout mouse models have been generated to investigate 
the biological functions of GFI1B during adult hematopoiesis140,141. Conditional loss of GFI1B 
has been shown to affect dormancy and mobilization of HSCs, resulting in a large expansion 
of HSCs in both bone marrow and blood140. Because HSCs from these mice retain the capacity 
to self-renew and differentiate towards all the lineages, this suggests that GFI1B inhibits 
their proliferation, while it is dispensable for HSC maintenance and clonogenic capacity. 
Besides HSCs, GFI1B is essential for proper red cell and platelet formation.  Conditional 
inactivation of GFI1B in adult mice has been shown to affect erythroid and megakaryocytic 
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development at different stages141. Upon GFI1B knockout, erythroid development is 
blocked at the progenitor stage, while megakaryopoiesis does not proceed beyond nuclear 
polyploidization. In these mice, MKs fail to undergo cytoplasmic development and thus 
fail to produce platelets, suggesting that GFI1B is required for MK maturation. GFI1B is 
also expressed in specific subsets of B- and T- cells144. However, the importance of GFI1B in 
the development and function of these cell types remains to be elucidated. 
Despite the molecular mechanisms controlled by GFI1B are poorly understood, all 
the phenotypes mentioned thus far have been associated with aberrant expression of 
several genes. For example, GFI1B seems to be important for the expression of cell surface 
molecules in HSCs140, although it is not clear whether these genes are directly or indirectly 
controlled. Following animal and in vitro studies, it has been proposed that GFI1B targets 
the growth factor-β receptor III gene171 and genes involved in embryonic globin expression138 
during erythroid development. Although several other genes have been reported to be 
directly targeted by GFI1B transcriptional activity during erythropoiesis, the putative 
targets of GFI1B during megakaryopoiesis are, as yet, less known. GFI1B has been shown to 
repress the expression of meis1172, an important proto-oncogene associated with malignant 
transformation, in erythrocytic, but not megakaryocytic cells, suggesting functional and 
regulatory differences between the two lineages. Thus, to fully decipher the intricate fashion, 
through which GFI1B controls proliferation, differentiation and survival of blood cells, it 
will be necessary not only to determine additional target genes, but also the co-factors 
used in the various hematopoietic subsets and how these cooperate with GFI1B to control 
gene expression.
Pathological role of GFI1B in blood-related diseases
In spite of the fact that loss of GFI1B function causes various defects in mouse models, 
the direct involvement of GFI1B in the development of hematological diseases is still 
controversial. Early studies have demonstrated that GFI1B co-operates with known 
oncogenic genes in hematological malignancies and regulate proliferation of erythoid and 
megakaryocytic malignant cell lines166,173. In addition, a short GFI1B isoform (GFI1B p32), 
lacking the zinc fingers 1 and 2, was found to be over-expressed in patients with AML and 
chronic myeloid leukemia (CML)174. However, in contrast to GFI1, that is mutated in patients 
with neutrophilia175 and predispose to leukemia when a specific polymorphism is present in 
its coding sequence176, genetic variations in the GFI1B gene have not been found in blood 
related disorders. Part of this thesis, presented in chapter 2, will describe the discovery of 
a dominant-negative mutation in the GFI1B gene to be causal to an autosomal dominant form 
of GPS177, thereby illustrating the crucial importance of GFI1B in human MK development 
and platelet production.
Acute Myeloid Leukemia
AML is a disease of the myeloid lineage characterized by the clonal expansion of dysfunctional 
cells that have lost their proliferative control and the ability to differentiate. These immature 
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cells, denominated blasts, amass within the bone marrow microenvironment and they can 
frequently be found in the peripheral blood, where they account for the high white blood cell 
count often found in AML patients. The accumulation of leukemic cells in the bone marrow 
results in the suppression of normal hematopoiesis with the consequential manifestation of 
typical clinical symptoms such as fatigue, anemia, bleeding disorders and infections. AML 
is an aggressive type of cancer with an incidence that increases with age178. In children, 
although the incidence is lower, AML is among the most frequently occurring malignancies. 
Therapeutic strategies in medically ﬁt patients involve high-dose chemotherapy and in many 
cases HSC transplantation179. Current treatment can be divided in two phases: induction and 
consolidation therapy. Induction therapy aims at the eradication of the bulk of leukemic 
cells and the restoration of normal hematopoiesis. Complete remission is achieved when 
patients display normal cell count in the peripheral blood and the leukemic blast counts in 
the bone marrow drops from more than 20% to below 5%. Consolidation therapy is then 
applied to eliminate residual leukemic cells and to prevent the risk of relapse. This phase 
requires additional chemotherapy and allogeneic stem cell transplantation, which is usually 
performed in selected patients at high risk of relapse. In the past years, intensive efforts have 
been made to improve survival of AML patients, but still only 40% of individuals younger 
than 60 years survive more than 5 years from diagnosis180–182. This is largely due to the high 
relapse rate observed in patients, indicating that current therapies are unable to completely 
eradicate the disease in the majority of the cases. Because of this, it is believed that there 
is a rare subset of malignant cells that can survive treatment. These cells are responsible for 
relapse and are recognized as leukemia stem cells (LSCs).
Leukemia stem cells
AML arises following a stepwise accumulation of multiple genetic defects. These alterations 
affect critical genes involved in proliferation, differentiation and apoptosis, thus perturbing 
normal cellular functions. The series of transforming events is thought to start with 
the formation of pre-LSCs (Figure 2). These cells arise early in leukemic transformation and 
are considered to be HSCs that acquire initiating alterations which promote their clonal 
expansion. Consistently, pre-LSCs have been shown to possess a multi-lineage repopulation 
advantage over non-mutated HSCs in the reconstitution of xenograft models, but they 
are unable to induce AML183. Thus, although pre-LSCs can sustain blood cell development, 
they represent a pool of abnormal cells from which LSCs can evolve. The transition into 
fully transformed LSCs requires the co-occurrence of cooperating alterations, which 
collaborate with the initiating events to transform pre-LSCs in leukemia-generating LSCs. 
Xenograft studies have revealed that only a specific population of primary AML material 
can induce and sustain the growth of leukemia in mice184, showing that the leukemic clone 
in AML is organized in a hierarchical fashion. As in normal hematopoiesis, LSCs sit at the 
apex of the organization, are highly-quiescent and retain the capacity to generate more 
differentiated proliferating leukemic blasts. The fact that serial transplantation of LSCs in 
immuno-deficient mice repeatedly induces leukemia indicates that these cells also possess 
a self-renewing capacity. The acquisition of this feature is essential for these cells to 
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survive and continuously replenish the bulk of the tumor population. Because unlimited 
self-renewal is an intrinsic feature of normal HSCs, but not of normal hematopoietic 
progenitors, it was originally assumed that LSCs may be exclusively present in the CD34+CD38- 
cell subset, which defines HSCs. However, LSC activity has also been found in the more mature 
CD34+CD38+ and CD34- cell subsets185,186. This indicates that the cell of origin of AML may 
also derive from more mature cell fractions, and thus it may differ between AML patients. 
In addition, consistent with the proposed hierarchical organization, immature LSCs can 
give rise to both immature and mature phenotypes when transplanted in secondary 
recipients, while more mature LSCs can only give rise to the same mature phenotype186. 
Because mature LSCs cannot regress to an immature phenotype, this supports the existence 
of a different degree of differentiation between LSCs, which may reflect the differentiation 
status of the cell-type originally involved in LSC transformation. Classical treatment 
regimens are mainly targeted at the highly proliferative bulk of leukemic cells. However, 
the quiescent nature of LSCs may confer an important tolerance against conventional 
Progenitor cells
pre-LSC
Mature cells
LSC/LICHSC
Pre-leukemic
state
Normal
hematopoiesis
Leukemic
transformation
Blasts accumulation
Figure 2. Schematic representation of leukemia transformation. During normal hematopoiesis, 
hematopoietic stem cells (HSCs) give rise to committed progenitors, which in turns generate all 
mature blood cell types (left side). Following the acquisition of an initial genetic defect (yellow 
lightening symbol), pre-leukemic stem cells (pre-LSC) are formed. These acquire additional 
aberrations, resulting in the generation of LSCs, or leukemia initiating cells (LICs), which are 
characterized by increased self-renewal (circular arrow) and block of differentiation, leading to 
the accumulation of dys-functional leukemic blasts that form the bulk of tumor cells.
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chemotherapy, explaining the high relapse rate observed in patients. Because LSCs represent 
a self-renewing population that is capable to resist treatment and maintain the disease, it is 
believed that the identification and elimination of this population is fundamental to increase 
survival of AML patients.
Prognostication in AML 
AML is a clinically and genetically heterogeneous disease characterized by the presence 
of recurrent genetic defects187–189. Some of these acquired aberrations have been shown 
to correlate with distinct clinical outcomes. Because these abnormalities carry important 
prognostic information, they are used as risk factors to predict survival and therapy 
response190. In clinical practice, AML patients can be classified in four distinct groups with 
very poor, poor, intermediate and relatively good prognosis based on these and few other 
risk factors, such as age and white blood cell count (Table 2)191. Their presence strongly 
influences the therapeutic approach and thus their identification has a crucial relevance 
in the management of AML patients. Frequently observed genetic changes in AML include 
abnormalities at the cytogenetic level, like for instance gain or loss of genomic material and 
translocations, or more subtle abnormalities observable at the molecular level, such as single 
gene mutations and altered gene expression179,192–195. Prognostically significant cytogenetic 
abnormalities that are currently used in diagnostic protocols include the t(8;21), inv(16), and 
t(15;17) translocations, which result in the RUNX1-ETO, CBFB-MYH11 and PML-RARA fusion 
proteins, respectively, and predict a relatively good clinical outcome190,191,195. Furthermore, 
loss or gain of genetic material, as seen in monosomies of chromosome 5 or 7, deletion 
of the long arm of chromosomes 3, 5 and 7 are considered as poor prognostic markers191. 
Complementarily, molecular lesions are particular important to improve the diagnostic 
stratification of otherwise undefinable risk-groups. In line with this, patients with normal 
cytogenetics are routinely screened for the presence of these alterations. Frequently 
observed molecular defects are found in the fms-like tyrosine kinase 3 (FLT3), the CCAAT/
enhancer binding protein alpha (CEBPA) and nucleophosmin 1 (NPM1) genes. In combination 
with TP53, ASXL1, RUNX1 and c-KIT, these are the genes predominantly screened to guide 
risk assessment and consequential treatment decisions. With the implementation of next 
generation sequencing techniques, an emerging number of additional somatic mutations 
have been detected, particularly targeting genes involved in epigenetic regulation such as 
TET2, IDH1/2, DNMT3A, EZH2, and ASXL1187,188. Although the underlying mechanisms through 
which these alterations contribute to leukemia are still elusive, they nonetheless have 
been shown to represent an additional source of prognostic information. As illustrated in 
chapters 3196 and 4197, also analysis of gene expression, either of single genes or of multiple 
genes may improve the stratification of patients into different risk groups. Several genes, 
of which expression is dys-regulated in AML, have been shown to be of clinical relevance. 
The most important example is high expression of EVI1, which is detected in roughly 8% of 
AML patients and which is associated with an extremely poor prognosis198,199. Besides EVI1, 
also the differential expression of BAALC200,201, MN1202, ERG200,203 and BRE204 has been shown 
to predict disease outcome, but the incorporation of these risk factors in clinical protocols 
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is still very limited. Over the last decade, several studies using gene expression profiling 
(GEP) have been conducted on large series of AML patients192,193,205–207. These studies have 
shown that genetic aberrations associated with favorable survival, such as inv(16), t(15;17) 
and t(8;21) and double CEBPA mutations, can be linked to distinct expression profiles206,207, 
indicating that GEP could be useful in diagnostication. Although not all known aberrations 
can be tracked back to a reciprocal gene expression signature, the use of GEP has also led 
to the discovery of novel disease entities and expression signatures associated with disease 
outcome. Importantly, GEP provides transcriptome-wide information on genes of which 
expression is dys-regulated in the various subtypes of AML, allowing the identification of 
pathways that are targeted by the underlying genetic defects and thus revealing precious 
insights into the pathogenesis of AML205. 
The increasing availability of molecular and cytogenetic data has permitted 
the refinement of AML nosology and prognostication. However, many pathological events 
are still unknown and the majority of the currently delineated disease categories display 
a substantial heterogeneity. Therefore, the identification of additional risk factors that 
accurately predict outcome and that allow patients to be matched to the most appropriate 
therapies is warranted.
Towards targeted therapy 
The possibility to stratify patients based on risk factors has pushed the field of hematology 
towards more individualized therapies, which take into account both the clinical and 
the genetic background of AML patients. However, although most patients achieve complete 
remission with first line chemotherapy, the majority of them ultimately relapse180–182. 
With the exception of particular AML subclasses, such as those with t(8;21), inv(16), and 
t(15;17), it has not been possible to significantly improve the outcome of AML patients in 
the last three decades, particularly concerning patients older than 60-65 years. Intensification 
of the current therapeutic regimens or usage of higher doses of drugs is impaired by the fact 
that a large number of patients are not medically fit to undergo such arduous treatments 
(due to old age, co-morbidity, etc.) which employ toxic drugs. Thus, the identification of 
more selective approaches, which specifically target leukemic cells whilst minimizing side 
effects, is necessary to improve survival rates in AML. Important examples of successful 
application of targeted therapy include those interfering with the activity of the fusion 
oncoproteins BCR-ABL208,209 and PML-RARA210, which are typically found in patients 
suffering from chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL), 
respectively. In the former case, it has been shown that the treatment of CML patients with 
tyrosine kinase inhibitors that interfere with the activity of BCR-ABL dramatically improves 
the survival of CML patients208. In the case of PML-RARA, this abnormality induces an 
arrest in differentiation due to the repression of RARA signaling. Treatment with all-trans 
retinoic acid (ATRA) induces PML-RARA dependent transcription and subsequent release 
of the differentiation block. In combination with chemotherapy, the addition of ATRA to 
the treatment has resulted in an impressive improvement of survival211. In contrast to CML and 
APL, for which the therapeutic targets are well defined, the remaining types of AML are more 
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heterogeneous at the molecular level and the identification of critical targets for therapy 
may be more difficult. Nevertheless, besides refining patient stratification, our increasing 
knowledge of the genetic abnormalities present in AML has also led to the identification of 
several biological pathways that are disrupted in leukemic cells. It has become apparent that 
alterations driving neoplastic transformation and progression are not confined to tumor 
suppressors or oncogenes involved in cell growth and survival, but also affect proteins 
that have functional roles in the regulation of other global processes, such as chromatin 
remodeling and transcriptional regulation, cell adhesion, genome methylation and signal 
transduction. The targeting of these pathways, using inhibitors of DNA methyltransferases, 
histone deacetylases, tyrosine kinases or other, new drugs that specifically interfere with 
mutated oncoproteins, represents a promising opportunity to develop and refine targeted 
therapies and to meliorate the outcome of AML patients.
Table 2. European Leukemia Network (ELN) prognostic system (Adapted from191)
Prognostic group Subsets CR rate; relapse rate
Favorable Inv(16) or t(16;16); 
t(8;21) NK and NPM1+/FLT3 ITD-; 
NK and CEBPA +/+
>80-90%; 35-40%
Intermediate-1 NK and NPM1+/FLT3 ITD – 
or CEBPA +/-
50-80%; 50-60%
Intermediate-2 Cytogenetic abnormalities not in 
favorable or adverse groups; 
FLT3 ITD +
40-60%; 70-80%
50-80%; 70-80%
Adverse -5, -7, 5q-, abn 3q, 17p, 11q (other 
than t(9;11), t(6;9), complex
<50%; >90%
NK, normal karyotype; +, abnormality present; -, abnormality absent; +/+, double mutation; abn, 
abnormalities; CR, complete remission
NF-kB signaling and ubiquitination
Post-translational modifications are reversible additions of biochemical functional groups 
onto specific amino acid residues present within protein structures. More than 200 types 
of post-translational modifications including covalent attachments of lipids, carbohydrates, 
particular chemical groups or even proteins, have been documented thus far212. These 
transient alterations frequently affect protein function by changing the protein structure 
and dynamics or by modifying residues that may be implicated in the binding with 
a partner. Whether a protein is, for instance, (de)activated, degraded, assembled or activated 
for trafficking through the cell is determined by the type of modification and the amino 
acid residue involved. Biologically, post-translational modifications serve to coordinate 
the fate and function of proteins thereby governing protein signaling networks213. Indeed, 
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they are involved in the regulation of a large number of cellular activities, also including 
gene expression control. A post-translational modification that has gained increasing 
relevance in the past two decades is ubiquitination. Originally believed to be solely 
implicated in the proteosomal degradation of proteins214,215, ubiquitination has more 
recently been discovered to be involved in a plethora of cellular processes and it is nowadays 
regarded as an important signaling molecule216–221. An excellent example to illustrate 
the signaling role of ubiquitination is represented by the NF-kB signaling pathway222, which 
is essential for a large variety of biological processes including apoptosis, bone formation, 
viral replication, tumorigenesis, inflammation and immunity223,224. In hematopoiesis, 
several hematopoietic types of cells with either myeloid or lymphoid origin rely on the 
activity of NF-kB signaling for their development and function225,226. In addition, NF-kB is 
directly involved in the development of autoimmune and inflammatory diseases and 
it has been shown to be activated in leukemia227,228. In the next section, the relevance of 
a particular form of ubiquitination, namely linear ubiquitination, will be discussed in 
the regulation of NF-kB signaling229,230. 
Ubiquitin and the ubiquitination machinery
The central molecule of the ubiquitination pathway is a 76 amino acid globular peptide 
called ubiquitin, which is one of the most conserved proteins among eukaryotic species231,232. 
The fact that it is encoded by four different genes in humans underscores the fundamental 
and indispensable role that is covered by ubiquitin in nature231. The linkage of ubiquitin to 
specific targets consists of the sequential transfer of a single ubiquitin moiety through three 
distinct types of specialized enzymes (Figure 3). First, an E1 ubiquitin-activating enzyme 
activates the carboxyl group of the C-terminal glycine residue of a free ubiquitin through 
the hydrolysis of ATP to ADP233. As such, this residue can form a thioester bond with a specific 
cysteine residue that is located within the active site of the E1 activating enzyme, resulting 
in the loading of ubiquitin. 
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Figure 3. The ubiquitin system. The ubiquitination reaction begins with the ATP-dependent 
activation of ubiquitin (Ub, green) by the E1-enzyme, and continues with the formation of 
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This initial step is subsequently followed by the transfer of ubiquitin to an E2 
ubiquitin-conjugating enzyme to form another intermediate thioester bond with an 
active site cysteine residue234. Finally, an E3 ubiquitin ligase recognizes and brings in close 
proximity both the E2 conjugating enzyme and the target protein, catalyzing the formation 
of an isopeptide bond between the C-terminus of a donor ubiquitin and the ε-amino group 
of lysine (K) residues within the substrate protein. Lysine is not the only amino acid that may 
serve as a final acceptor for ubiquitin. Also serine, threonine and cysteine residues have been 
reported, although the underlying biochemical mechanism and the biological relevance of 
these modifications remain elusive235,236. The mode of action of the E3 ligases is dependent 
on the motif that mediates the interaction with the E2 enzyme. E3 ligases can be subdivided 
in several classes because distinct structural domains that interact with E2s have been 
identified. All E3 ligases bind an ubiquitin-charged E2 and catalyze the transfer of ubiquitin 
from the E2 either directly to a substrate lysine, as this is the case for RING237 (really interesting 
new gene) E3s, or through the formation of an intermediate linkage with an active-site 
cysteine within the E3 itself, as it is the case for HECT238,239 (homologous with E6-associated 
protein C-terminus) and RBR240,241 (ring in-between fingers) E3s. Although the RING-type 
ligases do not physically participate to the transfer of ubiquitin, they greatly increase 
the efficiency of E2 activity and enhance the conjugation reaction237. On the other hand, 
HECT- and RBR-type ligases play a direct role in substrate ubiquitination by forming a thioester 
intermediate bond necessary for E2-independent conjugation to the substrate238,239,242. 
As E3 ligases determine the substrate to be ubiquitinated, these components are responsible 
for the specificity of the ubiquitination machinery, while the E2-E3 combination generally 
determines the site of the attachment to the substrate. Although only one E1 activating 
enzyme and about 50 E2 conjugating enzymes have been described, a large number of 
approximately 1000 putative E3 ligases have been identified in the human genome243. 
Finally, ubiquitination is opposed by the activity of roughly 90 different de-ubiquitinating 
enzymes (DUBs)231, which selectively cleave ubiquitin from the substrate, thereby enabling 
a time dependent reversibility of the process. The balance between ubiquitination and 
de-ubiquitination determines the fate of target proteins. As DUBs are outside of the scope of 
this thesis, they will not be introduced further.
The fate of substrates depends on the type of ubiquitin modification
Distinct types of ubiquitin modifications can occur in nature, each of them with a specific 
signaling function and biological meaning (Figure 4). The attachment of a single ubiquitin 
molecule is referred to as mono-ubiquitination and can induce a variety of regulatory 
events that usually promote the recruitment or the displacement of proteins to and from 
a thioester bond between Ub and an active-site cysteine present in the E2 enzyme. The final 
transfer of Ub onto its target is mediated by E3 Ub-ligases, which promote a direct transfer from 
the E2 enzyme (as it is the case for RING ligases), or involve the formation of an intermediate 
thioester with Ub (HECT-, RBR-ligases).
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functional complexes244–247. Mono-ubiquitination targeting of distinct lysine residues within 
the same substrate is defined as multi-mono-ubiquitination, and it has, for example, been 
described to be involved in the nuclear export of p53246,247.  In addition, because ubiquitin 
itself contains seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) that can be 
substrates for ubiquitination, several ubiquitin molecules can be serially linked together to 
generate chains248. All lysine residues in ubiquitin can be involved in poly-ubiquitination. 
A homotypic chain is formed when the same lysine residue of consecutive ubiquitin 
molecules are used for the assembly. When different lysine residues are implicated, a mixed 
chain is constituted249,250. Due to limitations of the current technologies applied to study 
ubiquitin chain topologies, only a small part of ubiquitin chain types has been investigated, 
with K48- and K63-linked ubiquitin chains being the most well characterized types of chains 
thus far251,252. The classical form of ubiquitination, involving the formation of K48-linked 
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Figure 4. Ubiquitin chain topologies. Different forms of ubiquitination are presented. Ub can be 
linked to the substrate (purple) as a monomer on either a single K residue (mono-ubiquitination) 
or multiple K residues (multimono-ubiquitination) of the same target. Multiple Ub molecules can 
be linked together through internal K residues to form chains (poly-ubiquitination), as seen, for 
example, in K48-linked, K63-linked and mixed chain ubiquitination. Linear chain ubiquitination 
occurs when the linkage between Ub molecules involves the C-terminus of the donor Ub and 
the N-terminus of the acceptor Ub. Abbr.: K: lysine; C: cysteine; M: methionine.
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polyubiquitin chains, functions as a signal for proteasomal degradation of proteins253–255. 
Briefly, these structures are recognized by specific ubiquitin binding domains (UBDs)256 that 
facilitate the association of K48-ubiquitinated proteins to the regulatory 19S subunit of 
the proteasome. This mediates the unfolding and the transport of targets into the catalytic 
20S core of the complex, which consists of a barrel-shaped subunit with protease activity 
that degrades cellular proteins into peptides255. In contrast to K48-linked chains, labeling 
with K63-polyubiquitin chains do not mark proteins for degradation, but rather modulates 
the activity of substrates. These chains are created through the specific activity of UBC13257,258, 
the only E2 enzyme known to catalyze their formation, and usually function as a scaffold to 
facilitate the recruitment of signaling proteins. Consistent with this, K63-ubiquitination has 
been implicated in the internalization of surface receptors259,260, DNA repair mechanisms257 
and signal transduction261,262. Besides K48- and K63-linked ubiquitin chains, unconventional 
types of chain topology are represented by K11-linked chains248, that have been proposed 
to function as a recruiting signal261,263,264 and play a role in cell division265, and linear chains, 
which will be discussed next in more detail.
Linear ubiquitination and LUBAC
Linear chains represent a unique type of ubiquitination. In these chains, the linkage 
between ubiquitin moieties does not consist in the attachment of the C-terminus of 
the donor ubiquitin to one of the ε-amino group of lysine residues of the acceptor 
ubiquitin, but rather to the N-terminal amino-group of the final methionine. Because 
the end of an ubiquitin moiety is then attached to the beginning of the preceding 
molecule, this type of modification was defined ‘’head-to-tail’’ and generates ‘’linear’’ or 
M1- chains266. Linear ubiquitination is catalyzed by a tripartite complex denominated LUBAC266 
(Linear-UBiquitin-Assembly-Complex), which is composed of HOIL-1L267 (haem-oxidized IRP2 
ubiquitin ligase 1L, RBCK1), HOIP268 (HOIL-1L-interacting protein, RNF31) and SHARPIN269 
(SHANK-associated RH domain interacting protein). The catalytic activity of LUBAC resides 
within HOIP, while HOIL-1L and SHARPIN binds to HOIP and act as crucial activators266–269. 
Figure 5 illustrates the domains involved in the interaction between LUBAC components. 
Although the existence of other E3 complexes equipped with linear ubiquitination activity 
cannot be excluded, LUBAC is currently the only complex described to assemble linear 
ubiquitin chains. 
HOIP acts as RBR ubiquitin ligase
Upon LUBAC formation, HOIP generates linear chains through a mechanism that is typically 
found in the small family of E3 RBR (RING-in-between-RING) ligases240–242. A total of fourteen 
different RBR ligases have been identified in humans to date270. They are complex multi-
domain proteins characterized by the presence of a highly conserved catalytic unit, which 
contains an IBR (in-between-RING) domain flanked by two RING structures, of which RING1 
resembles the catalytic domain of RING-type ligases, while RING2 does have a peculiar 
structure271,272. These proteins function through a HECT/RING hybrid mechanism242. 
According to the current model, RBR-mediated linear ubiquitination initiates with 
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the association of RING1-IBR region of HOIP to an ubiquitin-charged E2 conjugating 
enzyme, an activity that is typically observed in RING-type E3 ligases. However, before 
being eventually attached onto the acceptor ubiquitin, the donor ubiquitin is transferred 
to a conserved cysteine located in RING2, where it forms an intermediate thio-ester bond 
reminiscent to that of HECT-type ligases. In RBR ligases, the linkage specificity and the length 
of the chain are generally determined by the E2 enzyme. In the case of LUBAC, however, the 
specificity for linear ubiquitination prevails over that of the E2 enzyme and is intrinsic to 
HOIP, which produces linear chains regardless of the type of E2 that is used in the catalysis. 
The region that determines the linear specificity in LUBAC is a particular domain called the 
linear ubiquitin chain-determining (LDD) domain, which is unique to HOIP, as it has not been 
found in any other RBR ligases273. Situated in the C-terminal part of the protein, LDD captures 
the acceptor ubiquitin and positions its N-terminal amino-group in a specific orientation 
that facilitates the formation of the ‘’head-to-tail’’ linkage, as described in chapter 5.
LUBAC-mediated linear ubiquitination of NEMO is crucial for NF-kB activation
NF-kB is implicated in an important signal transduction route that translates various 
extracellular signals into transcriptional events. Stimulation by cytokines, oxidative stress 
or pathogens results in the activation of the Rel family of NF-kB transcription factors223,224. 
Depending on the nature of the stimuli, these proteins determine the expression of specific 
sets of genes that mediate cellular responses. Two distinct pathways are responsible for 
the activation of NF-kB, the canonical and the non-canonical. The canonical pathway 
(Figure 6), which induces the expression of several genes involved in proliferation, 
differentiation and survival, is highly regulated at the post-translational level. As depicted 
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Figure 5. Schematic representation of LUBAC. LUBAC is composed of HOIL-1L, HOIP and 
SHARPIN. Domains involved in LUBAC formation are shown by double arrows.  The interactions 
between HOIP NPL4 zinc finger 2 (NZF2) and the ubiquitin-like (UBL) domain of SHARPIN has 
also been proposed to be involved in LUBAC formation (not shown). The PUB domain (peptide:N-
glycanase/UBA or UBX-containing proteins) interacts with the de-ubiquitinating enzyme OTULIN 
(also not shown).
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in Figure 7, the activation of this signaling route requires an intricate cross talk between 
different types of ubiquitin chains and other post-translational modifications222,229,263,274. 
LUBAC and related linear ubiquitination play a prominent and exclusive role in this process, 
as they contribute to the activation of NEMO (NF-kappa B Essential Modulator), 
which is a crucial mediator of the NF-kB signaling cascade267,269. In short, following the 
activation of this pathway by pro-inflammatory cytokines, such as TNF-α and IL-1β , LUBAC 
is recruited to the TNF-α receptor where it interacts with and linearly ubiquitinates specific 
components of the NF-kB signaling cascade such as NEMO275 and, to a lesser extent, RIP1 
(Receptor-Interacting Protein 1)276. LUBAC-mediated linear ubiquitination of NEMO is 
important for the activation of the IKK complex, which is required for the degradation of 
IkBs and subsequent translocation of NF-kB transcription factors to the nucleus267,268,277. 
The molecular mechanism underlying the involvement of LUBAC has been partially resolved. 
Upon receptor activation, LUBAC is recruited to the receptor together with IKK, and this 
process has been shown to depend on the activity of TRADD, TRAF2 and c-IAP proteins277. 
At the receptor complex, the recognition of NEMO by LUBAC is mediated by the ZF domains 
of HOIP and HOIL267. Linear ubiquitination of NEMO occurs within its UBAN domain, which 
is required for IKK activation, and it may induce conformational changes required for NEMO 
activation. In addition, the UBAN domain functions as a specific binding region for linear 
chains. Consistently, it has been shown that NEMO-bound linear chains serve as a binding 
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Figure 6. Schematic representation of the canonical NF-kB pathway. In resting cells, NF-Kb 
transcription factors (p50 and p65) are sequestered in the cytoplasm by inhibitory proteins, known 
as inhibitors of NF-kB (IkBα in this case), which prevent their translocation to the nucleus. Upon 
binding of TNF-α (or IL-1β) to its receptor, LUBAC mediated-linear ubiquitination activates NEMO, 
resulting in the phosphorylation of IKKβ and the activation of the IKK complex. Activated IKK is 
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platform for the recruitment of additional NEMO proteins277. Multimerization of NEMO is 
thought to stabilize the NEMO-IKK complex, thereby promoting NF-kB activation. Of note, 
as depletion of LUBAC does not completely impair, but rather attenuates, canonical NF-kB 
signaling in response to pro-inflammatory cytokines, this indicates that LUBAC is dispensable 
for canonical NF-kB activation, but it operates to enforce and prolong the intensity of 
NF-kB activity. Finally, control over the balance between formation and degradation of 
linear chains is essential for proper signaling. Consistently, it has been reported that LUBAC 
is counteracted by the activity of specific DUBs, which interact with LUBAC, cleave linear 
polyubiquitin chains and consequentially prevent an excessive activation of NF-kB signaling. 
These include OTULIN278–281 (ovarian tumor DUB with linear linkage specificity /Gumby/
FAM105B) and CYLD282 (cylindromatosis). The roles of these proteins in the regulation of 
linear ubiquitination will not be discussed. 
Biological functions of LUBAC
Consistent with the fact that canonical NF-kB is crucial to a variety of biological processes, 
LUBAC has been implicated in the regulation of various cellular functions besides TNF-α 
response. Important data on the physiological role of LUBAC has been obtained from 
animal studies. With the exception of HOIP, whose deletion in mice is embryonic lethal283, 
ablation of the other two LUBAC components has been shown to cause several types of 
defects. Absence of SHARPIN activity is found in cpdm (chronic proliferative dermatitis 
in mice) mice, which lack SHARPIN due to germline mutations284. These animals develop 
a spontaneous inflammatory syndrome, which has been associated to reduced NF-kB 
activation and increased TNF-α-induced cell death. In addition to dermatitis, cpdm mice 
exhibit several abnormalities including defective organ development and various immuno-
deficiencies285,286. Unlike cpdm mice, ablation of HOIL does not result in apparent overt 
phenotypes268,285. However, cells derived from HOIL-deficient mice do not respond properly 
to NF-kB stimulation. In cpdm and HOIL-deficient mice, many cellular pathways implicated in 
innate and adaptive immunity have been identified to rely on the linear activity of LUBAC at 
various levels. Known examples include the TLR (Toll-like receptors)269,287, RLR (retinoic acid-
inducible gene (RIG)-I-like receptors)288,289 and NLR (nucleotide-binding oligomerization 
domain (NOD)-like receptors)290 pathways, which are known to modulate the response of 
monocytes and macrophages to microbial and viral infections. In adaptive immunity, LUBAC 
is indispensable for CD40 signaling, which is required for the activation of B-cells and the 
humoral immunological memory response268,269,285. Finally, LUBAC-mediated activation of 
NF-kB seems also to be involved in the response to genotoxic agents291, indicating that 
LUBAC may activate NF-kB to protect cells from DNA damage.
responsible for the phosphorylation and subsequent proteasomal degradation of IkBα. This event 
induces K-48 ubiquitination and subsequent proteasomal degradation of IkBα, which results in 
the translocation of NF-kB proteins to the nucleus to eventually promote gene transcription.
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LUBAC and human disease
In human disease, aberrant NF-kB signaling has been implicated in a plethora of 
inflammatory, infectious and autoimmune disorders such as rheumatoid arthritis, 
atherosclerosis, inﬂammatory bowel disease, systemic inﬂammatory response syndrome, 
diabetes, septic shock and psoriasis. Given its central role in NF-kB regulation, future 
studies are warranted to determine the relevance of LUBAC in the development of these 
pathologies. Constitutive activation of NF-kB signaling is found in leukemia227,228. Inherited 
mutations in either both HOIP and HOIL-1L have been identified in patients with a rare fatal 
disorder characterized by autoinflammation, infections and muscular amylopectinosis292. 
Two germ line polymorphisms in HOIP are frequently observed in patients with B cell-like 
(ABC) subtype of diffuse large B-cell lymphoma (DLBCL)293. These findings have provided 
evidence that aberrations affecting components of LUBAC can contribute to the etiology 
of a broad variety of disorders. Because of the specificity to uniquely generate linear chains 
and consequentially activate NF-kB signaling, LUBAC represents a very attractive target for 
the development of new therapies to fight cancer, inﬂammatory and autoimmune diseases. 
In this respect, it will be important to fully understand how LUBAC is regulated and how it 
governs the formation of linear chains.
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Figure 7. Involvement of ubiquitination in the canonical NF-kB pathway. In addition to 
the linear chains and K-48 linked polyubiquitin chains, ubiquitination is essential for early 
steps of NF-kB activation. The binding of TNF-α to its receptor induces the recruitment of the 
TNF receptor signaling complex (TNF-R1), which is composed of receptor interacting kinase 1 
(RIP1), TNF-R1 associated death domain (TRADD), TNF receptor-associated factor 2 (TRAF2), and 
the cellular inhibitors of apoptosis protein 1 and 2 (c-IAP1/2). The latter two initiate the NF-kB 
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signaling cascade by labeling RIP1 with K11- and K63-linked chains. These provide a platform for 
the recruitment of the adaptor complexes, such as TAK1 (TGFβ-activated kinase 1)-TAB1-TAB2/3 
complex, which are required for the phosphorylation of IKKβ. The activity of TRADD, c-IAPs and 
TRAF2 is also important for the recruitment of LUBAC at the receptor, where it mediates linear 
ubiquitination of NEMO, thus activating NF-kB transcription factors.
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Abstract
The gray platelet syndrome is a hereditary, usually autosomal recessive bleeding disorder 
caused by a deficiency of alpha granules in platelets. We detected a nonsense mutation in 
the gene encoding the transcription factor GFI1B (growth factor independent 1B) that causes 
autosomal dominant gray platelet syndrome. Both gray platelets and megakaryocytes had 
abnormal marker expression. In addition, the megakaryocytes had dysplastic features, and 
they were abnormally distributed in the bone marrow. The GFI1B mutant protein inhibited 
nonmutant GFI1B transcriptional activity in a dominant-negative manner. Our studies show 
that GFI1B, in addition to being causally related to the gray platelet syndrome, is key to 
megakaryocyte and platelet development.
Introduction
Platelets are formed through fragmentation of megakaryocytes that reside in the bone 
marrow1,2. Platelet alpha granules, which are by far the most abundant platelet organelles, 
store proteins that stimulate platelet adhesiveness, hemostasis, and wound healing3,4. 
The gray platelet syndrome is an inherited bleeding disorder characterized by defective 
production of alpha granules5,6. Patients with this syndrome have reduced numbers of 
larger-than-normal platelets, and on light microscopy these platelets have a typical gray 
appearance caused by the lack of alpha granules. For a final diagnosis, the lack of alpha 
granules must be confirmed by means of electron microscopy7. Clinically, patients 
with the gray platelet syndrome have bleeding tendencies with variable severity8. 
Additional features associated with this syndrome are bone marrow fibrosis and the 
capture of neutrophils within megakaryocytes in a process known as emperipolesis 
(the presence of an intact cell within the cytoplasm of another intact cell)6,8. It has been 
proposed that the alpha-granule deficiency in the gray platelet syndrome can be attributed 
to the failure of megakaryocytes to efficiently route endogenous proteins into alpha 
granules, thereby hampering the maturation of these granules9,10. Although the gray 
platelet syndrome is most often an autosomal recessive disease, families with an autosomal 
dominant inheritance pattern have been described as well6,11. Recently, biallelic NBEAL2 
missense mutations have been identified in an autosomal recessive form of the gray platelet 
syndrome12–14. NBEAL2 localizes to the dense tubular system in platelets12, but how NBEAL2 
mutations contribute to defective alpha-granule formation remains unknown. No genes 
have been implicated in autosomal dominant gray platelet syndrome. Here we report on 
the identification of a nonsense mutation in the transcription-factor gene, growth factor 
independent 1B (GFI1B), in a family with autosomal dominant gray platelet syndrome. 
GFI1B and its paralog GFI1 function as transcriptional repressors and play fundamental 
roles during hematopoiesis15–20. Both proteins contain a highly conserved C-terminal region 
that includes three zinc fingers that are necessary for interaction with DNA and an identical 
N-terminal region through which epigenetic modifiers required to inhibit transcription are 
recruited16,21–23. In addition, GFI1 and GFI1B interact directly with other transcription factors 
to coregulate gene expression during blood-cell development15. 
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Materials and Methods 
Study family
We studied a large family with an autosomal dominant form of thrombopathic 
thrombocytopenia characterized by mild-to-severe bleeding complications, a diagnosis 
originally described in 196824. The thrombopathic disorder in this family consisted of a low 
platelet count, an increased platelet size, and few alpha granules. An updated evaluation 
of affected family members according to the current disease classification allowed us to 
redefine the clinical diagnosis as the gray platelet syndrome (number 139090 in the Online 
Mendelian Inheritance in Man database). The study was approved by the institutional review 
board of Radboud University Medical Center. Written informed consent was obtained from 
all family members who underwent evaluation. 
Laboratory analyses
The bleeding score was calculated, and morphologic and immunohistochemical studies, 
electron microscopy, flow cytometry, GFI1B sequencing, and platelet-related analyses were 
performed according to standard procedures (see Supplementary Material and Methods). 
Measurements of plasma glycocalicin (Cusabio) and megakaryocyte colony-forming assays 
(StemCell Technologies) were performed according to the manufacturers’ instructions. 
Linkage analysis based on genomewide single-nucleotide polymorphism array with 
the use of Linkage 24 DNA Analysis BeadChips (Illumina), GFI1 and GFI1B gene-reporter 
assays, the method of retroviral transduction, and primary cell cultures are described in 
the Supplementary Information.
Results
Clinical findings and laboratory analyses
Morphologic analysis of blood smears from the six affected family members who 
were evaluated showed a ghostlike, gray appearance of enlarged platelets, in 
contrast to the normal platelets observed in the two unaffected family members 
(Figure 1A and Figure 1B). Electron-microscopic analysis confirmed a marked 
reduction in the number of alpha granules (Figure 1C, Figure 1D and Figure 
1E). Affected family members had moderate-to-severe bleeding tendencies 
(Table S1). In addition to reduced platelet counts, diminished platelet factor 
4 and β-thromboglobulin levels were observed in platelets obtained from 
the affected family members (Table S1).
Histopathological findings
Histopathological examination of a bone marrow biopsy specimen obtained from 
family member III.2 (Figure 2A) showed stage I myelofibrosis (Figure 1F) and cellular 
marrow with an increased number of megakaryocytes that were pleomorphic in 
size and shape (Figure 1G and Figure S1). Emperipolesis was frequently observed 
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Figure 1. Characteristics of autosomal dominant gray platelet syndrome. (A) May–Grünwald-
Giemsa staining showed normal platelets (arrows) obtained from unaffected family member II.4. 
(B) May–Grünwald-Giemsa staining showed large gray platelets (arrows) obtained from affected 
family member II.2. (C) Electron-microscopic analysis showed a normal platelet with numerous 
alpha granules (arrows) in a specimen obtained from unaffected family member II.4. (D-E) 
Electron-microscopic analysis shows gray platelets with few alpha granules, which are poorly 
developed (arrows), in a specimen obtained from family member III.2 (D), and no alpha granules 
in a specimen obtained from family member II.2 (E). (F-I) Abnormalities in a bone marrow–biopsy 
specimen obtained from affected family member III.2. Laguesse staining (F) revealed stage I bone 
marrow fibrosis, consisting of a focal network of fine, dark-staining reticulin fibers that extend from 
the sinuses. Hematoxylin and eosin staining (G) showed megakaryocytes that are both larger 
and smaller than normal, with shapes that deviate from the normal round form (arrows). Some 
nuclei are irregular and hyperchromatic. Periodic acid–Schiff staining (H) showed the capture of 
neutrophils (arrows) by megakaryocytes (emperipolesis). β3 integrin–CD61 staining (I) showed 
stretched megakaryocytes abnormally positioned in tandem along the sinuses (arrows).
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(Figure 1H and Figure S1). Megakaryocytes were clustered along bone marrow sinuses and 
had stretched features (Figure 1I and Figure S1).
Linkage and sequence analyses
To determine the disease-causing mutation, we first performed linkage analyses in 14 family 
members and identified a candidate locus on chromosome 9q34 with a maximum LOD score 
of 3.9 (Figure S2 and Figure S3). Within the linked region, we considered GFI1B to be an excellent 
candidate gene because it encodes a transcriptional repressor that has been implicated 
in megakaryopoiesis17–19. Sequence analysis detected a nonsense mutation in exon 6 
(c.859C→T, p.Gln287*) of GFI1B that completely cosegregated with the gray platelet 
syndrome (Figure 2A, Figure 2B, Figure S4 and Table S2). The mutation introduces a premature 
stop codon that is predicted to lead to the formation of a truncated protein (GFI1BTr) that 
lacks 44 carboxy-terminal amino acids (Figure 2B). Since premature stop codons can induce 
nonsense-mediated messenger RNA (mRNA) decay, we determined whether mutated GFI1B 
was expressed at the mRNA level. Sequencing of complementary DNA generated from 
CD34+ progenitor cells obtained from two affected family members showed that mutated 
and nonmutated GFI1B transcripts were expressed, indicating that the mutated transcript is 
not targeted for decay (Figure S4).
Molecular and functional characterization of mutant GFI1B
GFI1B functions as a transcriptional repressor. The truncating mutation is located within 
zinc finger 5, which is required for DNA binding. This zinc finger is 100% identical between 
humans and rodents (rats and mice), and it is identical to zinc finger 5 of the paralog GFI1 
(Figure 2B)20. Murine Gfi1 and Gfi1b bind the same DNA consensus sequence, and Gfi1 zinc 
finger 5 directly interacts with the major groove of the DNA core sequence AATC through 
four amino acids22. Because the truncated protein GFI1BTr lacks all these DNA-interacting 
amino acids (Figure 2B), we hypothesized that it would be unable to repress gene expression. 
To test this hypothesis, we introduced the truncating mutation in a GFI1B expression vector 
and performed transcriptional repression assays using the Gfi1 promoter as a validated 
Gfi1B target25. In line with the lack of an intact DNA-binding zinc finger, we observed that 
GFI1BTr did not repress the Gfi1 promoter, whereas the nonmutant GFI1 and GFI1B did 
(Figure 2C and Figure S5). When coexpressed, GFI1BTr inhibited repression mediated 
by nonmutant GFI1B, indicating that the mutant interferes with nonmutant GFI1B in 
a dominant-negative fashion (Figure 2C).
To validate that GFI1BTr adversely affects normal GFI1B, we expressed GFI1BTr in mouse 
bone marrow cells and then induced megakaryocytic differentiation. GFI1BTr-positive 
megakaryocytes had several dysplastic features, including hypolobulation of the nuclei, 
irregular contours, and multiple separated nuclei; these features were not observed in 
control cells (Figure 2D and Figure S6). These abnormalities are very similar to those observed 
in cells obtained from affected family members with the gray platelet syndrome (Figure 3E), 
indicating that expression of GFI1BTr is sufficient to cause megakaryocytic abnormalities and 
that it functions in a dominant-negative manner.
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Figure 2. GFI1B nonsense mutation in the gray platelet syndrome, inhibiting the function of 
nonmutant GFI1B. (A) The pedigree of the studied family with the gray platelet syndrome is shown. 
Squares denote male family members, circles female family members, solid symbols affected family 
members, open symbols unaffected family members, and slashes deceased family members. 
Mutation status is indicated below the number of each family member, with −/− indicating the absence 
and +/− the presence of the GFI1B c.859C→T, p.Gln287* mutation. (B) On top, human GFI1B (hGFI1B) 
contains an N-terminal Snail/Gfi-1 (SNAG) domain through which epigenetic modifiers are recruited. 
At the C-terminal, GFI1B contains six zinc fingers, of which three through five are essential for DNA 
binding. The GFI1B nonsense mutation (c.859C→T, p.Gln287*) is located in zinc finger 5 (arrow). 
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Cellular analyses
Studies involving Gfi1b knockout mice have shown that Gfi1b plays an important role in 
the development of several hematopoietic lineages15,17,19. In humans, GFI1B is required for 
in vitro differentiation of erythrocytic and megakaryocytic lineages18. We observed that 
megakaryocyte colony-forming cells were significantly more frequent in a bone marrow 
specimen from affected family members than in a specimen from a healthy person. In 
addition, the colonies from the affected family member were larger than those from a 
healthy control (Figure 3A and Figure S7); this is in line with the increased number of 
megakaryocytes in the biopsy specimen from affected family member III.2 (Figure 1I).
To determine whether GFI1BTr was associated with other hematopoietic abnormalities, 
we performed immunophenotypic analyses of peripheral-blood specimens obtained from 
eight family members and five healthy controls. Myeloid and erythroid lineages were 
unaffected (data not shown). The surface expression of characteristic platelet markers, such 
as β3 glycoprotein–CD36, αIIβ integrin–CD41, and β3 integrin–CD61, was also unperturbed 
in all tested persons. However, as compared with unaffected family members and healthy 
controls, five of six affected members had a marked decrease in the level of platelet surface-
membrane glycoprotein 1bα–CD42B within the αIIβ integrin–CD41 platelet compartment 
(Figure S8). In addition, strong expression of CD34, which is usually confined to immature 
hematopoietic progenitors, was detected on platelets from all affected family members in 
the study (Figure 3B).
Because platelets are derived from megakaryocytes1,2, we evaluated whether aberrant 
expression of surface molecules was also present on megakaryocytes. Immunostaining 
(with β3 integrin–CD61) of a bone marrow–biopsy specimen obtained from affected 
family member III.2 confirmed the presence of megakaryocytes that had high levels of 
CD34 expression (Figure 3C). Electron-microscopic analysis of the same biopsy specimens 
showed megakaryocytes with few alpha granules, which were small, irregularly shaped, 
and centrally located; the megakaryocytes were characterized by an extensive peripheral 
cytoplasm with irregular proplatelets, largely devoid of cell organelles (Figure 3D and Figure 
S9). Consistently, bone marrow smears obtained from the same patient (family member 
III.2) and her mother (family member II.2) showed dysplastic megakaryocytes that were 
pale, as a result of diminished alpha granules (Figure 3E). To determine whether these 
 The resulting truncated protein, GFI1BTr, lacks four DNA-interacting amino acids in zinc finger 5 
(bottom, arrows). GFI1B zinc finger 5 is identical to zinc finger 5 of human, rat, and mouse GFI1 
(h/r/mGFI1). (C) Expression of GFI1 and GFI1B in HEK293T cells resulted in 60 to 75% repression 
of the reporter construct; GFI1BTr did not repress the reporter. In cotransfection experiments, 
GFI1BTr inhibited the repression mediated by GFI1B. T bars represent standard errors. (D) May–
Grünwald-Giemsa staining showed abnormal megakaryocytes (right) characterized by dysplastic 
features, including hypolobulation of the nucleus and multiple separated nuclei. These abnormal 
megakaryocytes developed after retroviral expression of GFI1BTr in murine lineage c-kit–positive 
progenitor cells, followed by megakaryocytic differentiation. Megakaryocytes derived from 
control vector–transduced bone marrow cells (left) had normal morphologic features.
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abnormalities were intrinsic to the cell, we stimulated CD34+ cells obtained from affected 
family members II.2 and III.2 to differentiate along the megakaryocytic lineage in culture. 
Megakaryocytic cells had dysplastic features such as those observed in the bone marrow 
aspirates (Figure  3E). In addition, altered expression of CD34 and glycoprotein 1bα–CD42B 
was observed in megakaryocytic cells that were positive for αIIβ integrin–CD41 (Figure S10).
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Figure 3. GFI1BTr-associated platelet and megakaryocyte abnormalities. (A) αIIβ integrin–
CD41 staining showed the results of a megakaryocyte colony-forming assay of bone marrow cells 
from family member III.2, as compared with normal bone marrow cells from a healthy control. 
The cells from affected family member III.2 developed into more and bigger colonies. CFU 
denotes colony-forming units, and GPS the gray platelet syndrome. (B) Platelets obtained from 
affected family members II.2, II.3, II.6, II.8, II.10, and III.2, as compared with platelets obtained from 
unaffected family members II.4 and II.7 and healthy controls, had high levels of CD34 expression. 
MFI denotes mean fluorescence intensity. (C) CD34 staining of a bone marrow–biopsy specimen 
obtained from affected family member III.2 (left) showed a high level of CD34 expression on 
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affected megakaryocytes. β3 integrin–CD61 staining of a subsequent section from the same 
biopsy specimen (right) was performed to confirm that the megakaryocytes were CD34-positive. 
(D) An electron micrograph of a biopsy specimen obtained from family member III.2 showed 
a megakaryocyte containing a few poorly developed alpha granules (arrows). (E) May–Grünwald-
Giemsa staining showed a normal megakaryocyte (upper left) in a bone marrow aspirate 
obtained from a person without the gray platelet syndrome and megakaryocytes generated in 
an ex vivo culture (lower left), as compared  with examples of pale dysplastic megakaryocytes 
in a bone marrow aspirate obtained from family member III.2 (upper middle and right) and ex 
vivo–generated megakaryocytes from family member II.2 and family member III.2 (lower middle 
and right, respectively), which were characterized by nuclear hypolobulation and pale cytoplasm.
Discussion
The gray platelet syndrome is a hereditary bleeding disorder characterized by platelets 
that lack alpha granules5–10. Recently, mutations in NBEAL2 have been shown to cause an 
autosomal recessive form of the gray platelet syndrome12–14. We found that a mutation 
in GFI1B was causally related to autosomal dominant gray platelet syndrome. In addition 
to large gray platelets that are almost devoid of alpha granules, other phenomena 
associated with the gray platelet syndrome, such as thrombocytopenia, emperipolesis, mild 
myelofibrosis, and low expression of platelet factor 4, were observed in affected persons. 
However, we also found new features of the gray platelet syndrome such as megakaryocytes 
and platelets that were strongly positive for the stem-cell and progenitor-cell marker CD34, 
and had a diminished expression of glycoprotein 1bα–CD42B. Diminished glycoprotein 
1bα–CD42B platelet expression may contribute to the pathogenesis of the gray platelet 
syndrome, since glycoprotein 1bα–CD42B plays an important role in the initial adhesion of 
platelets to vascular subendothelium after injury. Low platelet expression of glycoprotein 
1bα–CD42B may be related to the large platelets observed in affected persons, since large 
platelets are present in the Bernard–Soulier syndrome, a bleeding disorder caused by GP1BA/
CD42B mutations. In addition, and possibly consequential to aberrant marker expression, 
we observed that megakaryocytes were abnormally distributed within the bone marrow, 
and they were frequently aligned in clusters along the sinuses in a stretched fashion. These 
features, in combination with the presence of morphologic and nuclear abnormalities in 
megakaryocytes, indicate that GFI1BTr affects the terminal maturation of megakaryocytes. 
GFI1B silencing and Gfi1b ablation studies have shown that the protein is fundamental 
to the development of several blood-cell lineages15,17–20. In the affected members of 
the family we studied, the presence of GFI1BTr was associated with major abnormalities only in 
the megakaryocytic lineage. The mutation in the gray platelet syndrome introduces a stop 
codon that results in a truncated GFI1B protein. The deleted region includes four amino acids 
that directly interact with DNA. Indeed, GFI1BTr expression did not inhibit gene expression, but 
it inhibited the function of nonmutant GFI1B. This indicates that the gray platelet syndrome 
may be caused not by GFI1B haploinsufficiency but rather by dominant-negative inhibition 
of the nonmutant protein. Indeed, forced GFI1BTr expression in normal bone marrow cells 
resulted in severely dysplastic megakaryocytes that were similar to those observed in affected 
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persons. These findings are consistent with mouse models showing that only complete Gfi1b 
ablation disturbs in vitro development of megakaryocytes, whereas the loss of a single Gfi1b 
allele is not sufficient to yield a clear phenotype17. GFI1BTr retains several corepressor and 
transcription factor–interacting domains and may act in a dominant-negative manner by 
quenching proteins that would normally cooperate with nonmutant GFI1B. The identification 
of GFI1B target genes that may be disturbed by GFI1BTr would provide relevant insight into 
the molecular pathways that are key for megakaryopoiesis and platelet production. In 
summary, our data indicate that GFI1B is a causative gene in autosomal dominant gray 
platelet syndrome. The truncated GFI1B mutant acts in a dominant-negative manner 
over the nonmutant protein and affects the normal development of megakaryocytes and 
platelets, reflecting the pivotal role of GFI1B in governing normal megakaryopoiesis and 
platelet production.
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Supplementary Information
Supplementary Materials and Methods
Genome wide linkage analysis and GFI1B sequencing
DNA was extracted using standard methods. Fourteen family members 
(Figure 2A,  Table S1) were genotyped using the Linkage-24 DNA Analysis BeadChip, containing 
6000 Single Nucleotide Polymorphisms (SNPs), according to the manufacturers’ guidelines 
(Illumina). The initial (fast) linkage analysis was carried out using Merlin version 1.1.2 (1) with 
SNP data from twelve family members (omitting cases II:11 and IV:3 because of the limitations 
of the Merlin program) (Figure S2)1. To use the full potential of the family and to reach 
the maximum lod score, linkage analysis was subsequently carried out using SIMWALK2 on 
a limited region from chromosome 9, from 103 to 140 kb, with the data from all genotyped 
family members (Figure S3)2. Since the SIMWALK2 algorithm is non-deterministic, 
the analysis was repeated six times. The mean and standard error of the maximal LOD scores 
from all six runs were calculated.
The coding exons and intron-exon borders of GFI1B were amplified using the primers 
listed in Table S2 and standard PCR conditions. PCR products were bidirectionally sequenced 
using the BigDye Terminator Cycle Sequencing kit (Applied Biosystems) and separated on 
an ABI 3130XL Genetic Analyzer (Applied Biosystems). Sequence numbering was based 
on Ensembl transcript ENST00000450530, with the A nucleotide of the start-codon ATG 
indicated as position +1.
Total RNA was isolated from bone marrow FACS-sorted CD34+ cells using RNA-Easy 
Mini-Kit  according to the manufacturer’s protocol (Qiagen). RNA was transcribed into cDNA 
using M-MLV reverse transcriptase according to manufacturer’s instructions (Invitrogen). 
cDNA was amplified using primers listed in Table S3. The same primers were used to 
bidirectionally sequence purified PCR products. 
GFI1B gene reporter assays
As readout for GFI1BTr transcriptional activity we performed a Dual Luciferase Reporter 
Assay (Promega)3. HEK293T cells were cultured in Dulbecco modified Eagle medium 
(DMEM; GIBCO) supplemented with 10% non-heat-inactivated fetal calf serum (GIBCO), 1% 
penicillin/streptomycin (MP Biomedical), 1% non-essential amino acids (GIBCO) and 1% 
L-glutamine (MP Biomedical). Cells were cultured in 24-well plates at 37˚C supplied with 5% 
CO2. For transient expression, in total 2 µg of DNA were used. Amounts of used pcDNA3.1-
GFI1-FLAG, pcDNA3.1-GFI1B-FLAG, pcDNA3.1-GFI1BTr-FLAG are indicated in Figure 2C. Empty 
vector pcDNA3.1 was used to compensate for differences in DNA amounts. In all experiments, 
800 ng of luciferase reporter construct (pGfi1-pGL34) and 200 ng of Renilla luciferase vector 
(pRL-TK) were used.  Transfections were performed at 60% cell confluency with Lipofectamine 
2000 (Invitrogen). Forty-eight hours after transfection, cells were washed with phosphate 
buffered saline (PBS) and lysed in 100 µl of passive lysis buffer (Promega) for 1 h. Luciferase 
assays were performed according to the protocol provided by the manufacturer (Promega). 
Luciferase signals were measured on a Lumat LB 9507 (EG&G Berthold). Luciferase activity 
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was normalized to renilla activity. Each condition was experimentally tested in triplicate. 
Western blot analysis was performed to confirm protein expression. Proteins of total lysates 
generated as described above were separated on 10% polyacrylamide gels and transferred 
onto polyvinylidenefluoride (PDVF) membranes (Bio-Rad). PVDF membranes were probed 
with anti-FLAG (Abcam) primary antibodies, followed by probing with HRP-conjugated 
secondary antibodies. Antibody signal was visualized by chemiluminescence using 
a Bio-Rad ChemiDox XRSþ.
Electron microscopy
Blood was collected in a tube with 3.8% sodium citrate and centrifugated at room 
temperature for 10 minutes at 1800 rpm. The plasma was removed and the buffy coat was 
fixed with 2% glutaraldehyde in phosphate buffer. After 4 hours fixation at 4˚C, the buffy coat 
was isolated and cut in small blocks and further fixed in the same fixative for at least 24 hours. 
The blocks were washed with phosphate buffer and fixed in 1% osmic acid in Pallade buffer 
containing 1% potassium ferrocyanide for 1 hour. A fresh bone marrow biopsy fragment 
was fixed in 2% glutaraldehyde in phosphate buffer for 24 hours at 4˚C. After fixation, the 
tissue was decalcified in 10% EDTA and 5% glutaraldehyde in phosphate buffer (pH 7.4). 
After six days, a X-Ray photograph was taken to check if the bone marrow decalcification was 
complete. The tissue was rinsed in phosphate buffer during 24 hours. Post fixation treatment 
was performed in 1% osmic acid in pallade buffer containing 1% potassium ferrocyanide 
for 1 hour. The samples were dehydrated in a graded series of ethanol and propylene 
oxide, followed by propylene with a decreasing concentration epon until pure epon resin 
embedding. Ultrathin sections were cut on a Leica Ultracut and stained with uranyl acetate 
and lead citrate. Examinations were made on a Jeol 1200 EX/II electron microscope at 60 kV.
Flow cytometry
For flow cytometry, expression of surface molecules on peripheral blood and ex vivo 
cultured cells was analyzed by staining with the following fluorochrome-conjugated 
antibodies: CD11b, CD13, CD34, CD41, CD42b, CD45, CD61, CD105, CD117, CD235a, HLA-DR 
(Beckman Coulter), CD15, CD16, CD36 (BD Biosciences) and CD71 (Dako). After staining, cells 
were analyzed using a Coulter FC500 flow cytometer (Beckman Coulter). Peripheral blood 
from healthy donors was used as control.
Microscopy
Images were obtained using a Leitz microscope DMRB (Leitz) with Leica DFC320 camera 
(Leica) and a Zeiss AxioImager M1 with a Zeiss Plan Apochromat 63 / 1,4 Oil objective 
(Zeiss, MGG staining only). 
Ex vivo generation of megakaryocytes
CD34+ cells were cultured for 1 day in Iscove’s Modified Dulbecco’s Medium (IMDM;GIBCO) 
supplemented with 10% human serum, recombinant human stem cell factor (100 ng/mL) and 
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recombinant human Flt3-ligand (100 ng/mL). Subsequently, megakaryocyte differentiation 
was induced by culturing cells in IMDM supplemented with 10% human serum, recombinant 
human stem cell factor (20 ng/mL, Immunotools) and recombinant human Thrombopoietin 
(20 ng/mL, Immunotools). The medium was refreshed every 4 days. At day 12, cells were 
harvested and analyzed.
Platelet factor 4 and β-thromboglobulin in platelets
Platelet factor 4 (PF4) and β-thromboglobulin (β-TG) levels were measured in theophilline, 
adenosine and dipyridamole (TAD) containing platelet rich citrated plasma. Theophilline, 
adenosine and dipyridamole were added to avoid any platelet activation. Additionally TAD 
containing citrated platelet poor plasma was obtained to correct for potential circulating 
PF4 and β-TG levels, either due to in vivo platelet activation or artificial phlebotomy. Platelet 
rich plasma was subjected to three cycles of freeze (-80˚C) and  thawing (37˚C). PF4 levels 
were measured with the Zymotest PF4-ELISA kit (Hyphen Biomed) and β-TG levels were 
analyzed using the Asserachrom β-TG ELISA kit (Diagnostica Stago). Both PF4 and β-TG levels 
were normalized for platelet count measured in platelet rich plasma.  Plasma of a healthy 
volunteer, treated similarly as described above, was used as control for both determinations.
CHAPTER 274
2
Supplementary Figures
Figure S1. Characteristics of autosomal dominant GPS. (A) HE staining of a bone 
marrow biopsy from patient III:2 showing pleomorphic megakaryocytes in size and shape 
(dysmorphic, a-c). Emperipolesis is also visible (c). (B) PAS staining of a bone marrow biopsy from 
patient III:2 showing dysmorphic and stretched megakaryocytes abnormally positioned in tandem 
along sinus (a,b). Emperipolesis is also visible (b). (C) PAS staining of a bone marrow biopsy from 
patient III:2 showing stretched megakaryocytes abnormally positioned in tandem along sinus 
(a,b). Emperipolesis (c) and hyperchromatic nuclei are also visible (b). (D-F) CD61 staining (brown) 
showing dysmorphic megakaryocytes abnormally positioned in tandem along sinuses. 
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Figure S2. Linkage analysis on family with autosomal dominant GPS. LOD scores on 
chromosomes 1 to 22  obtained using Merlin version 1.1.2  with SNP-array data from twelve 
family members.
CHAPTER 276
2
LO
D
 s
co
re
Position (cM)
 Figure S2. (continued)
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Figure S3. Linkage analysis on chromosome 9. LOD scores using SIMWALK2 on a limited region 
from chromosome 9 with the data from all genotyped family members. The analysis was repeated 
six times since the SIMWALK2 algorithm is non-deterministic. 
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DNA
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Figure S4. GFI1B mutation in autosomal dominant GPS. Representative GFI1B c.859C>T mutation 
in DNA (pink shading) and RNA (cDNA, arrow) obtained from affected family member II:2.
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Figure S5. Protein expression validation for GFI1B gene reporter assay. Western blot analysis 
confirming proper protein expression of GFI1 (upper intense band), GFI1B and GFI1BTr in 293T 
cells used for luciferase reporter assay. A GAPDH staining was performed to show equal loading.
 
Figure S6. Exogenous GFI1BTr expression results in abnormal megakaryocytes. 
Retroviral expression of GFI1BTr in murine Lin-kit+ progenitor cells followed by 
in vitro megakaryocytic differentiation resulted in abnormal megakaryocyte 
development characterized by a pale cytoplasmatic appearance and dysplastic 
features such as multiple separated nuclei. Magnification used is indicated below 
the pictures. When using Lin- cells similar results were observed (data not shown).
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Figure S7. GPS derived megakaryocyte colonies are larger compared to control colonies. 
Representative examples of megakaryocyte colonies showing that bone marrow cells from 
patient III:2 (GPS) develop into bigger colonies than bone marrow cells from a healthy individual. 
Magnification used is indicated below the pictures.
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Figure S8. Reduction of GP1BA/CD42B expression on GPS platelets. (A) Platelets from affected 
family members (II:2, II:3, II:6, II:8, II:10, III:2) have low GP1BA/CD42B expression. (B) GP1BA/CD42B 
may be cleaved resulting in the formation of glycocalicin in plasma. Extensive cleavage may result 
in low GP1BA/CD42B levels observed on affected platelets. Glycocalicin levels were not increased 
in plasma from affected individuals indicating that the low expression on platelets is not caused 
by increased cleavage of GP1BA/CD42B.
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Figure S9. GFI1BTr-associated megakaryocyte abnormalities (family member III:2). (A-B) 
GPS megakaryocytes with a cytoplasm largely devoid of α-granules, that showed a very irregular 
disintegration of the cytoplasm into large irregular proplatelets (cytoplasmic extensions that will 
detach to form platelets). Also the proplatelets lack alpha granules. (C-D) GPS megakaryocytes 
with a central perinuclear cytoplasmic area with few alpha granules, surrounded by an extensive 
system of membranes (demarcation membrane), believed to mark the future platelets. 
The surrounding cytoplasm is abnormally wide and lacking cell organelles as α-granules and 
mitochondria. (E) Additional example of megakaryocyte with a diminished number of α-granules.
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Figure S10. Reduction of GP1BA/CD42B expression and CD34 expression in GPS cultured 
cells. FACS analysis showing high CD34 and low GP1BA/CD42B expression in cultured 
megakaryocytes from patients II:2 and III:2 (green and red, respectively) compared to a healthy 
control (blue).
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Supplementary Tables
Table S1: Hematological and genetic data of analyzed family members
Family 
member
GFI1B 
Mutational 
status Sex
Platelet 
count 
(109/L) 
(150-450)
PF4 in 108 
platelets (µg) 
(0.7-1.5)
BTG in 106 
platelets (IU) 
(18.6-47.1)
Bleeding 
score (F<5)
(M<3)
II:4 wt F 275 1.3 42.4 2
II:7 wt M 254 1.3 41.5 0
II:2 mut F 85 0.2 10.6 19
II:3 mut M 49 0.3 12.9 10
II:6 mut M 42 0.4 19.3 25
II:8 mut M 56 0.4 17.2 7
II:10 mut M 116 0.2 9.8 12
III:2 mut F 80 0.3 10.2 11
wt = wild type, mut = mutated, PF4 = Platelet factor 4, BTG = β-Thromboglobulin. 
Reference values are indicated between brackets in italics. Bleeding scores were determined as 
described elsewhere5.
Table S2: GFI1B PCR and sequencing primers (DNA)
Forward primer Reverse primer
Exon 2 ATTCACAGGTTCTGGGTGGA CTTTCATCTGCAACCCACAG
Exon 3 CAGTCTAGGGCTGGAGTTGG CAAGCAGAAGCCACAGAGC
Exon 4 GTTGGTCCGCCTGGTCTT CCCAACATTCACAGCACAGA
Exon 5 TCCCCTCTCTCACATCCAAC ACCCCTCCCAATCTGTGTC
Exon 6 AGACTCCAAGCCCCAGTTTC GCAGTGGCCTTTGACTTTGT
Exon 7 ATCCAGTAGGGGTGGAGGAG CTCCCTGGGGGTATTCTAGC
Exons were determined from transcript ENST00000450530.
Table S3: GFI1B sequencing primers (cDNA)
Primers
Forward ccacctgctcatccactcaga
Reverse ctttggtgcacagctcacag
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DNA methyltransferases (DNMTs) are epigenetic regulators targeted to the treatment of 
hematological malignancies1–4. Mutations in the DNA methyltransferase DNMT3A and high 
expression of its paralogue DNMT3B have been associated with inferior outcome in acute 
myeloid leukemia (AML) and other hematological malignancies5–8. Using a publicly available 
gene expression data set9, we studied whether DNMT3B expression correlates with outcome 
in genetically well-defined AML subgroups. We first validated the expression data from 
the microarray by quantitative PCR, using 39 patient samples (Figure S1A). DNMT3B 
micro-array analyses showed that the expression was not normally distributed among 
AML patients; in the quartile with highest expression, a larger variation in expression was 
observed compared to the three quartiles with relatively lower expression (Figure S1B). 
The median DNMT3B expression in AML samples was significantly lower compared with that 
observed in normal bone marrow (NBM)-derived CD34+ cells (P<0.0001), while it was higher 
compared to NBM cells, but the latter difference was not statistically significant (Figure S1B). 
Subsequently, we investigated the correlation between DNMT3B expression and overall 
survival (OS) and event-free survival (EFS). In univariate Cox regression analyses, continuous 
DNMT3B expression was significantly associated with poor survival (P<0.001 for both 
OS and EFS, data not shown). To visualize the prognostic impact, we performed Kaplan–
Meier analyses on the four quartiles based on expression levels. The quartile including the 
patients with the highest DNMT3B expression, exhibiting the largest variation in expression, 
showed a significantly reduced OS and EFS compared to the other quartiles (Figure S2). 
As the survival between the lower three quartiles did not differ significantly, we grouped 
these patients together as having lower DNMT3B expression, whereas the remaining 
patients were ranked as having higher DNMT3B expression. Using these criteria, the 5-year 
OS and EFS were 17.2%±3.3% and 13.6%±3.0% for patients with higher DNMT3B expression 
compared to 43.8%±2.5% and 34.4%±2.4% for patients with lower DNMT3B levels 
(P<0.001, Figure 1A). We next performed a multivariate Cox regression analysis including 
known prognostic factors (including age >60 years; white blood cell counts >100 × 
109/l; transplantation status; karyotypes t(8;21), t(15;17) and inv(16); nucleophosmin 1 
(NPM1), FLT3-ITD, DNMT3A and double CEBPA mutations, and ecotropic viral integration 
site 1 (EVI1) overexpression), which revealed that higher DNMT3B expression carried 
an independent prognostic risk for both OS and EFS (hazard ratio (HR): 1.768, 95% 
confidence interval (CI): 1.384–2.260; P<0.001 and HR: 1.706, 95% CI: 1.342–2.168; 
P<0.001, respectively, Table 1), in line with a recently published study7. In fact, higher 
DNMT3B expression showed a higher hazard ratio for OS than that of well-known adverse 
prognostic factors such as internal tandem duplications of the fms-related tyrosine kinase 
3 (FLT3-ITD, HR: 1.675, 95% CI: 1.287–2.179; P<0.001) and overexpression of the EVI1 
gene (HR: 1.430, 95% CI: 0.999–2.047; P=0.051).
We then studied the association of higher DNMT3B expression with specific AML 
subcategories. Higher DNMT3B expression was under-represented in FAB-M4 and mutually 
exclusive with the favorable karyotypes t(8;21) and inv(16), as shown in Table S1. In contrast, 
higher DNMT3B expression was over-represented in the FAB-M1 subcategory (Table S1), and 
predicted poor OS and a trend toward poor EFS in this group (data not shown). A significant 
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Figure1. Higher DNMT3B expression correlates with inferior OS and EFS in AML. 
(A) Kaplan-Meier plots for OS and EFS showing that higher DNMT3B expression correlated 
significantly with a poor OS and EFS among AML patients (5-year OS of 17.2% ± 3.3% vs 43.8% ± 
2.5% and 5-year EFS of 13.6% ± 3.0% vs 34.4% ± 2.4% for patients with higher and lower DNMT3B 
expression, respectively). (B) Higher DNMT3B expression predicted a very poor OS and EFS among 
patients with normal karyotype carrying NPM1 and FLT3-ITD mutations compared to patients 
with lower DNMT3B expression (5-year OS; 16.7 ± 6.2% vs 47.6 ± 8.8%, P = 0.001 and 5-year 
EFS: 16.7± 6.2% vs 39.0 ± 8.6%, P = 0.005 for patients with higher and lower DNMT3B expression, 
respectively). (C) Within the group of patients with normal karyotype that carry NPM1 mutations with 
high FLT3-ITD allelic burden, higher DNMT3B expression correlated with an extremely poor OS and 
EFS compared to patients with lower DNMT3B expression (5-year OS: 0% ± 0.0% vs 38.9% ± 12.9%, 
P < 0.001 and 5-year EFS: 0% ± 0.0% vs 32.0% ± 12.4%, P < 0.001 for patients with higher and lower 
DNMT3B expression, respectively). P values were determined with the log-rank test. In agreement 
with Jonge et al.13, high FLT3-ITD allelic burden was defined as an allelic FLT3-ITD/FLT3 ratio 
higher than 1.
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association between higher DNMT3B expression and EVI1 overexpression and IDH2 
mutations was also observed (Table S1), but not with IDH1 mutations. DNMT3B expression 
did not predict clinical outcome in these subgroups (data not shown). We also observed 
that higher DNMT3B expression was associated with a normal karyotype (NK, P=0.017), 
and strongly associated with mutations in NPM1 (NPM1+, P<0.001) and FLT3-ITD (FLT3-ITD+, 
P<0.001, Table S1). Patients with NK can be classified based on NPM1 and FLT3-ITD mutational 
status. NPM1 mutations, particularly in the absence of FLT3-ITD, display a favorable disease 
outcome, whereas the presence of a FLT3-ITD mutation is generally considered as an adverse 
prognostic factor10. Remarkably, among patients with NK, higher DNMT3B expression did 
not significantly associate with NPM1−/FLT3-ITD− status and was under-represented in 
the NPM1+/FLT3-ITD− and NPM1−/FLT3-ITD+ groups, but was significantly over-represented in 
the NPM1+/FLT3-ITD+ group (Table S2). Within the latter group, patients with higher DNMT3B 
expression showed a significantly worse outcome than patients with lower DNMT3B 
expression (Figure 1B). The 5-year OS and EFS of patients with higher DNMT3B expression 
were 16.7%±6.2% (P=0.001) and 16.7%±6.2% (P=0.005) compared to 47.6%±8.8% and 
39.0%±8.6% in patients with lower DNMT3B expression. The survival of patients with 
co-occurring NPM1 and FLT3-ITD mutations is negatively influenced by high FLT3-ITD allelic 
burden11–13. Higher DNMT3B expression was observed in both patients with low and those 
with high FLT3-ITD allelic burden (Table S2). We next analyzed whether DNMT3B expression 
had an effect on survival among these subgroups. Higher DNMT3B expression did not 
exhibit a significant effect on OS and EFS among patients with low FLT3-ITD allelic burden 
(data not shown). However, patients with higher DNMT3B expression showed an extremely 
poor OS and EFS (5-year OS: 0.0%±0.0%, 5-year EFS: 0.0%±0.0%, P<0.001), compared to 
patients with lower DNMT3B expression (5-year OS: 38.9%±12.9%, 5-year EFS: 32.0%±12.4%) 
within the subgroup with high FLT3-ITD allelic burden (Figure 1C). In multivariate analysis, 
higher DNMT3B expression showed an independent prognostic value for OS and EFS, with 
a high hazard ratio both in the NPM1+/FLT3-ITD+ subgroup (HR: 4.850, 95% CI: 1.980–11.880) 
and among those patients with high FLT3-ITD allelic burden, indicating that the latter 
subgroup can be separated into two groups, one with an intermediate and the other with an 
extremely poor survival, based on DNMT3B expression (Table 1).
In conclusion, these data show that higher DNMT3B expression is a strong independent 
predictive factor for poor disease outcome in AML in general, and especially among NPM1+/
FLT3-ITD+ patients with normal karyotype. Drugs that inhibit DNA methylation are tested 
for clinical efficacy in AML1–4. Because DNMT3B catalyzes DNA methylation, its expression 
level may affect the therapeutic sensitivity to these drugs. Thus, it will be interesting to 
investigate whether DNMT3B expression predicts therapy responses to treatments affecting 
DNA methylation.
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Table 1. DNMT3B expression is a prognostic factor in AML, particularly among NPM1+/ FLT3-ITD+ 
with normal karyotype
OS EFS
HR (95%Cl) P HR (95%Cl) P
AML
Higher DNMT3B exp. 1.768 (1.384-2.260) <0.001 1.706 (1.342-2.168) <0.001
Age > 60 y 1.523 (1.111-2.087) 0.009 1.339 (0.985-1.821) 0.063
WBC count > 100*109/L 1.448 (1.098-1.909) 0.009 1.531 (1.173-1.997) 0.002
FLT3-ITD mutations 1.675 (1.287-2.179) <0.001 1.649 (1.274-2.136) <0.001
NPM1 mutations 0.397 (0.291-0.541) <0.001 0.381 (0.280-0.518) <0.001
Favorable karyotype 0.388 (0.266-0.565) <0.001 0.457 (0.323-0.646) <0.001
CEBPA double mutation 0.338 (0.177-0.645) 0.001 0.361 (0.199-0.653) 0.001
DNMT3A mutations 1.631 (1.204-2.210) 0.002 1.531 (1.136-2.063) 0.005
EVI1 overexpression  1.430 (0.999-2.047) 0.051 1.711 (1.208-2.423) 0.002
Transplantation status  0.700 (0.610-0.806) <0.001 0.758 (0.665-0.865) <0.001
Normal karyotype
NPM1+/ FLT3-ITD+ 
Higher DNMT3B exp. 3.090 (1.623-5.883) 0.001 2.414 (1.309-4.451) 0.005
Age > 60 y 2.703 (1.134-6.438) 0.025 1.951 (0.831-4.583 0.125
WBC count > 100*109/L 2.365 (1.270-4.404) 0.007 1.763 (0.958-3.246) 0.069
High FLT3-ITD A.B. 3.791 (1.971-7.294) <0.001 3.130 (1.685-5.813) <0.001
NPM1+/ FLT3-ITD+ 
with high FLT3-ITD A.B.
Higher DNMT3B exp. 4.850 (1.980-11.880) 0.001 4.428 (1.824-10.749) 0.001
Age > 60 y 2.007 (0.660-6.101) 0.219 1.478 (0.489-4.464) 0.489
WBC count > 100*109/L 1.356 (0.634-2.901) 0.433 0.954 (0.446-2.043) 0.904
Multivariate Cox regression model for probability of Overall Survival (OS) and Event Free 
Survival (EFS). Favorable karyotype include: inv(16), t(8;21) and t(15;17). Transplantation status 
includes either no transplantation, autologous transplantation, or allogeneic transplantation. 
Age, WBC-count are dichotomized. DNMT3B expression is dichotomized in multivariate analysis. 
P-values (bold) indicate whether differences are significant at the level of 0.05. HR=hazard ratio. 
95%CI: 95% confidence interval. WBC = white blood cell. A.B. = allelic burden.
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Supplementary Information
Supplementary Materials and Methods
For the present study, a database from previously published cohort of 525 AML patient 
samples, 11 CD34+ donor samples, and 5 normal bone marrow (NBM) control samples was 
used. Details on clinical data and experimental procedures of the microarray profiling on 
the Affymetrix HG-U133 plus 2.0 arrays can be found elsewhere1. The array data are accessible 
online at the Gene Expression Omnibus (GSE14468).  DNMT3B expression was determined 
using the probe 220668_s_at. This probe-set targets all the functional DNMT3B isoforms 1, 
2, 6 (ENST00000353855, ENST00000328111, ENST00000201963), the truncated DNMT3B 
isoform 3 (ENST00000348286) and the coding DNMT3B isoform 201 (ENST00000344505). 
DNMT3B expression was validated by q-PCR on cDNA samples from 39 patients using 
a commercially available primer/probe set (Applied Biosystems, probe Hs00171876_m1), 
and data were normalized to β-ACTIN gene expression levels. Data regarding FLT3-ITD allelic 
burden were described elsewhere2. SPSS version 20.0 software (SPSS inc, Chicago, IL) was 
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used for statistical analyses. Clinical and molecular characteristics were compared using 
the Pearson’s chi-squared test. Survival curves were calculated by the Kaplan-Meier method 
and compared using the log-rank test. Univariate and multivariate survival analyses were 
carried out using the Cox proportional hazards model; covariates included in the analyses 
are indicated in the corresponding tables. We considered P<0.05 as statistically significant.
Supplementary Figures
A B
Figure S1. DNMT3B expression in AML. (A) DNMT3B expression from microarray data was 
validated by q-PCR. DNMT3B expression measured through the HGU133 plus2.0 array was 
compared with q-PCR data of the same samples using β-ACTIN expression for normalization. Data 
were represented as the ΔCt of DNMT3B and β-ACTIN (2ΔCt). Included for analysis were 20 samples 
with higher DNMT3B expression and 19 samples with lower DNMT3B expression according to 
the array data. Correlation was found using the Spearmann’s test (P < 0.001). (B) Whisker-box plots 
showing micro-array based DNMT3B expression distribution among AML patients in comparison 
with CD34+ and normal bone marrow (NBM) cells. Each box represents a quartile of the AML 
cohort based on DNMT3B expression. 
A B
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Figure S2. High DNMT3B expression correlates with inferior OS and EFS in AML. (A-B) Kaplan-
Meier plots for OS (A)  and EFS (B)  showed that patients included in the higher quartile of DNMT3B 
expression (5-year OS: 17.2 ± 3.3 % and 5-year EFS: 13.6 ± 3.0%) exhibited a significantly poor OS 
and EFS when compared to patients classified within the lower (5-year OS: 51.5 ± 4.4 and 5-year 
EFS:39.1 ± 4.3%),  lower intermediate  (5-year OS: 38.0 ± 4.3% and 5-year EFS: 32.6 ± 4.2%) and 
higher intermediate (5-year OS: 41.8 ± 4.4% and 5-year EFS: 31.6 ± 4.1%) quartiles. P values were 
determined with the log-rank test. Survival data were available for 518 patients. The number of 
patients included in each group is shown in brackets.
Supplementary Tables
Table S1. Characteristics of patients with lower and higher DNMT3B expression
Lower DNMT3B 
expression
Higher DNMT3B 
expression P
Sex (N=518), no. (%) 0.289†
Female 191 (49.4) 69 (52.7)
Male 196 (50.6) 62 (47.3)
Age (N=518), no. (%) 0.482†
    < 60 y 331 (85.5) 113 (86.3)
    > 60 y 56 (14.5) 18 (13.7)
WBC x 109/L (N=516), no. (%) 0.227†
 < 100 316 (82.1) 103 (78.6)
 > 100 69 (17.9) 28 (21.4)
Transplantation status (N=504), no. (%) 0.886‡
No transplantation 219 (58.7) 80 (61.1)
Autologous transplantation 53 (14.2) 17 (13.0)
Allogeneic transplantation 101 (27.1) 34 (26.0)
FAB classification (N=525), no. (%)
M0 12 (3.1) 6 (4.5) 0.285†
M1 57 (14.5) 43 (32.6) <0.001†
M2 94 (23.9) 37 (28.0) 0.203†
M3 19 (4.8) 4 (3.0) 0.272†
M4 78 (19.8) 15 (11.4) 0.016†
M5 94 (23.9) 22 (16.7) 0.051†
M6 6 (1.5) 1 (0.8) 0.440†
Other/Unknown 33 (8.4) 4 (3.0) 0.023†
Cytogenetics, no. (%)
t(15;17) (N=522) 22 (5.6) 3 (2.3) 0.086†
t(8;21) (N=522) 38 (9.7) 0 (0.0) <0.001†
inv(16) (N=522) 42 (10.8) 0 (0.0) <0.001†
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Table S1. (continued)
Lower DNMT3B 
expression
Higher DNMT3B 
expression P
Normal (N=525) 153 (38.9) 66 (50.0) 0.017†
11q23 (N=513) 21 (5.4) 6 (4.8) 0.490†
Complex (N=525) 14 (3.6) 10 (7.6) 0.052†
Other genetic aberrations, no. (%)
NPM1 mutations (N=525) 101 (25.7) 57 (43.2) <0.001†
FLT3-ITD mutations (N=525) 91 (23.2) 52 (39.4) <0.001†
FLT3-TKD mutations (N=523) 43 (11.0) 10 (7.6) 0.177†
CEBPA single mutations (N=525) 8 (2.0) 4 (3.0) 0.355†
CEBPA double mutations (N=525) 20 (5.1) 6 (4.5) 0.507†
IDH1 mutations (N=522) 31 (7.9) 7 (5.3) 0.210†
IDH2 mutations (N=522) 31 (7.9) 18 (13.6) 0.042†
DNMT3A mutations (N=512) 78 (20.5) 34 (26.0) 0.118†
EVI1 overexpression (N=518) 33 (8.5) 19 (14.5) 0.039†
WBC indicates white blood cell count; and FAB, French-American-British. P-values (bold) indicate 
whether differences are significant at the level of 0.05.
†P values are based on Fisher exact tests.
‡P values are based on Pearson Chi-Square.
Table S2. Characteristic of patients with normal karyotype (n=219)
Lower DNMT3B 
expression
Higher DNMT3B 
expression P
Normal karyotype patients, n. (%) 153 (69.9) 66 (30.1) <0.001‡
NPM1- / FLT3-ITD- 51 (33.3) 19 (28.8) 0.309†
NPM1+ / FLT3-ITD- 47 (30.7) 8 (12.1) 0.002†
NPM1- / FLT3-ITD+ 22 (14.4) 3 (4.5) 0.025†
NPM1+ / FLT3-ITD+ 33 (21.6) 36 (54.5) <0.001†
NPM1+ / FLT3-ITD+ patients, n. (%) 0.144†
without high FLT3-ITD A.B. 18 (54.5) 14 (38.9)
with high FLT3-ITD A.B. 15 (45.5) 22 (61.1)
A.B. indicates allelic burden. P-values (bold) indicate whether differences are significant at 
the level of 0.05. In line with de Jonge et al.2, high FLT3-ITD allelic burden was defined as an allelic 
FLT3-ITD/FLT3 ratio higher than 1.
†P values are based on Fisher exact tests.
‡P values are based on Pearson Chi-Square.
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Improved classification of MLL-AF9-positive AML patients based on BRE and EVI1 expression
Letter to the editor:
The 5-year overall survival (OS) rate of patients with acute myeloid leukemia (AML) 
containing an MLL-AF9 fusion gene is approximately 40%1,2. We recently showed in 2 
independent cohorts that the prognosis among MLL-AF9 positive patients can be refined 
based on BRE mRNA expression3. MLL-AF9 positive patients with outlier high BRE expression 
exhibited a superior outcome (5-year OS of 80% and 64% for the 2 cohorts, respectively) 
while patients with normal BRE expression exhibited a very poor outcome (5-year OS of 0% 
and 7%, respectively). Thus, BRE expression may be used for refined risk stratification among 
MLL-AF9 positive cases. However, the identification of patients with high BRE expression 
with routinely available techniques such as qPCR is difficult as the fold-difference between 
normal and high BRE expression is small3. 
High EVI1 expression occurs in approximately 10% of AML cases and is associated 
with an inferior outcome. High EVI1 expression has recently been associated with MLL 
rearrangements including MLL-AF94–6. To determine the correlation between BRE and 
EVI1 expression, we reanalyzed the 2 MLL-AF9 cohorts for which we reported high BRE 
expression3,7,8. This showed that high BRE and high EVI1 expression are mutually exclusive 
(Figure 1A). Hence, the poor prognosis of the patients lacking high BRE expression could be 
explained by EVI1 expression (Figure 1B). Of note, in both MLL-AF9 cohorts we identified a 
few cases without high BRE or EVI1 expression (Figure 1A). As the number of these patients is 
low, additional studies are required to reliably determine their prognosis.
To study whether the mutually exclusive expression of BRE and EVI1 is accompanied by 
distinct expression profiles, we performed unsupervised genome-wide cluster analysis. The 
results showed that among MLL-AF9 patients, high BRE expressing patients clustered apart 
from EVI1-positive patients (Figure 1C). Although the EVI1-positive patients were separated 
from the BRE-positive patients, they did not share highly similar expression profiles, while 
BRE-positive patients did. Indeed, in an unsupervised cluster analysis of the total AML 
cohort, MLL-AF9 positive patients with high EVI1 expression clustered only partially, showing 
modest similarities in expression profiles (Figure 2). This was in contrast to patients with 
high BRE expression that were almost completely confined to one distinct AML cluster, 
as described before3. Thus, MLL-AF9 positive patients with high BRE expression seem to 
represent a specific AML subclass with highly similar expression profiles, while the MLL-AF9 
positive patients with high EVI1 expression do not.
In our previous study, 40% of the MLL-AF9 positive cases were missed by routine 
cytogenetics3. In addition, MLL-AF9 positive cases with high EVI1 expression lack 
chromosomal rearrangements encompassing the EVI1 locus on chromosome 34,5. Therefore, 
risk stratification of these patients could be improved by molecular screening for MLL-AF9–
positivity and EVI1 overexpression, in addition to routine cytogenetics.
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Figure 1. High BRE and high EVI1 expression are mutually exclusive in MLL-AF9 leukemia. 
(A) BRE expression was plotted against EVI1 expression for MLL-AF9 positive cases in 2 separate 
MLL-AF9 cohorts. In the first cohort (left plot), 33% (6/18) of the samples showed high EVI1 expression, 
and 55.6% (10/18) showed high BRE expression. In the second cohort (right plot), 27.3% of 
the samples showed high EVI1 expression (3/11), and 54.5% showed high BRE expression (6/11). 
Both cohorts contained 2 patients with neither high BRE nor high EVI1 expression. High BRE 
expression was defined as described before. High EVI1 expression was defined as the expression 
of the upper 10% of the total cohort. P values for negative correlations were calculated using 
Spearman correlation tests. (B) Kaplan-Meier plots showed that patients with high BRE expression 
had significantly better overall survival than patients with high EVI1 expression among MLL-AF9 
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positive cases. P-values were determined with the log-rank test. The number of patients 
included in the analyses is shown in brackets. (C) EVI1-positive patients cluster apart from high 
BRE expressing patients among MLL-AF9 positive patients in unsupervised clustering analysis. 
However, EVI1-positive patients show less similar expression profiles among each other compared 
with high BRE expressing patients (indicated by faint red color compared with bright red color, 
respectively). Unsupervised clustering was performed on the first cohort as described elsewhere 
and clustering is represented as pairwise correlations between samples with a gradient from red 
to blue indicating degree of correlation (bright red: high correlation, blue: poor correlation). Black 
bars represent relative BRE (212645_x_at) and EVI1 (221884_at) expression, as indicated. 
AML cohort 1
1 2 3 4
1. MLL-AF9 status
2. 11q23 status
3. BRE expression
4. EVI1 expression
Figure 2. Unsupervised clustering of 525 AML patients. Unsupervised cluster analysis of 
the first AML cohort shows that MLL-AF9 patients with high BRE expression cluster together 
almost completely, in contrast to EVI1-positive MLL-AF9 patients that show partial clustering. 
This graph was adapted from a previously published figure (Noordermeer et al.3), by including 
EVI1 expression (221884_at). MLL-AF9 and 11q23 status (red: positive, green: negative) and 
relative BRE and EVI1 expression are indicated along the pairwise correlation graph by 
the numbers 1-4, respectively.
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Abstract
Activation of the NF-kB pathway requires the formation of Met1-linked ‘linear’ ubiquitin 
chains on NEMO, which is catalysed by the Linear Ubiquitin Chain Assembly Complex 
(LUBAC) E3 consisting of HOIP, HOIL-1L and Sharpin. Here, we show that both LUBAC catalytic 
activity and LUBAC specificity for linear ubiquitin chain formation are embedded within 
the RING-IBR-RING (RBR) ubiquitin ligase subunit HOIP. Linear ubiquitin chain formation by 
HOIP proceeds via a two-step mechanism involving both RING and HECT E3-type activities. 
RING1-IBR catalyses the transfer of ubiquitin from the E2 onto RING2, to transiently form 
a HECT-like covalent thioester intermediate. Next, the ubiquitin is transferred from HOIP 
onto the N-terminus of a target ubiquitin. This transfer is facilitated by a unique region 
in the C-terminus of HOIP that we termed ‘Linear ubiquitin chain Determining Domain’ 
(LDD), which may coordinate the acceptor ubiquitin. Consistent with this mechanism, 
the RING2-LDD region was found to be important for NF-kB activation in cellular assays. 
These data show how HOIP combines a general RBR ubiquitin ligase mechanism with unique, 
LDD-dependent specificity for producing linear ubiquitin chains.
Introduction
Ubiquitin conjugation is a highly versatile system for conferring post-translational 
modifications, since this 76-amino acid protein can make a variety of chains that signal to 
different downstream effectors. The ubiquitins in these chains are usually linked between 
the ubiquitin C-terminus of the donor ubiquitin and any of the seven lysines in the acceptor 
ubiquitin, but the donor ubiquitin can also link to the amino group in the N-terminal 
methionine of the acceptor ubiquitin, leading to the formation of linear ubiquitin chains. 
Linear ubiquitin chains are assembled by the Linear Ubiquitin Chain Assembly Complex 
(LUBAC), which plays a critical role in the activation of the NF-kB pathway that is involved 
in various functions, including cell survival and inflammation. NF-kB activation can be 
induced by e.g. cytokines or DNA-damage, which lead to LUBAC-mediated ubiquitination 
of NEMO with linear ubiquitin chains1,2. This linear ubiquitination of NEMO causes IKKβ 
phosphorylation and activation. Subsequently, IκBα is degraded and free NF-kB translocates 
to the nucleus to activate the transcription of target genes2–5. The LUBAC complex consists 
of at least three different proteins, HOIP (RNF31), HOIL-1L (RBCK1) and Sharpin5–8. HOIP and 
HOIL-1L belong to the RING-in-between-RING (RBR) class of E3-ligases. However, only the RBR 
domain of HOIP and not HOIL-1L is required for linear ubiquitin chain formation by LUBAC 
and subsequent IKKβ phosphorylation5,9. Nevertheless, a combination of HOIP with either 
HOIL-1L or Sharpin is the minimal requirement for linear ubiquitin chain catalysis5,6. The RBR 
class of E3-ligases, also known as the TRIAD class (two RING fingers and DRIL (double RING 
linked)), was first described in 199910,11. The structures of the separate RING domains and the 
in-between RING (IBR) have been solved (PDB entry 1WIM)12,13, however it remains unclear 
how the RBR forms a functional unit. RING1 has a classical RING fold, which is typically used 
for E2-E3 interactions14,15. Also RING2 interacts with different E2s in yeast-two-hybrid studies 
and the cysteine and histidine distribution of RING2 suggests that it forms a RING domain16–19. 
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However, even though Zn2+ stochiometry analysis indicates that all RING domains in Parkin 
coordinate two zinc ions19, the solution structure of HHARI RING2 does not have a classical 
RING fold and coordinates only one zinc ion per monomer. Furthermore, the HHARI RING2 
domain was recently shown to form a thioester adduct with ubiquitin (HHARI~ubiquitin) 
on a free cysteine as an intermediate step in the ubiquitin transfer20, similar to that found in 
HECT domains. Although the thioester adduct could not be visualized on the RBR protein 
Parkin in the same study, mechanistic analysis indicated that both RBR proteins include 
a HECT-like step in the ubiquitin transfer. An intact RBR domain is necessary for efficient 
E3-ligase functioning, however Parkin IBR-RING2 can mediate the formation of ubiquitin 
linkages in the absence of RING121,22. In addition to the interaction of both RING domains 
with E2 enzymes, the RBR of Parkin also interacts non-covalently with ubiquitin during chain 
formation23. The specificity for ubiquitin chain types is regulated completely at the level of 
the E3-ligase in HECT domains24,25. In contrast, with RING domain E3-ligases the E2 enzymes 
contribute to the chain types that are formed. Some E2s directly mediate the formation of 
specific ubiquitin chains via the non-covalent binding of an acceptor ubiquitin, positioning 
a particular lysine residue to attack the thioester bond between the E2 and the donor 
ubiquitin26–28. A single RING E3 can recruit several of these E2s and makes different chains 
dependent on the E2 specificity29,30. Occasionally the chain type that is being formed by 
a combination of a RING E3 and a less specific E2, such as Ube2D3 (UbcH5c), is determined 
by the specific E2-E3 combination31,32. So far LUBAC is the only E3-ligase complex that is 
known to promote linear ubiquitin chain formation. Although it contains RING domains, 
its ubiquitin chain forming specificity overrides that of the collaborating E2 enzymes. 
Thus even highly specific E2s that are known to catalyze the formation of very specific 
chain types, such as Ube2K (E2-25K) that forms K48-linked chains33, will form linear 
ubiquitin chains in the presence of LUBAC5. Therefore, chain type specificity is thought to 
be embedded within the LUBAC complex, but it is unclear how this specificity is organized. 
We performed an in-vitro analysis of HOIP ubiquitin chain assembly activity to investigate 
the mechanism underlying linear ubiquitin chain formation by the LUBAC complex. 
We show that a truncated form of HOIP is active in in-vitro linear chain formation in 
the absence of HOIL-1L and Sharpin. The catalytic activity and specificity for linear ubiquitin 
chain assembly of the LUBAC complex is completely embedded within HOIP RING2 and 
a newly identified Linear ubiquitin chain Determining Domain (LDD) in the C-terminus 
of HOIP. Furthermore, we show that the ubiquitin thioester is first transferred from the 
E2 onto HOIP and is subsequently linked to a target ubiquitin that is docked on the LDD. 
This study strengthens the knowledge on the general mechanism for RBR mediated 
ubiquitin chain formation and provides novel mechanistic insights in linear ubiquitin chain 
assembly by HOIP. 
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Materials and methods
Construction of plasmids
Codon optimized cDNA for E. coli expression of HOIP and HOIL-1L was obtained from 
Genscript. The cDNA was subcloned into pGEX-6P-1 vectors (GE Healthcare) with an 
N-terminal GST-tag for E. coli expression. HOIPRBR-LDD, HOIPR2-LDD and HOIPLDD were cloned into 
a pETNKI-His-3C-LIC-amp vector for E. coli expression34. Mammalian expression constructs 
pcDNA3.1-HOIL-1L-His, pcDNA3.1-Myc-HOIP and pcDNA3.1-Myc-HOIP-ΔUBA563-616 were 
kindly provided by Dr. K. Iwai (Osaka University, Japan). UbiquitinΔGly76, Ubiquitin 
single and triple point-mutations and point-mutations in HOIP were introduced by using 
the QuikChange Mutagenesis Kit from Stratagene (La Jolla, CA, USA). The luciferase 
NF-kB reporter construct, pNF-κB-Luc, and the positive control pFC-MEKK were obtained 
from Agilent Technologies. Renilla luciferase vector, pRL-null, was obtained from Promega.
General, proteins and antibodies
Ubiquitin, hUba1, Ube2D3 and Ube2L3 were expressed and purified as 
described previously18,35–37. TAMRAUbiquitin, ubiquitinTAMRA, His6ubiquitin and biotinubiquitin 
(inhibition assay) were generously provided by Remco Merkx, Dharjath Hameed and Huib 
Ovaa36. BiotinUbiquitin (di-ubiquitin formation assays) and ubiquitin lysine mutants were 
obtained from Boston Biochem. 
Protein expression and purification
Full-length HOIP and HOIL-1L were expressed in E. coli Bl21 (DE3) pLysS cells by induction 
with 0.8 mM isopropyl-1-thio-b-D-galactopyranoside (IPTG) and 0.2 mM ZnSO4 over night 
at 18°C. Cells were resuspended in 20 mM Tris/HCl pH 8.0, 100 mM NaCl, 5 mM bME and 
Complete EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland). Cells were lysed 
by a high-pressure EmulsiFlex-C5 device (Avestin, Mannheim, Germany). Initial purification 
was achieved by binding the proteins to glutathione beads, washing the beads with buffer 
supplemented with 0.5 M NaCl and elution in buffer containing 50 mM GSH. The GST-tag was 
cleaved by incubation with 3C protease, followed by gel filtration (Superose6) online with 
a GST-column in 20 mM Hepes/HCl pH 8, 100 mM NaCl, 1 µM ZnCl2 and 5 mM bME. 
HOIPRBR-LDD (699-1072) was produced in E. coli Bl21 (DE3) pLysS cells. Expression was 
induced by the addition of 0.4 mM IPTG and 10 µM ZnCl2 at an OD600 of 0.8 in LB medium 
supplemented with 50 µg/ml carbenicillin and chloramphenicol. Expressions were further 
cultivated over night at 16°C. The cells were lysed in 50 mM Tris/HCl pH 8, 150 mM NaCl, 
2 mM Imidazole, 1 µM ZnCl2, 5 mM b-mercapto-ethanol (bME) in the presence of complete 
EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland), DNAse and 1 mM MgCl2 
by a high-pressure EmulsiFlex-C5 device (Avestin, Mannheim, Germany). Cleared lysate was 
incubated with Talon beads. The protein was eluted from the beads in buffer containing 
200 mM imidazole and was subsequently loaded on a Resource-Q column. The His-tag 
was cleaved in solution with 3C protease. Further purification was achieved by a Heparin 
column followed by size-exclusion chromatography (Superdex 200) in buffer containing 
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25 mM Hepes/HCl pH 7.0, 150 mM NaCl, 1 µM ZnCl2 and 5 mM bME. HOIP
RBR-LDD point-mutants, 
HOIPR2-LDD and HOIPLDD were expressed and purified as described for HOIPRBR-LDD, excluding 
the cleavage of the His-tag and size-exclusion chromatography. For comparison with 
the HOIPRBR-LDD point-mutants, wild type HOIPRBR-LDD was prepared following the same protocol. 
In-vitro ubiquitin chain formation
In-vitro ubiquitin chain formation reactions were performed in standard conditions, unless 
specified otherwise. Standard conditions for ubiquitin chain formation  were 100 nM hUba1, 
600 nM of the indicated E2, 1 µM E3, 15 µM ubiquitin and 10 mM ATP in buffer containing 
20 mM Hepes/HCl pH 8, 150 mM NaCl, 10 mM MgCl2, 0.5 mM DTT. Reactions were performed 
at 37°C and stopped by the addition of protein loading buffer containing bME. Samples were 
separated on 4-12% NuPAGE gels (Invitrogen) in MES-buffer and analyzed by western blot 
using ubiquitin antibody (P4D1, Santa Cruz biotechnology) and HRP conjugated anti-Mouse 
antibody (BioRad). 
Single-cycle turnover assays
Single-cycle turnover assays were performed in the same buffer conditions as described 
for the ubiquitin chain formation. TAMRAubiquitin (500 nM) was loaded onto E2 (600 nM) 
in an ATP (1 mM) dependent manner via hUba1 (100 nM) in 120 µL final reaction volume 
for 20 min at 37°C. The charging reaction was terminated by depleting the ATP with 2U 
apyrase. After 5 min incubation at room temperature, the sample was divided into smaller 
aliquots to compare the effects of the addition of HOIPRBR-LDD (1 uM) and ubiquitinΔGly76 
(500 nM). BiotinUbiquitin was added simultaneously with HOIPRBR-LDD and wtUbiquitin in 
the acceptor ubiquitin competition assays. Reactions were performed at 37°C and stopped 
by the addition of non-reducing loading buffer on ice. Samples were analyzed on 4-12% 
NU-PAGE gels (Invitrogen) in MES buffer and the TAMRA signal was visualized on a ChemiDoc 
XRS (BioRad). Band quantification of Ube2D3~TAMRAubiquitin was done with the ImageJ 
program (http://imagej.nih.gov/ij). Loading differences were accounted for by measuring 
the total amount of TAMRA signal per lane. Percentages normalized for the total amount 
of Ube2D3~TAMRAubiquitin at T=0. Western blot analysis was performed using anti-HOIP 
(ab85294, Abcam) and HRP-conjugated anti-Rabbit (BioRad) antibodies.
Covalent HOIP~ubiquitin intermediate formation
E2~ubiquitin was prepared as described for the single-cycle turnover assays in buffer 
containing 20 mM Hepes pH 8.5 and 5 mM bME. After the addition of Apyrase, HOIP (2 uM) 
was added to the mixture. Reactions were performed for 5 min on ice. The TAMRA signal 
was visualized on a ChemiDoc XRS (BioRad) and HOIPRBR-LDD was visualized on non-reducing 
western blots with anti-HOIP antibody (ab85294, Abcam). Sample loading buffer was 
supplemented with 1 M Urea to partially unfold the proteins.
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Fluorescence polarization assays
The fluorescence anisotropy of the C-terminal TAMRA-labeled ubiquitin (1nM) in binding 
buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM bME and 1 g/l chicken ovalbumin) was 
measured on a PerkinElmer EnVision 2010 Multilabel Reader. The binding was measured 
in 75 µL reactions. Serial 1:1-dilutions, starting at 220 µM HOIP, were performed in three 
repeats. Reactions were incubated for 20 min at 4°C before the measurements.The samples 
were excited at 531 nm and emission was measured at 579 nm, with correction for both 
the buffer background and G-factor of the instrument. The assays were performed in 
“non binding surface flat bottom” black 96-well plates (Corning) at room temperature. 
The resulting binding isotherms (anisotropy vs. HOIP concentration) were fit to 
a 1:1 non-linear binding model (Y=Bmax*X/(KD+X)). All experimental data were processed 
using Ms Excel and Prism 4.03 (GraphPad Software, Inc.).
Multi-angle laser light-scattering (MALLS)
MALLS experiments were performed on a Mini-Dawn light scattering detector 
(Wyatt Technology) inline with a Superdex S200 10/30 column at 4°C in buffer containing 
25 mM Hepes/HCl pH 7, 150 mM NaCl, 1 µM ZnCl2 and 5 mM bME. Refractive index and light 
scattering detectors were calibrated against toluene and BSA. Data were analyzed using 
the Astra software.
Cell culture and transient transfection
HEK293FT cells were cultured in Dulbecco modified Eagle medium (DMEM; GIBCO) 
supplemented with 10% non-heat-inactivated fetal calf serum (GIBCO), 1% penicillin/
streptomycin (MP Biomedical), 1% non essential amino acids (GIBCO) and 1%  L-glutamine 
(MP Biomedical). Cells were cultured in 24-wells plates at 37°C supplied with 5% CO2. 
For transient expression, 400 ng plasmid DNA (pcDNA3.1-HOIL-1L-His, pcDNA3.1-Myc-HOIP, 
pcDNA3.1-Myc-HOIP-mutants, pFC-MEKK) was used. Empty vector pcDNA3.1 was used 
to compensate for differences in DNA amounts. Furthermore, 400 ng of luciferase NF-kB 
reporter construct and 200 ng of Renilla luciferase vector were added to the transfection 
medium. In total 2 µg of DNA was transfected in each condition. Transfection was performed 
at 60% confluence with lipofectamine 2000 (Invitrogen). Each condition was experimentally 
tested in triplicate.
NF-kB transactivation assay
As readout for NF-kB activation we performed a Dual luciferase™ reporter assay (Promega). 
48 Hours after transfection cells were washed with PBS and lysed in 100µL of passive lysis 
buffer (Promega) for 1 hour. Luciferase assays were performed according to the protocol 
provided by the manufacturer (Promega). Luciferase signals were measured on the Lumat LB 
9507 (EG&G Berthold). Western blot analysis was performed to confirm protein expression. 
Proteins of total lysates generated as described above were separated on 10% polyacrylamide 
gels and transferred to polyvinylidenefluoride (PDVF) membranes (Bio-Rad, Hercules, CA). 
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PVDF membranes were probed with anti-Myc (Santa Cruz) and anti-His (Abcam) primary 
antibodies, followed by probing with HRP-conjugated secondary antibodies. Antibody 
signal was visualized by chemiluminescence using the Biorad ChemiDox XRS+.
Results
Linear ubiquitin chain formation specificity is embedded within HOIP
To study linear chain formation, we expressed full-length human HOIL-1L, full-length HOIP 
and a series of HOIP deletion constructs in E. coli. We used synthetic genes that are optimized 
for bacterial expression (Figure 1A) and used the purified proteins for in-vitro reactions, 
analyzing free ubiquitin chain formation. As expected, full-length HOIP alone was not active 
in forming ubiquitin chains, but in the presence of HOIL-1L robust chain formation was 
observed (Figure 1B).  Since previous published data were derived from assays performed 
in the absence of sodium chloride5,6 under conditions that are far from physiological 
(~150 mM NaCl), we tested the influence of NaCl and pH on the in-vitro reactions. 
In the absence of salt the reactions were more active and it was easier to visualize detailed 
chains (Figure S1A, S1B), but the overall pattern of the bands on gel remained the same. 
Furthermore, the proteins were only active in conditions above pH 7 and raising the pH up to 
pH 9.5 caused a minor extra activation of the reactions (Figure S1C). We mainly used reaction 
conditions with 150 mM NaCl at pH 8; however, conditions without NaCl are used in some 
of our experiments as a tool to improve visualization of the activity of the LUBAC proteins. 
Next, we used an N-terminally truncated form of HOIP, which includes only the RBR 
domain and the C-terminal region that we have named Linear ubiquitin chain Determining 
Domain (HOIPRBR-LDD, Figure 1A). The sequence of the LDD is not conserved between RBR 
proteins, and Psi-BLAST searches and a Phyre threading analysis on this region reveal 
that it is exclusive to HOIP. Nevertheless, between HOIP orthologues the LDD is highly 
conserved (Figure S1D), which suggests that the LDD functions specifically in the context 
of the upstream RBR domain in HOIP. When we tested HOIPRBR-LDD for in-vitro activity we 
found, surprisingly, that this construct does not require HOIL-1L and Sharpin for in-vitro 
activity (Figure 1B, Figure 1C). HOIPRBR-LDD does not contain the UBA domain that is needed 
for the interaction with HOIL-1L and Sharpin2,5,8, explaining why the activity of HOIPRBR-LDD 
is hardly increased by the addition of HOIL-1L in the reactions (Figure 1D). As HOIL-1L and 
Sharpin have been shown to be important for HOIP activity, we wondered whether the short 
RBR-LDD construct of HOIP retained the specificity for making N-terminally linked ubiquitin 
chains. We tested chain formation, using either Ube2D3 (UbcH5c) or Ube2L3 (UbcH7) as E2 
enzymes. In both cases, HOIPRBR-LDD forms ubiquitin chains with lysine-less ubiquitin (K0) and 
mutated ubiquitins that contain either a single lysine or a lysine point mutation (Figure S1E). 
In addition, when the ubiquitin N-terminus is blocked with a His-tag, a biotin or a TAMRA-
label, the ubiquitin chain formation is eliminated (Figure 1E, Figure S1F and Figure S1G), 
indicating that the accessibility of the N-terminus is critical for this reaction. Combinations of 
any of the N-terminally blocked ubiquitins with ubiquitinΔGly76, which can only function as 
an acceptor ubiquitin, produces solely di-ubiquitins (Figure 1E, Figure S1F and Figure S1G), 
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Figure 1. HOIP mediates linear ubiquitin chain formation. (A) HOIP and HOIL-1L constructs 
used in this study. Ubiquitin Like domain (UBL), Npl4 Zinc Finger (ZF), Ubiquitin Associated 
domain (UBA), Linear chain Determining Domain (LDD) and a RING-in-Between-RING 
domain (RBR) consisting of two RING domains (R1, R2) and an in-between RING domain (IBR). 
The domain borders of the UBL, ZF, UBA and RBR-domains are drawn to scale according to 
Uniprot definitions (www.uniprot.org). (B) Ubiquitin chain formation with Ube2L3 in combination 
with 2 µM of the different E3s after 0, 10, 20 and 40 min. Standard reaction conditions are 
described in the materials and methods. Reactions were performed without NaCl. (C)  Increasing 
amounts of ubiquitin chain formation with increasing concentrations of HOIPRBR-LDD. Reactions 
were performed in the presence of Ube2D3 and were stopped after 1 hour. (D) HOIPRBR-LDD 
cannot be further activated by HOIL-1L in a 1 hour reaction with Ube2L3. Reactions were 
performed without NaCl. (E) Ubiquitin chain formation by HOIPRBR-LDD with N-terminally blocked 
ubiquitin (biotinubiquitin) and C-terminally truncated ubiquitin (UbiquitinΔGly76). Reactions 
were stopped after 90 min at 32°C. (F) HOIPRBR-LDD activity with and without Ube2D3 and the 
Ube2D3 active site mutant (Ube2D3C85A). Reactions were stopped after 15, 30, 60 and 120 min. 
(G) Di-ubiquitin linkage formation with TAMRAubiquitin in the presence and absence of 
ubiquitinΔGly76 and Ube2D3 after 2 hours.
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confirming that a free ubiquitin N-terminus is essential for ubiquitin chain formation by HOIP. 
Consequently, the RBR-LDD in the C-terminus of HOIP is sufficient for the linear ubiquitin 
chain formation specificity of the LUBAC complex and does not require the presence of other 
LUBAC-proteins.  Since HOIL-1L and Sharpin are essential for full-length HOIP activity, but 
not for the HOIPRBR-LDD, it seems that the catalytic center is not available for catalysis in the 
full-length protein. The UBL domains of either HOIL-1L or Sharpin have to bind to the UBA 
domain of HOIP, which lies N-terminally of the catalytic RBR-LDD, to activate the proteins 
in the NF-Kb pathway38,39. This could suggest some level of auto-inhibition within HOIP, 
similar to that seen in the RBR protein Parkin, where the N-terminal UBL is binding  to the 
C-terminal ubiquitin binding domain to block the catalytic center23. Therefore, we tested if 
the N-terminus of HOIP can inhibit HOIPRBR-LDD in trans. Full-length HOIP, HOIPN-term or HOIPUBA 
were added to the reaction with HOIPRBR-LDD, but the constructs did not inhibit the HOIPRBR-LDD 
mediated chain formation (Figure S1H). Apparently the covalent linkage of the N-terminal 
domains to the RBR is required for the inhibition, either by increasing the local concentration 
or by arranging some position specific conformational change that can be released by 
the Sharpin or HOIL-1L interaction. Consequently, the exact mechanism by which the catalytic 
domain is kept in an inactive state in full-length HOIP remains to be resolved. The active 
LUBAC complex mediates the specific formation of linear ubiquitin chains in cooperation 
with many different E2 enzymes that are normally highly specific in the formation of different 
types of ubiquitin chains5. This ability to override the E2 specificity is retained in HOIPRBR-LDD. 
It specifically catalyses the formation of linear ubiquitin chains in the presence of the E2s 
Ube2D3, which can mediate the formation of many different types of lysine-linked ubiquitin 
chains30, and Ube2L3, which targets to cysteines20,  indicating that the E2s are important 
to deliver the activated ubiquitin to the complex, but do not contribute to the chain 
type specificity.
HOIP has E2-independent linear chain forming activity
Interestingly, we observed very weak chain formation activity with HOIPRBR-LDD even with an 
inactive Ube2D3 mutant (C85A) (Figure 1F). Therefore, we analyzed the HOIPRBR-LDD activity in 
the absence of E2 enzymes and still observed HOIP dependent activity (Figure 1F), confirming 
that the E3 does not require an E2 for activity. However, in the absence of the E1 no activity 
is observed (Figure 1F). The chains formed in the E2-independent reaction are exclusively 
linear ubiquitin chains (Figure 1G). A similar E2-independent activity was recently described 
for the RBR-protein Parkin21, indicating that this may be a general feature of RBR proteins. 
Nevertheless, E2-independent activity is unlikely to reflect a physiological activity, since 
the reaction is much more efficient in the presence of an E2~Ub thioester. However, these 
data emphasize that linear chain specificity does not rely on E2s, but is completely embedded 
within HOIP.
HOIP RING1 and IBR are involved in E2 mediated activity 
We next examined how HOIP promotes linear ubiquitin chain formation. To address this point, 
we made a series of point mutations and deletion constructs to unravel the contributions of 
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the various domains within HOIPRBR-LDD (Figure S2). The activities of all point mutants that are 
used in this study are shown in Figure 2 and are summarized in supplementary Figure S2. 
The effect of the mutations in the different domains of HOIP will be discussed throughout 
this article. First, the importance of RING1 and the IBR were analyzed. RING and IBR domains 
coordinate two zinc-ions via 8 Cys/His residues, whereby each zinc-ion is coordinated 
by 4 Cys/His residues. Cysteine mutations in RING1 that disrupt the coordination of 
the zinc-ions caused reduced E2 dependent activity with both Ube2D3 and Ube2L3 
(Figure 2). Also HOIPRBR-LDD V701A, which was designed to interfere directly with the E2-E3 
interaction but not to disrupt the RING fold40, inhibited the ubiquitin chain formation. 
Interestingly, the C171,179A mutant solely disrupted Ube2L3 dependent activity and not 
Ube2D3 mediated chain formation, revealing a difference in the binding-interface between 
HOIP and different E2s. Nevertheless, the complete set of mutants reveals that RING1 is 
essential for the activity with both E2s. The E2-independent activity of HOIPRBR-LDD was not 
affected by the RING1 mutations, indicating a classical RING-type role for RING1 where the 
RING domain catalyzes the transfer from the E2 onto a target site. The IBR cysteine mutants also 
influenced the E2 dependent ubiquitin chain assembly, but not for E2-independent activity 
(Figure 2). Therefore, both RING1 and the IBR are important for E2 mediated ubiquitin chain 
formation by HOIP. 
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Figure 3. HOIPR2-LDD is the catalytic centre for in cis linear ubiquitin chain assembly. 
(A) Di-ubiquitin formation with HOIPRBR-LDD RING1 mutants with TAMRAubiquitin in 
the presence and absence of ubiquitinΔGly76 and Ube2D3. Reactions were stopped after 
60min. (B) HOIPR2-LDD mediated ubiquitin chain assembly after 2 hours cannot be activated 
by Ube2D3. (C) Activity of different HOIP constructs after 1 hour in the presence of Ube2D3 
reveals that HOIPLDD is not active. (D) S200 10/300 gel filtration elution profile of HOIPRBR-LDD 
(black line) and HOIPR2-LDD (dotted line). Maximum absorbance has been set at 100 mAU. 
The according calculated molar mass from the MALLS for HOIPRBR-LDD (gray dots) is plotted 
against the elution volume. Three peaks are identified, correlating to HOIPRBR-LDD monomers 
(42.9 kDa), dimers (85.8 kDa) and multimers (> 85.8 kDa). (E) Ubiquitin chain formation by 
HOIPRBR-LDD monomers and multimers. Monomers and multimers were taken from corresponding 
single fractions from the middle of the different peaks of the gel filtration profile and used 
immediately (without concentrating the samples) in ubiquitin chain formation reactions. 
HOIPRBR-LDD was assayed at 0.5 µM in the presence of Ube2D3. Time points were taken after 
0, 10, 20, 40, 60 min. (F) Combinations of HOIP mutants do not rescue ubiquitin chain formation 
activity with Ube2D3 (assay performed in absence of NaCl). Mutations were introduced in RING1 
(C699A, K873A), RING2 (C871,874A), and LDD (C998A).
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HOIPR2-LDD forms the minimal domain for linear ubiquitin chain formation
The linear ubiquitin chain assembly specificity of HOIP is preserved in HOIP RING1 
mutants (Figure 3A) and RING1/IBR mutations do not affect the E2-independent activity 
(Figure 2), indicating that these domains are not used in the actual linkage formation 
between two ubiquitins. Accordingly, when the RING1 and IBR domains are deleted 
(HOIPR2-LDD, Figure 1A), the ability to form ubiquitin linkages in an E2 independent manner is 
retained (Figure 3B). HOIPR2-LDD cannot be further activated by Ube2D3 (Figure 3B, Figure S3), 
showing the importance for RING1-IBR in E2 dependent activity. Thus a completely intact 
HOIPRBR-LDD is needed for efficient ubiquitin chain formation that is facilitated by the E2, but 
the intrinsic ubiquitin chain assembly activity is located more C-terminally in the RING2 and 
the LDD. We aimed at mapping the regions in HOIPR2-LDD that are essential for ubiquitin chain 
catalysis. The importance of RING2 was explored by comparing the activity of HOIPR2-LDD 
and a construct that lacks all of the RBR-domain (HOIPLDD, Figure 1A). Although HOIPR2-LDD 
can still form E2 independent di-ubiquitin linkages, HOIPLDD is catalytically inactive even at 
high concentrations (Figure 3C). In addition, single cysteine to alanine mutants of HOIPRBR-LDD 
RING2 are catalytically inactive (Figure 2). Therefore, RING2 is essential for ubiquitin chain 
assembly. Next, the relevance of the LDD in ubiquitin chain formation was investigated. 
We were unable to express constructs of HOIP that lack the LDD and all LDD mutants are 
catalytically inactive (Figure 2). Nevertheless, the LDD alone is not sufficient for catalysis. 
Consequently, the integrity of both RING2 and the LDD are needed for linear ubiquitin chain 
assembly by HOIP.
HOIP mediates ubiquitin chain formation in cis
The presence of multiple copies of HOIP within the LUBAC complex5 suggests that HOIP 
might assemble ubiquitin chains in trans. Therefore we next examined if the ubiquitin chain 
formation reaction is catalyzed by single HOIP molecules (in cis) or by the cooperation 
of multiple copies of HOIP (in trans). The gel filtration profile and multi angle laser light 
scattering (MALLS) of HOIPRBR-LDD show that the protein is purified as a mixture of monomers, 
dimers and multimers (Figure 3D). Nevertheless, the different fractions of the gel filtration 
profile show equal activity in free ubiquitin chain formation assays (Figure 3E), implying 
that the multimerization of HOIPRBR-LDD is not a requirement for activity. To confirm these 
data, we combined inactive HOIPRBR-LDD mutants in chain formation assays to test whether 
they would collaborate to rescue the ability to form ubiquitin linkages. RING1 mutants are 
affected in E2 dependent chain formation and LDD mutants cannot support the formation of 
the isopeptide bond between two ubiquitins. Consequently, a combination of a RING1 
mutant and a LDD mutant is expected to be effective in chain formation if the reaction 
occurs in trans. 
The combination of a RING1 and a LDD mutant did not lead to effective ubiquitin chain 
assembly, showing that the mutants do not complement each other (Figure 3F). Furthermore, 
a combination of a RING1 mutant and a RING2 mutant, or a RING2 mutant and a LDD mutant 
did not result in chain formation (Figure 3F), suggesting again that HOIPRBR-LDD proteins act 
individually and do not collaborate in ubiquitin chain formation. Finally, HOIPR2-LDD is purified 
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mainly as a monomer (Figure 3D) and is still active in E2-independent chain formation. 
Therefore we conclude that multimerization of HOIP is not a requirement for activity and 
linear ubiquitin chain formation is catalyzed within single HOIP molecules. 
HOIP forms a reversible covalent intermediate with ubiquitin
In light of the HECT-like character of RING2 in other RBR proteins20, we tested whether HOIP 
could make a covalent thioester intermediate. We used single-cycle turnover assays, with 
pre-charged E2~TAMRAubiquitin thioester and were able to trap an E3-ubiquitin intermediate 
with HOIPRBR-LDD. A covalent E3~TAMRAubiquitin complex could be visualized on non-reducing 
gels using anti-HOIP western blotting or, more clearly, by the TAMRA signal of ubiquitin 
(Figure 4A, Figure 4B, Figure S4A (Ube2D3), FigureS4B (Ube2L3)). The HOIPRBR-LDD~ubiquitin 
intermediate could be disrupted by the addition of reducing loading buffer, which 
illustrates that HOIPRBR-LDD forms a reversible covalent bond with ubiquitin in cooperation 
with both Ube2D3 and Ube2L3. Here we show for a second RBR protein the presence of 
an E3~ubiquitin thioester bond. The covalent HOIP~ubiquitin is transient, as indicated by 
the low signals, however the bond could be detected in the RING1 mutants as well as in 
the C916A LDD mutant (Figure 4A, Figure S4B). The RING2 mutants were completely impaired 
in forming this intermediate (Figure 4A, Figure S4B). RING2 has been suggested in literature 
as the actual site for the E3~ubiquitin thioester in RBR proteins, although visualization of 
the E3~thioester has only been successful for HHARI20. We could not assign the thioester 
forming cysteine, since several cysteines in RING2 are impaired in thioester formation. 
The HOIP Cys885 that aligns with the thioester-forming Cys357 in HHARI, could not form 
an oxyester HOIP~ubiquitin intermediate, when mutated to serine (Figure S4C). However, 
this could be due to detection limits of the assay, since the reaction is less favorable. Unlike 
the LDD, RING2 is conserved between RBR proteins (Figure S4D) and it is essential for 
E2~ubiquitin discharge and E3~ubiquitin formation. Therefore, it seems likely that RING2 
provides the actual site on which the E3~ubiquitin is formed. 
HOIP mediated ubiquitin transfer from the E2 onto a target is a two-step 
mechanism
To understand how the different domains within HOIPRBR-LDD contribute to the assembly 
of ubiquitin chains, we monitored the in-vitro E2~ubiquitin discharge and di-ubiquitin 
formation in single-cycle turnover assays with TAMRAubiquitin and the selected purified 
HOIPRBR-LDD mutants. The amino-terminus of TAMRAubiquitin is not available for linear ubiquitin 
chain formation and can only be linked to a ubiquitin with a free N-terminus by HOIPRBR-
LDD. This feature allowed us to uncouple the discharge of ubiquitin from the E2 active site 
cysteine (in the absence of ubiquitinΔGly76) and the formation of the isopeptide bond 
between the N- and C-terminus of two ubiquitins (in the presence of ubiquitinΔGly76). 
HOIPRBR-LDD completely discharged TAMRAubiquitin from the E2 over time in the single-cycle 
turnover assays and formed di-ubiquitins when ubiquitinΔGly76 was added to the reaction 
(Figure 4C, Figure S4E). The E2~ubiquitin discharge is less efficient when RING1 mutants 
are used in the reaction and also the amount of di-ubiquitin that is formed declines 
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HOIPRBR-LDD mutants. Ube2D3 was used as the E2 enzyme. The TAMRA-signal is visualized on a 
reduced gel and at two contrast levels on a non-reduced gel. (B) Single-cycle turnover assay 
monitoring Ube2D3~TAMRAubiquitin discharge and HOIP~TAMRAubiquitin formation after 0, 4, 16 
min at 37°C. (C) Single-cycle turnover assays showing Ube2D3~TAMRAubiquitin discharge by HOIP 
mutants (left half of each gel), and di-ubiquitin formation upon the addition ubiquitinΔGly76 
(right half of each gel). Discharge reactions were stopped after 0, 2, 4, 8, 16, 32, 64 min. RING1 
(R1), RING2 (R2). (D) Ube2D3~TAMRAubiquitin discharge rates in the presence and absence of an 
acceptor ubiquitin. Standard error for the Ube2D3~TAMRAubiquitin were calculated over three 
independent experiments.
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16, 32, 64 µM. Control reactions at the highest concentration of HOIPLDD do not contain either 
HOIPRBR-LDD (-E3) or Ube2D3 (-E2). The molecular weight marker is indicated by the asterisk 
(*). (C) Single-cycle turnover assays in the presence and absence of the acceptor ubiquitin-
competitor: biotinubiquitin. The TAMRA-signal visualizes di-ubiquitin formation by HOIPRBR-LDD 
and Ube2D3~ubiquitin discharge by HOIPRBR-LDD C930A after 0, 2, 4, 8, 16 minutes. (D) 
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triple mutant.
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(Figure 4C, Figure S4E). This confirms the role of RING1 in E2 mediated activity. Nevertheless, 
the E2-independent activity of the RING1 mutants is hardly affected (Figure 2), showing that 
RING1 is less important for the E2 independent driven activity and the ubiquitin linkage 
formation. The discharge of the ubiquitin from the E2 on HOIP and the linkage of the ubiquitin 
to a target ubiquitin by RING2-LDD were uncoupled in the single-cycle turnover assays. 
Although LDD mutants do not have any ubiquitin linkage formation activity in ubiquitin 
chain formation reactions, they are capable of efficiently discharging ubiquitin from the E2 
(Figure 4C, Figure S4E). This indicates that the LDD is not involved in the destabilization of 
the E2~ubiquitin thioester, but is critical for ubiquitin chain assembly. Apparently the trans-
thiolation of the ubiquitin from the E2 onto HOIP is independent of ubiquitin chain assembly. 
Accordingly, the E2~ubiquitin discharge efficiency is not dependent on the presence of an 
acceptor ubiquitin to which the donor ubiquitin can be transferred (Figure 4D). Interestingly, 
RING2 mutants are impaired in both the E2~ubiquitin discharge and the ubiquitin linkage 
formation (Figure 4C, Figure S4E), suggesting that RING2 is required for both steps of 
the ubiquitin transfer. This central role for RING2 in the transfer of the ubiquitin further 
supports its role as acceptor site for the E3~ubiquitin intermediate. Consequently, efficient 
ubiquitin chain formation is initiated by the E2-dependent delivery of ubiquitin to HOIP 
RING2 and is completed by subsequent LDD mediated ubiquitin chain assembly.
HOIP LDD catalyzes the final step of the ubiquitin transfer
The binding of ubiquitin to ubiquitin docking sites in E3-ligases is suggested to play a role in 
ubiquitin chain formation specificity by bringing a specific ubiquitin lysine residue in close 
proximity of the ubiquitin thioester bond14. HOIP has several known ubiquitin interaction 
motifs (UBA and the NFZs), but since these are not present in HOIPRBR-LDD they cannot explain 
the linear ubiquitin chain formation. We found that the LDD is important for linking ubiquitins 
together, but not for E2~ubiquitin discharge and HOIP~ubiquitin intermediate formation. 
Therefore we wondered whether the LDD could function as a ubiquitin docking site. We 
measured the affinity of ubiquitin for HOIPRBR-LDD and HOIPLDD by fluorescent polarization 
(FP) with TAMRA labeled ubiquitin (TAMRAubiquitin and ubiquitinTAMRA). Both HOIPRBR-LDD 
and HOIPLDD interacted with ubiquitinTAMRA with an affinity of approximately 100 µM, and 
do not bind to the free TAMRA-dye, showing that the LDD does interact with ubiquitin 
(Figure 5A, Figure S5A, Figure S5B). Then we analyzed the effect of the C930A mutant of 
the LDD, which is impaired in ubiquitin chain formation, on the affinity for ubiquitin in 
the FP assays. Unexpectedly, in the context of HOIPRBR-LDD, the C930A mutation did not affect 
affinity for ubiquitinTAMRA. In contrast, in the LDD alone, the HOIPLDD C930A has a greatly 
reduced affinity for ubiquitinTAMRA (Figure 5A, Figure S5A). The loss of activity of the HOIPRBR-LDD 
C930A was not caused by unfolding of the protein as was shown by the gel filtration profile 
(Figure S2D). Therefore, the loss of binding of the LDD C930A mutant indicates interference 
with ubiquitin binding. In the longer construct, the mutation is possibly not strong enough 
to disrupt the complete interaction and just interferes with the proper ubiquitin orientation 
for chain formation or a second ubiquitin interaction site may be present elsewhere outside 
the LDD. The interaction between the LDD domain and ubiquitin was verified in in-vitro 
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ubiquitin chain formation assays. First, HOIPLDD was titrated into the ubiquitin chain reaction 
with HOIPRBR-LDD. The increasing amounts of HOIPLDD inhibited HOIPRBR-LDD mediated ubiquitin 
chain formation, presumably by competing away the freely available ubiquitin (Figure 5B). 
Importantly, addition of the HOIPLDD C930A to linear ubiquitin chain formation assays did not 
inhibit HOIPRBR-LDD mediated ubiquitin chain formation (Figure 5B). The loss of inhibition by 
the LDD C930A mutant indicates that this site is indeed important for ubiquitin interaction. 
We then tested if the interaction between the acceptor ubiquitin and HOIP is needed for 
di-ubiquitin formation in a single-cycle turnover assay. Ube2D3 was loaded with TAMRAubiquitin, 
after which the HOIPRBR-LDD dependent discharge of the E2~TAMRAubiquitin, and the linkage 
of TAMRAubiquitin to wild type ubiquitin was monitored. To test if the acceptor ubiquitin 
interacts with HOIP during the di-ubiquitin formation, a biotinubiquitin, which cannot act as an 
acceptor, was added during the discharge reaction to compete with the wild type ubiquitin 
(Figure 5C). Under these conditions the E2~TAMRAubiquitin discharge and HOIP~ubiquitin 
intermediate formation were unaffected by the presence of biotinubiquitin, showing that 
the transfer of the donor ubiquitin from the E2 onto HOIP was not affected 
(Figure 5C, Figure S5C). In contrast, the di-ubiquitin formation was inhibited by 
the biotinubiquitin, suggesting that the N-terminally blocked ubiquitin competes with the wild 
type ubiquitin for binding to HOIP in the final step of the ubiquitin transfer. These results are in 
line with the fact that the LDD mutants are impaired in ubiquitin-ubiquitin linkage formation 
but not in E2~ubiquitin discharge (Figure 4C, Figure S4E), showing that the LDD does not 
interact with the donor ubiquitin, but rather with the acceptor ubiquitin. Interestingly, 
the LDD/ubiquitin interaction does not require the ubiquitin hydrophobic patch, which is 
used by many ubiquitin interaction motifs41, since point mutants of the hydrophobic patch 
still accept TAMRAubiquitin via HOIPRBR-LDD (Figure 5D, Figure S5D). Consequently, the interaction 
between the LDD and ubiquitin is specific to HOIP, which is in line with the unique linear 
ubiquitin specificity that is evoked by HOIP. 
The HOIP RING2 and LDD domains are crucial for NF-kB activation
Both RING2 and the LDD of HOIP are essential for linear ubiquitin chain formation in 
vitro. To determine the biological relevance of this finding, we tested wild type HOIP and 
the RING2 C885A, LDD C916A, LDD C930A, single and LDD C916,930A double mutants in 
HEK293FT cells. First, we verified the expression levels of the mutants and their capacity to 
interact with HOIL-1L in pull-down assays. All of the mutants retained the capacity to bind 
to HOIL-1L (Figure S6A), showing that the mutations did not cause major deficiencies in 
the folding of the full-length protein. Next, we tested the activity of the mutants in NF-Kb 
luciferase reporter assays. In line with published data2, the combined expression of HOIP and 
HOIL-1L resulted in NF-kB activation to levels approaching those when using MEK-kinase 1 
(Figure 6)42. However, the combined expression of HOIL-1L with any of the HOIP cysteine 
mutants did not activate NF-κB. As expected, the observed NF-kB signaling activity 
was dependent on the presence of the presence of the HOIL-1L interaction domain, 
the ubiquitin-associated-domain (UBA domain) in HOIP, as well as on the co-expression with 
HOIL-1L, since neither wild-type nor HOIP mutants were active without it (Figure S6B). These 
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data show that RING2 and the LDD are essential for linear ubiquitin chain formation and 
LUBAC mediated NF-kBactivation in cells.
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Figure 6. HOIP RING2 and LDD are essential for NF-kB pathway activation. Dual Luciferase™ 
reporter assay for NF-kB activation. Full-length HOIP wild type or HOIP cysteine mutants were 
co-expressed together with HOIL-1L (see lower panel) and a luciferase reporter construct, 
containing 5 NF-kB binding sites. A luciferase renilla construct was used as transfection control. 
Firefly luciferase values were normalized to renilla luciferase values. Normalized luciferase activity 
of 5x NF-kB reporter vector (upper panel) is shown as mean ± s.e.m. (*P < 0.001, Student’s t-test, 
representative experiment of n=4).
Discussion
NF-Kb activation is an important signal during immune and DNA-damage responses. Upon 
stimulation, the formation of linear ubiquitin chains on NEMO forms an essential early event 
in the activation of the pathway. The linear ubiquitin chains are assembled by the LUBAC 
complex, which contains the two RBR E3-ligases HOIP and HOIL-1L. It is poorly understood 
how RBR proteins form functional units to mediate the assembly of ubiquitin chains or how 
linear ubiquitin chain specificity is determined by the LUBAC complex. Our results give 
a detailed insight in the molecular mechanism by which linear ubiquitin chains are formed 
by HOIP (Figure 7). We show that removing the N-terminal 698 residues of HOIP unmasks 
the full linear ubiquitin chain formation activity and bypasses the need for HOIL-1L and 
Sharpin. Within this active region of HOIP, the first two domains (RING1-IBR) are needed 
for the catalysis of the E2-mediated delivery of ubiquitin to the E3, but the mechanism 
that directs the linkage to the N-terminus of a target ubiquitin is embedded within 
HOIP RING2-LDD. The relevance of this activity in the context of the full-length protein within 
the LUBAC complex was verified by experiments in HEK293FT cells, showing that single 
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point mutations in either RING2 or the LDD impair NF-kB signaling. The transfer of ubiquitin 
from the E2 onto an acceptor ubiquitin is mediated by HOIP in a two-step mechanism. First, 
the ubiquitin thioester is transferred from the E2 onto HOIP, most likely on RING2, to form 
a reversible covalent intermediate (Figure 7C). This step can be catalyzed by the RING1-IBR 
mediated interaction with an E2~Ub thioester. Second, the ubiquitin is transferred 
from HOIP onto the N-terminus of the target ubiquitin to form an isopeptide bond. This 
uncoupling of the E2 catalyzed step from the transfer step to the acceptor ubiquitin explains 
why E2 enzymes do not affect the chain type specificity of HOIP. The LDD is essential 
for the specific transfer of the donor ubiquitin from HOIP onto the acceptor ubiquitin 
(Figure 7). We have shown that the interaction between the LDD and the acceptor ubiquitin 
is important during this process, suggesting that it functions as an ubiquitin docking domain 
for the acceptor ubiquitin. The need for a C-terminal ubiquitin interaction-domain within 
HOIP is likely to reflect a general feature for ubiquitin chain catalysis of RBR proteins, since 
Parkin also contains a recently identified ubiquitin interaction domain, which is located 
just before RING2 of the RBR domain, that is used in ubiquitin chain formation23. Among 
RBRs, the RING2-LDD uniquely promotes linear ubiquitin chain formation. This selectivity for 
the amino terminus is exquisite since the ubiquitin N-terminus and K63 are located close to 
each other, indicating that precise positioning of the acceptor ubiquitin by the LDD is very 
important. It seems plausible that RING2-LDD provides additional contributions to selective 
targeting, possibly by preferring the chemical constellation of the ubiquitin amino-terminus 
over a lysine amino group.  
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Figure 7. Model for HOIPRBR-LDD mediated ubiquitination. (A-B) Linear ubiquitin chain 
assembly requires both (A) the binding and correct orientation of an acceptor ubiquitin by 
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the LDD and (B) the recruitment of an E2~ubiquitin to RING1-IBR. The ubiquitin is transferred 
from the E2 onto the acceptor ubiquitin in two independent steps. (C-D) First the ubiquitin 
thioester is transferred form the E2 onto RING2 (C) and second the ubiquitin is covalently linked to 
the N-terminus of the acceptor ubiquitin (D) that is oriented by the LDD. E. The E2 dependent 
activity can be bypassed by a less pronounced E2-independent activity.
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Supplementary information
Supplementary Materials and Methods
Multi-sequence alignment
Multi-sequence alignments were made in ClustalW and the figures were produced manually.
Co-immunoprecipitation (CO-IP)
For co-immunoprecipitation experiments, approximately 2.5 million cells were plated 
in standard round 9 cm culture petri dishes 24 hours prior to transfection. 16 hours post 
transfection the culture medium was refreshed and 40 hours post transfection, cells were 
harvested and lysed using RIPA buffer supplemented with complete protease inhibitors 
cocktail (Roche diagnostic) and benzonase (Novagen). Cell lysates were incubated with 
mouse anti Myc-antibody overnight at 4ºC. The remaining cell lysates were used as control 
for protein expression on immunoblot. The immunoprecipitation was performed using 
Protein G Sepharose beads (GE Health care). Beads were washed with RIPA buffer and 
incubated with the antibody-containing-lysates for 2.5 hours at 4ºC. After incubation, 
beads were washed with RIPA buffer to remove all non-specifically bound proteins. Proteins 
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bound to the beads were released by adding SDS loading buffer and boiling at 95ºC for 
five minutes. Western blot analysis was run to confirm protein expression. Proteins were 
separated on 10% polyacrylamide gels and transferred to polyvinylidenefluoride (PDVF) 
membranes (Bio-Rad, Hercules, CA). PVDF membranes were probed with anti-Myc (Santa 
Cruz) and anti-His (Abcam) primary antibodies, followed by probing with HRP-conjugated 
secondary antibodies. Antibody signal was visualized by chemiluminescence using 
the Biorad ChemiDox XRS+. 
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Figure S1. (A) Ubiquitin chain formation by HOIPRBR-LDD and Ube2D3 in the presence and absence 
of 150 mM NaCl. Time points were taken after 0, 10, 20, 40, 80 min. (B) Ubiquitin chain formation 
activity of HOIP and HOIL-1L in the presence and absence of 150 mM NaCl. Ube2D3 was used 
as the E2 enzyme. Reactions were stopped after 0 and 30 min. (C) Ubiquitin chain formation 
by HOIP and HOIL-1L with Ube2D3 at increasing pH-values in 50 mM MMT-buffer. Reactions 
were stopped after 40 min. (D) Multi-sequence alignment of the LDD-domain of different HOIP 
orthologues. UniprotID: Human (Q96EP0), Mouse (Q924T7), Rat (E9PU29), Xenla (A0JMU3), Drome 
(Q8IPJ3), Ciona (Q1RL47). The asterisks indicate the sites of the cysteine mutations that have been 
introduced in this study. (E) Ubiquitin chain formation by HOIPRBR-LDD, Ube2L3 or Ube2D3 and 
ubiquitin mutants. Single lysine ubiquitin point-mutants (K*R), all lysines mutated to arginine 
except for one lysine (K* only), all lysines mutated to arginine (K0). Control reactions lack either 
hUba1 (-E1); Ube2L3 and Ube2D3 (-E2); or HOIPRBR-LDD (-E3). Reactions were stopped after 1 hour 
at 32°C. (F, G) Ubiquitin chain formation by HOIPRBR-LDD with N-terminally blocked ubiquitin 
(His6Ubiquitin or TAMRAubiquitin) and C-terminally truncated ubiquitin (ubiquitinΔGly76). 2 Hour 
reactions contained hUba1 (E1), Ube2D3 or Ube2L3 (E2) and HOIPRBR-LDD (E3) unless indicated 
otherwise. (H) Ubiquitin chain formation with 600 nM HOIPRBR-LDD in the presence of 10 µM 
HOIPN-term, 100 µM HOIPUBA or 2 µM HOIP. The lane with the asterisk shows the reaction with HOIP 
in the absence of HOIPRBR-LDD. Reactions were stopped after 0, 10, 20, 40, 80 min at 37°C.
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Figure S2. (A) Schematic representation of the HOIPRBR-LDD point-mutants used in this study. 
Cysteine to alanine mutations in the RING domains and the IBR were designed to disrupt 
proper folding of the separate domains. The additional mutations were designed to explore 
RBR functioning without disrupting the fold of the domains, by interfering with possible E2-E3 
interaction sites in the RING domains (V701A/I, K873A), changing residues that are likely to be 
surface exposed in RING1 (H729A) and the IBR (E814A), or residues that are located just outside 
the RING domains (P750A, D751A, I869A). All other RBR mutations were introduced at random 
throughout the protein to enhance our changes to identify the importance of the separate domains 
in linear ubiquitin chain formation. The cysteine mutations in the highly conserved cysteines 
of the LDD were introduced to cause local changes in the LDD to help unravel the importance 
of this domain in linear ubiquitin chain formation. The table lists the E2 dependent activity 
(E2 dep.), E2 independent activity (E2 indep.), discharge of ubiquitin from an E2 (E2 discharge) 
and E3~ubiquitin thioester formation (E3 thioester) of the mutants in the different experiments 
in this study. (B) Final purification product of the HOIPRBR-LDD mutants shown on SDS-PAGE gel. 
Solid bars indicate the location (RING1 (R1), IBR, RING2 (R2), LDD) of the mutations within 
HOIPRBR-LDD. The molecular weight marker is marked with the asterisk (*). (C) Final purification 
product of  HOIPR2-LDD, HOIPLDD and HOIPLDD C930A shown on SDS-PAGE gel. The molecular weight 
marker is indicated by the asterisk. (D) Analytical gel filtration profiles of HOIPLDD and HOIPLDD 
C930A on a S200 5/150 column.
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Figure S3. Control reactions with HOIPRBR-LDD for E2 dependent activity in figure 3B. The E2 increases 
the amount of ubiquitin chain formation with HOIPRBR-LDD, but not with HOIPR2-LDD.  Reactions were 
stopped after 0, 1, 1.5, 2, 3, 4 hours.
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Figure S4. (A) Formation of a reversible covalent intermediate between HOIPRBR-LDD and 
TAMRAubiquitin. An anti-HOIP western blot and the according reduced and non-reduced gels 
for the TAMRA-signal are shown. The reversible covalent bonds are indicated as E1~Ub 
(hUba1), E2~Ub (Ube2D3) and E3~Ub (HOIPRBR-LDD). (B) Formation of a reversible covalent 
intermediate between HOIPRBR-LDD and TAMRAubiquitin with different HOIPRBR-LDD mutants. Same 
assay as in Figure 4A, but with UBE2L3 as the E2 enzyme. The TAMRA-signal is visualized on a 
reduced gel and at two contrast levels on a non-reduced gel. The reversible covalent bonds 
are indicated as E1~Ub (hUba1), E2~Ub (Ube2L3) and E3~Ub (HOIPRBR-LDD). (C)  Formation of a 
reversible covalent intermediate between HOIPRBR-LDD and TAMRAubiquitin with RING2 mutants in 
the presence of Ube2D3. The reversible covalent bonds are indicated as E1~Ub (hUba1), E2~Ub 
(Ube2D3) and E3~Ub (HOIPRBR-LDD). (D) Multi-sequence alignment of the C-terminus of human 
RBR protein sequences, including the RBR domain. UniprotID: HOIP (Q96EP0), HOIL-1L (Q9BYM8), 
ARIH1 (Q9Y4X5), Parkin (O60260), Triad1 (O95376). RING domains are underlined with the black 
line, the IBR is underlined with the dotted line and the LDD of HOIP is indicated by the gray line. 
Asterisks show the positions of the mutations in HOIPRBR-LDD that have been introduced in this 
study. (E) Single-cycle turnover assay with the E2 Ube2L3, corresponds to the assay with Ube2D3 
in Figure 4C (main text). Assay shows Ube2L3~TAMRAubiquitin discharge by HOIP mutants (left half 
of each gel) and di-ubiquitin formation upon the addition ubiquitinΔGly76 (right half of each gel). 
Discharge reactions were stopped after 0, 2, 4, 8, 16, 32, 64 min.
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Figure S5. (A) FP-assay for TAMRAubiquitin binding to HOIPLDD, as a control for the ubiquitinTAMRA 
binding to HOIP in figure 5A. The increase in FP is shown as a function of [HOIP]. 
HOIPLDD KD= 170 ± 21 µM, HOIPLDD C930A KD= 1218 ± 1437 µM. Standard deviations were 
calculated over three repeats. (B) FP-assay for free TAMRA-dye binding to HOIPRBR-LDD and HOIPLDD. 
The increase in FP is shown as a function of [HOIP].  (C) Formation of a reversible covalent 
intermediate between HOIPRBR-LDD and TAMRAubiquitin. Wild type HOIPRBR-LDD and HOIPRBR-LDD C930A 
were tested in the absence and presence of biotinUbiquitin. (D) Single-cycle turnover assay with 
TAMRAubiquitin. The formation of di-ubiquitin between the TAMRAubiquitin and different ubiquitin 
mutants was followed over time. Reactions were stopped after 0, 5 and 15 min at 37°C.
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Figure S6. (A) Co-immunoprecipitation of full-length HOIP, HOIP mutants and HOIL-1L. Western 
blots are shown for the immunoprecipitated protein (IP) and whole cell extracts (WCE). 
(B) Activity of HOIP and HOIP mutants in the absence of HOIL-1L in a Dual Luciferase™ reporter 
assay for NF-kB activation (control conditions for Figure 6).  Full-length HOIL-1L, HOIP or HOIP 
cysteine mutants (see lower panel) were expressed separately in the presence of a luciferase 
reporter construct, containing 5 NF-kB binding sites. A luciferase renilla construct was used 
as transfection control. Firefly luciferase values were normalized to renilla luciferase values. 
Normalized luciferase activity of 5x NF-kB reporter vector (upper panel) is shown as mean ± s.e.m. 
(*P < 0.001, Student’s t-test, representative experiment of n=4).
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Thesis objective
Transcriptional regulation is fundamental to the development of functional blood cells. 
Acquired and inherited changes in transcription factors and their up-stream regulators cause 
hematopoietic diseases ranging from bleeding disorders to leukemia. These alterations 
disrupt the control over gene expression resulting in the generation of pathogenic 
transcriptional programs that compromise proper blood cell development and function. 
Because aberrant gene expression contributes to disease formation, a better understanding 
of transcriptional regulation may provide important information for the design of more 
successful therapies.  In this light, the objective of this thesis was addressed to broaden 
the knowledge on the pathways and molecular mechanisms that regulate gene expression 
and the consequences of their alteration on hematopoiesis. A part of our studies was 
dedicated to the identification and characterization of a dominant-negative mutation in 
the transcription factor GFI1B that appeared to be causal to the gray platelet syndrome, 
a rare bleeding disorder of the megakaryocytic lineage. Chapter 2 describes the deleterious 
effects of this mutation on the development of megakaryocytes, defining GFI1B as a critical 
regulator of platelet production. Another part of this work focused on translational aspects 
of gene expression analysis in acute myeloid leukemia (AML).  By correlating gene expression 
data with clinical characteristics of patients, we defined novel AML subclasses based on 
the expression levels of the BRE, EVI1 and DNMT3B genes, thereby contributing to the 
refinement of AML patient stratification (chapters 3 and 4). Finally, the last part was aimed 
to investigate the role of ubiquitination in the control of NF-kB signaling, whose altered 
activity has been associated with the pathogenesis of blood diseases. In chapter 5, we 
performed a functional characterization of the E3-ligase LUBAC complex, whose exclusive 
ability to generate linear ubiquitin chains is required to fully activate the NF-kB pathway. 
Our results illustrate the identification of an essential domain involved in LUBAC mediated-
linear ubiquitination and reveal precious insight in the biochemical mechanisms that dictate 
the formation of linear ubiquitin chains.
GFI1B is a master transcriptional regulator of megakaryopoiesis
Our incomplete understanding of thrombopoiesis hampers diagnosis and treatment 
of patients with thrombocytopenia, and the ex vivo generation of thrombocytes for 
transfusion. Recently, we observed that the transcription factor Growth Factor Independence 
1B (GFI1B) plays a broad role in the proliferation and differentiation of megakaryocytes 
and the formation of platelets. In a family with an inherited autosomal dominant bleeding 
disorder1, we observed a heterozygous truncating mutation in GFI1B. Affected family 
members showed increased proliferation of megakaryocytes, severe morphological 
megakaryocyte abnormalities, abnormal expression of the stem cell marker CD34 and the 
membrane receptor glycoprotein 1bα–CD42B on megakaryocytes, and their dislocation 
in the bone marrow. In addition, platelet numbers were reduced, platelets were increased 
in size and, importantly, lacked α-granules. As α-granules are main platelet constituents 
contributing to wound healing, their paucity may contribute to the bleeding episodes 
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observed in affected individuals. The GFI1B mutation completely co-segregated with the 
disease in the analyzed family and predicted a C-terminally truncated protein lacking crucial 
DNA-binding sequences located in zinc finger 5. In a luciferase gene reporter assay, truncated 
GFI1B was not solely unable to repress gene transcription, but also inhibited the activity of 
the wild-type protein in a dominant-negative manner. Expression of the dominant-negative 
GFI1B mutant in normal hematopoietic stem cells, followed by megakaryocyte differentiation 
recapitulated MK defects as observed in patients. This confirmed that the heterozygous GFI1B 
mutation does not cause a loss of function, but it functions in a dominant-negative manner. 
Together, these data define a broad role for the transcription factor GFI1B in thrombopoiesis 
as it controls the expansion of megakaryocytes, the production of α-granules and 
the shedding of platelets.
Mode of action of GFI1B mutant
Conditional deficiency or silencing of GFI1B expression causes megakaryocyte abnormalities 
that are clearly distinct from those caused by truncated GFI1B2–4, indicating that 
the dominant-negative mutant is able to install an aberrant transcriptional program 
that drives the pathogenesis of the disease. The molecular mechanism through which 
truncated GFI1B interferes with the wild type protein is unclear. Although sequences 
essential for the binding to DNA are lost, the domains responsible for the interaction with 
co-repressor molecules are still intact. Thus, non-DNA bound GFI1B mutant may act in 
a dominant-negative manner by quenching essential factors that are normally used by 
the wild-type protein, resulting in aberrant expression of GFI1B target genes. In addition, 
truncated GFI1B may titrate away other transcription factors thereby deregulating 
the expression of genes normally not regulated by GFI1B. Mutant GFI1B also lacks zinc 
finger 6. This region has been shown to be responsible for the proteasomal degradation 
in GFI15, the closely related paralogue of GFI1B. Whether ubiquitination regulates 
the stability of GFI1B during erythrocytic and megakaryocytic differentiation is unknown 
and deserves further investigation. Nevertheless, because the zinc finger domain of GFI1B 
is highly homologous (97%) to GFI1, it is conceivable that GFI1B protein levels are regulated 
in a similar manner. The specific zinc fingers implicated in the proteasomal targeting of 
GFI1 proteins have not been mapped. If zinc finger 6 is involved, it is tempting to speculate 
that its absence may counteract proteasomal degradation, resulting in a more stable 
truncated protein. Increased stability of the mutant may enhance its potential quenching 
effect, exacerbating the competition for the wild-type protein to interact with co-repressor 
molecules. Importantly, during the preparation of this thesis, six additional GFI1B variants 
in cases with thrombocytopenia were reported6. Interestingly, as these alterations are 
spread across the N-terminal region outside the DNA-binding domain, it will be interesting 
to determine whether these variants cause similar defects as those caused by the GFI1B 
mutation reported by us. A detailed molecular and phenotypic characterization of all 
the reported GFI1B variants is required to identify through which molecular mechanisms 
GFI1B mutants interfere with normal megakaryopoiesis and shed more light on the still 
elusive mode of action of GFI proteins.
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GFI1B mutants: promising tools to zoom in on megakaryopoiesis
Mutant GFI1B represents a precious tool to decipher the transcriptional programs that 
drive thrombopoiesis. Gene expression programs installed by GFI1B are orchestrated in 
a hierarchical order, with genes early and later during differentiation that, in turn, may have 
impact of downstream changes in gene expression. Chromatin immunoprecipitation (CHIP) 
studies are required to map the genes that are directly bound by GFI1B at different stages 
of megakaryocyte development. By correlating gene expression and CHIP-profiles induced 
by normal and mutant GFI1B, it would be possible to identify those genes whose differential 
expression may contribute to the GPS and how these genes would normally function. These 
studies should be definitely supported by proteomic analysis as changes in RNA expression 
do not necessarily imply changes in protein expression. Depending on differences in gene 
expression, the expression of the identified genes may be corrected in rescue experiments, 
allowing the identification of players relevant for megakaryocyte proliferation, nuclear 
organization, α-granules biogenesis and platelet shedding. 
In addition to define the function of genes implicated in megakaryopoiesis and 
thrombopoiesis, mutant GFI1B can also be used to determine which epigenetic marks are 
applied by GFI1B to repress transcription, which protein complexes are associated to GFI1B 
at distinct stages of megakaryopoiesis, their relation to gene expression and for which 
process these interactions are required. For example, it would be particularly interesting 
to determine whether megakaryocytic abnormalities caused by GFI1B depend on 
the interaction with the histone H3K4/K9 demethylase LSD1. This co-repressor is required for 
proper megakaryopoiesis and is recruited through a conserved proline in the SNAG domain 
of GFI1B7,8. An alanine substitution at this position abrogates this interaction and inhibits 
the repressive function of GFI1B7. The introduction of this mutation in dominant-negative 
GFI1B, followed by expression of this ``double-mutant`` in megakaryocytic cells, should 
reveal whether quenching of LSD1 contributes to disease pathogenesis and potentially 
uncover specific functions for this protein during megakaryocyte development. 
In conclusion, the discovery of dominant-negative GFI1B offers an excellent opportunity 
to shed light on functional and molecular aspects of megakaryocyte development and 
platelet production. This increased knowledge would provide a better understanding 
of thrombopoiesis ultimately contributing to a better classification of platelet disorders, 
and more efficient diagnostic and treatment strategies, including the generation of 
thrombocytes for transfusion.
High DNMT3B expression levels predicts poor outcome in AML
The DNA methyltransferases DNMT1, DNMT3A and DNMT3B are epigenetic regulators that 
regulate gene expression through methylation of specific cytosines in the DNA. Because 
aberrant methylation profiles have been consistently found in patients with hematological 
malignancies9, pharmacological targeting of these enzymes with hypomethylating agents is 
currently being evaluated for therapeutic efficacy10,11. Notably, mutations in DNMT3A occur in 
25-30% of AML patients and predict poor prognosis, in particular within the cytogenetically 
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normal, intermediate risk group12. In contrast to DNMT3A, genetic variations in DNMT1 and 
DNMT3B have not been reported in leukemia as yet. Instead, a recent study associated high 
DNMT3B expression with an inferior outcome in AML13. However, the patient cohort used for 
this study was cytogenetically and molecularly not well characterized and included only 195 
de novo cases. In the work described in chapter 3, we examined the prognostic significance 
of DNMT3B expression in the context of several established molecular prognostic factors in 
a well-characterized cohort of 525 AML patients. Our results confirmed the association of high 
DNMT3B expression (corresponding to the top 25% highest DNMT3B-expressing patients) 
with an inferior disease outcome. Importantly, the adverse effect on survival was particularly 
evident in cases with normal karyotype, especially among those with co-occurring NPM1 
and FLT3-ITD mutations. Within this subgroup, survival is known to be negatively influenced 
by the presence of a high FLT3-ITD allelic burden14,15, a factor which is clinically used for risk 
stratification. Observed both in patients with high and low FLT3-ITD allelic burdens, high 
DNMT3B expression predicted poor survival especially among patients with high allelic 
burden. This allowed us to further separate this group into two subgroups: one with a survival 
similar to that of the established intermediate risk group and one with an extremely poor 
prognosis. In combination with the fact that high DNMT3B expression displayed a strong 
independent prognostic value in multivariate analyses, these data therefore defined high 
DNMT3B expression as a poor prognostic factor in AML, and in particular among patients 
with normal karyotype and co-occurring NPM1 and FLT3-ITD mutations. Thus, DNMT3B 
expression may be used to refine risk stratification. However, as the fold-difference between 
high and low DNMT3B expression is small, the definition of a cut-off to identify patients with 
high DNMT3B expression may prove to be challenging with routinely available techniques.
High DNMT3B expression: innocent by-stander or more?
Very recently, an independent study by Niederwieser et al. corroborated our results, also 
showing a significant adverse effect of high DNMT3B expression on survival of patients with 
normal karyotype older than 60 years of age16. Excluding our work, the adverse prognostic 
significance of high DNMT3B expression has been demonstrated by two other independent 
studies13,16, putting forth that high DNMT3B expression may predict poor response to current 
therapeutic regimens. Methylation studies have shown that global DNA methylation levels 
in leukemic blasts from AML cells with normal karyotype are not dependent on changes 
in DNMT3B expression, as inactive DNMT3B isoforms are primarily expressed in these 
cells17. In addition, a recent report has reported that changes in DNMT3B expression do not 
perturb the methylation status of putative DNMT3B target genes18. Although these findings 
suggest that patients with high DNMT3B expression may not benefit from hypomethylating 
therapies, it will be anyway interesting to determine whether DNMT3B levels influence 
the sensitivity of AML patient to such treatments. Further investigations are also necessary 
to establish the exact mechanisms underlying high DNMT3B expression in AML and its 
effect on disease outcome. Importantly, high DNMT3B expression was not observed in all of 
the AML subclasses, but only in specific subgroups, suggesting the existence of functional 
associations between high DNMT3B expression and specific molecular aberrations16. 
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Recent findings have associated the presence of specific gene polymorphisms in 
the DNMT3B gene locus with the predisposition for AML development19. As polymorphisms 
can influence the enzymatic activity of the protein, this suggests that DNMT3B functions 
need to be tightly regulated to prevent increased susceptibility to malignant transformation. 
However, conditional DNMT3B ablation does not cause leukemia in mice20, but only minor 
hematopoietic defects, suggesting that changes in DNMT3B expression may not be directly 
implicated in malignant transformation, but rather co-operates with other oncogenes. In 
this respect, ectopic over-expression in mouse models would be helpful to gather precious 
insights on the contribution of increased DNMT3B expression to leukemogenesis. As current 
data are insufficient to exclude the possibility that high DNMT3B expression is an innocent 
by-stander or a surrogate, additional investigations are therefore granted to understand 
the cryptic pathological role of DNMT3B and whether it directly affects treatment 
response in AML.
AML patients with MLL-AF9 rearrangements can be sub-divided 
based on BRE and EVI1 expression
The Mixed Lineage Leukemia (MLL) gene, encoding for a H3K4-methyltransferase, is 
recurrently involved in translocations with a large variety of fusion partners, which are found 
in about 10% of patients with acute myeloid leukemia21. In particular, the chromosomal 
rearrangement with the AF9 gene, resulting in the MLL-AF9 fusion gene, is associated 
with a five-year overall survival (OS) rate of approximately 40%21–23. Recently, we refined 
the prognosis of this intermediate risk group based on the mRNA expression levels of BRE24, 
a gene involved in DNA-damage response. High expression of BRE predicted a superior 
survival while normal expression levels predicted a very poor outcome in two independent 
cohorts (5-year overall survival of 80% vs 0%, respectively), defining high BRE expression as 
a favorable prognostic marker for patients with the MLL-AF9 translocation. As roughly 50% 
of MLL-AF9 positive patients displayed normal expression, high BRE expression associated 
only partially to this cytogenetic abnormality. Chapter 4 illustrates that virtually all MLL-AF9 
patients without high BRE expression show high expression of EVI1. High expression of 
the latter gene strongly associates with an inferior disease outcome25. As high expression 
levels of BRE and EVI1 predicted opposite disease outcomes, their mutually exclusive 
expression explains the poor prognosis of patients lacking high BRE expression. Thus, 
BRE expression may be used for refined risk stratification of MLL-AF9 positive patients. 
However, due to the small difference between normal and high BRE expression, it may be 
challenging to create diagnostic tools that are sensitive enough to allow the identification 
of high BRE expressing patients. In contrast, as screenings for EVI1 overexpression are 
currently feasible using conventional q-PCR techniques26, this could facilitate their potential 
incorporation into diagnostic protocols for MLL-AF9 patients. Importantly, as many of 
the MLL-AF9 positive patients with high EVI1 expression do not harbor chromosomal 
rearrangements encompassing the EVI1 locus on chromosome 325, a molecular screening 
for EVI1 over-expression would be therefore strongly recommended to improve MLL-AF9 
patient risk stratification.
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High BRE expression defines a distinct group of patients with a unique gene 
expression signature
In unsupervised genome-wide expression clustering analysis, a large fraction (85%) of 
patients with high BRE expression displayed highly similar expression profiles and commonly 
associated with a specific expression signature, suggesting that these patients share 
a common mechanism that govern gene expression24. Consistently, the BRE-associated 
gene expression clustered separately also within MLL-AF9 positive patients, completely 
separated from that of the remaining EVI1 positive MLL-AF9 patients. Interestingly, the latter 
presented only subtle similarities in gene expression profiles; suggesting that, in contrast 
to BRE positive patients, transcription programs are not commonly dys-regulated in EVI1 
positive patients.  In combination with the fact that high EVI1 expression was not found 
in all patients, despite being reported as a direct target of the MLL-AF9 fusion protein27, 
these findings suggest that global changes in gene expression are not solely attributable 
to the activity of the fusion protein. Possibly, they depend on the molecular context or 
the differentiation status of the transformed cells. Chromatin immunoprecipitation 
experiments using patient derived material would be helpful to understand which 
genes are direct targets of MLL-AF9 and which co-factors are used by the fusion protein. 
Also epigenetic profiling of chromatin modifications may reveal important insight in 
the molecular mechanisms underlying dys-regulated gene expression by MLL-AF9. 
Interestingly, recent data have shown that MLL-AF9 positive patients display aberrant 
methylation marks at lysine 79 on histone H3 (H3K79)28, an epigenetic modification that is 
associated with gene activation. Therefore, it would be interesting to determine whether, 
and to which extent, aberrant H3K79 methylation is implicated in the dys-regulated gene 
expression profiles that we observed in MLL-AF9 patients. The methyltransferase DOT-1L is 
the only enzyme known to catalyze H3K79 methylation and it has been shown to interact 
with the MLL-AF9 fusion29. Recruitment of DOT1L to the MLL-AF9 fusion protein causes 
chromatin hypermethylation and induces aberrant transcription of MLL-AF9 target genes, 
thereby promoting leukemic transformation30–32. DOT1L inhibitors, which are currently 
under clinical investigation, could be helpful to study the contribution of DOT1L to 
the de-regulated activity of the fusion protein more specifically. Nevertheless, how 
the expression of the genes clustering along with high BRE expression in MLL-AF9 patients 
is similarly de-regulated remains unclear. Since BRE positive patients partially co-occurred 
with the MLL-AF9 translocation in the total AML cohort, it cannot be excluded that other (epi)
genetic regulators, like for instance transcription factors, other than MLL-AF9, are exclusively 
responsible for the highly similar gene expression profiles observed in high BRE expressing 
patients. In conclusion, our data suggest that MLL-AF9 is likely to participate in malignant 
transformation through different molecular mechanisms, therefore warranting additional 
studies to determine how the malignant activity of the MLL-AF9 onco-protein is modulated.
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HOIP governs linear ubiquitin specificity of LUBAC
The biological relevance of LUBAC is emerging as it has recently been implicated in the 
regulation of other cellular processes beyond NF-kB-mediated transcriptional regulation33,34. 
For most of these pathways, it remains to be defined which substrates are recognized, whether 
they are targeted for linear ubiquitination and its molecular implications. Nevertheless, 
because of its exclusive ability to generate linear polyubiquitin chains, LUBAC represents 
a potential target for the development of targeted therapies for blood-related disorders 
that rely on the dys-regulated activity of the NF-kB signaling. Therefore, understanding how 
LUBAC dictates the formation of linear chains, the specific functions of the various domains, 
and how these are regulated could be very beneficial for the development of treatments 
capable to modulate LUBAC activity.  
The R2-LDD region of HOIP is required for linear ubiquitination
The specificity of LUBAC for linear ubiquitination activity is embedded within HOIP, 
the catalytic subunit of the complex. This E3 ligase belongs to the family of RBR ligases 
which is characterized by a conserved tri-partite region, called RBR domain, comprising 
a RING1, an in-between RING (IBR) and an atypical RING2 domain35,36. As shown for other 
RBR ligases, like Parkin and HHARI37, these domains act in concert to mediate the transfer 
of ubiquitin from E2 onto its target using a hybrid RING/HECT like mechanism that involves 
the formation of a thioester intermediate between the C-terminus of the donor ubiquitin 
and an active-site cysteine available on RING2. In line with recently published studies38, we 
were able to trap an intermediate transient interaction between ubiquitin and a catalytically 
active HOIP mutant, denominated HOIP RBR-LDD, which lacks the amino terminal region 
upstream of the RBR domain, proving that linear chains are also assembled through 
a two-steps mechanism. As described in chapter 5, the catalytic mechanism of HOIP involves 
the transfer of ubiquitin to form a covalent intermediate with RING2. This domain is essential 
for the RBR ligase activity of HOIP because it serves as acceptor for the transient linkage of 
the donor ubiquitin, and contains the recently identified residues responsible for its transfer 
onto the acceptor ubiquitin. Despite being similar to RING1, RING2 does not conform to 
the canonical RING structure. As observed in parallel studies37–40, RING2 of HOIP does not 
coordinate two zinc ions, but only one, leaving a cysteine residue, which is also conserved 
in the ubiquitin ligase HHARI, available for the formation of the thioester intermediate with 
the donor ubiquitin. The reaction initiates with the recruitment of the ubiquitin charged-
E2. In HOIP, the RING1-IBR region is involved in this process since mutations or deletions 
of these domains disrupt the E2-dependent chain-forming capacity of the protein. RING1 
is likely responsible for the interaction with E2s, as it closely resembles classical RING E3 
ligases which are known to allosterically activate the ligase activity of E2s to build ubiquitin 
chains41. However, RING1 does not discharge ubiquitin from the E2 enzyme in absence of 
an active site cysteine on RING2. This suggests that, unlike classical RING enzymes, RING1 
does not enhance the reactivity of E2s. Thus, the generation of the covalent intermediate 
within RING2 may take place via a different mechanism than that classically described for 
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RING ligases, warranting additional studies in this direction. Also the IBR domain seems to 
be involved in this process. Because this domain lacks ubiquitination activity and the active 
site cysteine necessary for the intermediate transfer of ubiquitin, it was originally thought 
to function as a mere linker between RING1 and RING2. However, the crystal structures of 
the RBR ligase Parkin revealed that this domain interacts with multiple sites of RING142, 
possibly contributing to regulate the accessibility and the extension of the docking surface 
for ubiquitin-charged E2s. Furthermore, it has recently been shown that IBR of Parkin adopts 
the same folding as that observed for RING243. Whether this implies a functional involvement 
of IBR in the catalytic activity is unclear. Nevertheless, as its high conservation suggests that 
the IBR may be more than a structural requirement of the RBR domain42, further investigations 
are obviously needed to decipher the enigmatic function of this region. 
HOIP acts as atypical RBR ligase in linear ubiquitination
LUBAC selectively produces linear polyubiquitin chains regardless of the type of E2s that 
is engaged, indicating that the E2 does not contribute to the chain formation specificity 
of HOIP. This is achieved through the overruling activity of the LDD domain, which is 
located at the carboxyl-terminal end of the protein and positions the amino-terminus of 
the acceptor ubiquitin facing the thioester ubiquitin intermediate in RING2. The recent 
structural resolution of RING2-LDD in complex with ubiquitin40 confirmed our results and 
revealed that LDD co-operates with RING2 to guarantee the accurate orientation between 
the two reactive groups. In addition, these studies identified a previously unpredicted zinc 
finger, adjacent to the end of RING2, which interacts with the acceptor ubiquitin. Despite 
the fact that this may indicate that RING2 forms a functional unit with LDD that determines 
the specificity for linear chains, it will be interesting to determine whether the particular 
positioning of the acceptor ubiquitin is sufficient to overrule the specificity intrinsic to E2s or 
other mechanisms are involved. Nevertheless, both this newly identified zinc finger and the 
LDD domain are not found in other RBR ligases, likely explaining the unique ability of HOIP 
to assemble linear polyubiquitin chains. 
In contrast to HOIP, the specificity for chain assembly of the majority of RBR ligases as 
yet characterized is determined by the E2 involved in the reaction. Parkin and Triad1, for 
example, have been shown to generate different ubiquitin signals by co-operating with 
a variety of conjugating enzymes35,37,44. Given the HECT-like mechanism used by this class of 
enzymes, the dependence on the recruitment of the E2 to determine the chain specificity 
is controversial. Possibly, the interaction with E2 enzymes may provide an additional level 
of regulation to the RBR mechanism or it may indicate that the E2 actively takes part to 
the reaction. Consistently, it has been shown for some RBR ligases that also RING2 is capable 
to bind to E2s44–46, despite the functional significance of this interaction remains to be 
evaluated. Although enormous advances in the understanding of the molecular mechanisms 
underlying the functioning of RBR ligases have been made, important aspects of catalysis as 
mentioned above necessitate further elucidation.
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Auto-inhibition regulates the functional state of HOIP
An interesting observation derived from our study is that the removal of the N-terminus from 
HOIP unleashes the ubiquitination activity of the protein. The addition of HOIL-1 did not 
increase the efficiency of the reaction mediated by our constitutively active HOIP mutant, 
indicating that the activity of HOIP is auto-inhibited by the domains present within its 
N-terminus. Consistently, the UBA- and NZF2 domains, which are implicated in the activation 
of HOIP through the interaction to the UBL-domain of HOIL-1L and Sharpin, respectively, are 
located in this region. Whether these domains inhibit HOIP by direct interaction with its 
RBR domain needs to be verified. Interestingly, the N-terminal region also did not activate 
HOIP in trans in our assays, indicating that the direct binding is not sufficient for activation 
and conformational changes may possibly be involved in the release of HOIP activity. 
With respect to these assumptions, the crystal structure of HOIP in its inactive state will 
definitely provide important information about the mechanism governing auto-inhibition. 
This auto-regulatory mechanism is also a typical feature of Parkin and HHARI, although 
HHARI is inhibited by the C-terminal part of the protein36,38,47,48. This reflects the structural 
heterogeneity observed outside the RBR domains in these enzymes, indicating that different 
mechanisms exist to activate the catalytic center.  Because RBR ligases have been shown to 
interact with several partners and undergo a variety of post-translational modifications, it 
is conceivable that their activation and activity are regulated at multiple levels. Additional 
efforts are therefore required to identify co-regulatory molecules that interact with LUBAC 
and characterize their functional contribution to the linear chain formation capacity.
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Summary
Vital activities required for the integrity and functionality of our body, such as oxygen 
transport, wound healing or protection against harmful pathogens, are performed by highly 
specialized cells present in our blood. These cellular blood components amount to more 
than 10 different cell types, each of them with a specific function. Leukocytes, for example, 
encompass several specialized cell types involved in innate and acquired immunity. 
Megakaryocytes produce platelets for blood clotting and wound healing, while erythrocytes 
are crucially implicated in O2 and CO2 transport. As many of these cell types are short-lived, 
the blood needs to be one of the most regenerative and plastic tissues in our body, with an 
enormous number of cells being constantly replaced with newly formed ones. The process 
of blood cell formation is called hematopoiesis and takes place, under normal circumstances 
and in the adult, within the bone marrow (BM), which consists of a soft spongy tissue filling 
the cavities of bones. Under the influence of the BM microenvironment, all blood cells 
originate from hematopoietic stem cells (HSCs) through a series of developmental stages 
that generally culminate with the release of mature cells into the circulation. HSCs represent 
a unique pool of long-lived quiescent cells endowed with multipotency and self-renewal 
capacity.  Thanks to these essential stem-cell characteristics, HSCs are meant to preserve 
a constant pool of undifferentiated cells, capable of generating all the different types of 
mature blood cells, throughout the lifetime of the organism. Control over the balance 
between self-renewal and differentiation as well as over the various transitions through 
consecutive differentiation stages is required for proper blood-cell development. Regulation 
of gene expression plays an essential role in this process. During hematopoiesis, specific sets 
of genes are differentially regulated to generate cell type-specific gene expression patterns 
that are characteristic of each stage of differentiation. These transcriptional programs 
coordinate cellular functions and can guide the progression of hematopoietic cells through 
subsequent developmental phases. Acquired and inherited changes in factors involved in 
gene transcription, or their upstream regulators, can cause hematological disorders ranging 
from bleeding disorders to leukemia. These alterations disrupt the genome-wide control of 
gene expression resulting in the generation of pathogenic transcriptional programs that 
contribute to disease onset. In addition, these altered expression patterns significantly 
influence the biological characteristics of the various diseases that they generate and 
thereby the severity of their clinical outcome. Because aberrant gene expression contributes 
to the pathogenesis of hematological diseases, a better understanding of how gene 
transcription is regulated during normal and abnormal hematopoiesis would be beneficial for 
the advancement of disease treatments. The scope of this thesis is to broaden our knowledge 
on the implications of dysregulated gene expression on the development of blood disorders, 
with a particular focus on the identification of dysregulated pathways that can serve as 
potential targets for the improvement of therapies.
The conversion, or transcription, of the genetic information contained in the DNA 
sequences of genes into messenger RNA is an essential step for the expression of genes. 
Transcription factors play a crucial role in this process as they determine whether a gene is 
transcribed or silenced. Genetic variations in these regulatory factors are often implicated 
Addendum158
7
in the etiology of blood disorders. In chapter 2, we describe the identification of a novel 
genetic alteration in the transcription factor GFI1B among patients affected by a rare 
bleeding disorder called the gray platelet syndrome (GPS). This disease encompasses 
a broad spectrum of clinical conditions characterized by low platelet counts and by platelets 
appearing gray due to a shortage of α-granules. We investigated a large family with an 
autosomal dominant form of GPS, the affected members of which showed an increased 
number of dysplastic megakaryocytes (MKs) that were abnormally located in clusters along 
the walls of the BM sinusoids. In addition, we also observed a reduced surface membrane 
expression of platelet glycoprotein Ib α-chain (CD42b) and an increased expression of 
the blood stem-cell marker CD34, in both MKs and platelets of affected individuals. Genetic 
linkage analysis and targeted sequencing identified a nonsense mutation in the GFI1B gene 
locus which completely co-segregated with the disease in the analyzed family. Using a gene 
repression reporter assay, mutant GFI1B was shown to inhibit wild-type GFI1B in a dominant 
negative manner. In addition, ectopic expression of mutant GFI1B in murine HSCs followed 
by ex vivo megakaryocytic differentiation recapitulated some of the disease characteristics, 
demonstrating that the identified GFI1B mutation is causal to the presented form of GPS. 
Taken together, these findings reveal a key role for GFI1B in MK cell growth and development, 
synthesis of α-granules, and platelet formation. These studies open new avenues to identify 
GFI1B-driven transcriptional programs, which will contribute to enlarge our understanding 
of megakaryopoiesis, platelet production and bleeding disorders.
Dysregulated gene expression is also one of the hallmarks of acute myeloid leukemia 
(AML). This is a clinically heterogeneous disease characterized by a premature block in 
the differentiation of one or multiple myeloid lineages. In AML, malignant cells also gain 
a proliferative advantage that leads to their accumulation in the peripheral blood and 
BM, where they interfere with the formation of normal blood cells. The five-year overall 
survival for AML patients younger than 65 years of age is only 40% and it declines with age. 
Underlying genetic defects are frequently observed and often involve signal transduction 
molecules, transcription factors and epigenetic regulators. Because these molecular 
alterations contribute to the pathogenesis of the disease, they represent potential targets 
for the development of targeted therapies. In addition, some of these aberrations have 
also been shown to correlate with clinical outcome, allowing the stratification of AML 
patients into risk-based prognostic groups. Despite the development of individualized risk-
adapted treatment strategies, survival within well-defined sub-groups fluctuates widely, 
indicating that additional prognostic markers are required to ameliorate the prediction of 
disease outcome. Chapters 3 and 4 illustrate the potential of gene expression analysis in 
the identification of genes and pathways that are dysregulated in the various subcategories 
of AML and their implications on the refinement of patient stratification. Using a publicly 
available gene expression data set, chapter 3 investigates the correlation between survival 
of patients and expression level of the DNA methyl-transferase 3B (DNMT3B) gene. 
Together with its paralogue DNMT3A, which is frequently mutated in AML, these genes are 
crucially involved in the silencing of gene expression through the methylation of specific 
DNA sequences. As no genetic changes in DNMT3B have been reported in AML as yet, 
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the contribution of this gene to the disease remains elusive. In line with independent studies, 
our data showed that higher expression of DNMT3B is a very strong independent predictive 
factor for poor disease outcome in AML in general, and especially in cases with normal 
karyotype and co-occurring NPM1 and FLT3-ITD mutations. Importantly, the prognosis of 
this sub-category is strongly influenced by the FLT3-ITD mutational burden, which usually 
associates with a poor survival. Based on DNMT3B expression level, the latter sub-group 
could be further separated into an intermediate risk group and an extremely poor risk group, 
further indicating that DNMT3B expression can be used to refine patient stratification. From 
the clinical diagnostic testing point of view, however, the fold-difference between high and 
low DNMT3B expression is small, thereby rendering the definition of a discriminative cut-off 
for the identification of high DNMT3B expressing patients rather challenging. Although 
our data support the prognostic relevance of high DNMT3B expression in AML, additional 
studies are required to determine whether high DNMTB expression is just an innocent 
bystander or is implicated in the pathogenesis of the disease. Chapter 4 describes the effort 
to improve the classification of AML patients carrying the MLL-AF9 translocation, who are 
currently classified as intermediate risk, with a five-year overall survival rate of roughly 40%. 
The prognosis of MLL-AF9–positive patients has been refined recently on the basis of the 
expression levels of BRE, a gene involved in DNA-damage response. High expression of BRE 
is associated with a superior survival while normal expression levels predict a very poor 
disease outcome. We revealed that the poor survival of patients with normal BRE expression 
can be associated with the high expression of EVI1, which is generally considered as an 
adverse prognostic factor in AML. In line with the fact that high expression of BRE and EVI1 
were almost completely mutually exclusive, MLL-AF9–positive patients could be subdivided 
into a very good risk group and a very poor risk group based on the expression of these 
genes, respectively. However, as the fold-difference in BRE expression among the patients 
is limited, the identification of an expression cut-off to discriminate patients with high BRE 
expression using routinely available techniques may be challenging. Notwithstanding, as 
screening for EVI1 overexpression is feasible with current diagnostic techniques, it could be 
incorporated into diagnostic protocols for MLL-AF9 patients. Interestingly, despite the fact 
that EVI1 has been described to be a direct target of the MLL-AF9 fusion protein, patients 
with high EVI1 expression did not exhibit a common transcriptional profile in our study. In 
combination with the fact that MLL-AF9 cases with high BRE expression have been previously 
shown to constitute a new AML subclass in terms of global gene expression profile, which 
co-occurred only partially with MLL-AF9 positivity, these findings suggest that dysregulated 
gene expression in MLL-AF9–positive patients also depends on other mechanisms 
than only those installed by the MLL-AF9 translocation itself. Further investigations are 
therefore warranted to identify the underlying pathways that co-operate with MLL-AF9 in 
malignant transformation. 
Various hematopoietic disorders are characterized by altered activity of the NF-kB 
transcription factors, which are crucial regulators of a large number of genes implicated in 
cell differentiation, proliferation and apoptosis. LUBAC, a multi-domain protein complex 
with ubiquitin ligase activity, is a critical component of the NF-kB pathway. Consisting of 
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two regulatory subunits, HOIL-1L and SHARPIN, and the catalytic subunit HOIP, LUBAC is 
the only protein complex that has been reported thus far to generate linear poly-ubiquitin 
chains, which work as signaling molecules for the activation of the pathway. Because 
of this exclusive ability, LUBAC may represent a potential target for the development of 
targeted therapies for blood disorders that rely on dysregulated activity of NF-kB signaling. 
Therefore, understanding how LUBAC dictates the formation of said linear chains, the 
specific functions of its various domains, and how these are regulated would be very 
helpful for the development of compounds capable of modulating functions of LUBAC, 
and possibly improving current treatments. Chapter 5 sheds light on important aspects of 
the biochemical mechanism that dictates the catalysis of linear poly-ubiquitin chains. In that 
section, we showed that both the catalytic activity and the specificity for linear chains of 
LUBAC reside within the ubiquitin ligase HOIP. This subunit is characterized by a conserved 
tripartite region, called RBR domain, comprising a RING1, an in-between RING (IBR) and an 
atypical RING2. According to our model, the formation of linear chains involves a two-step 
mechanism in which the RING1 and the IBR domains are responsible for the formation of 
a covalent thioester intermediate of ubiquitin with RING2. Subsequently, RING2 catalyzes 
the linkage between the C-terminus of the donor ubiquitin with the N-terminus of an 
acceptor ubiquitin. The formation of the linear” linkage is promoted by a unique C-terminally 
located region, exterior to the RBR domain and called the “Linear ubiquitin chain Determining 
Domain” (LDD). This area was shown to interact with the acceptor ubiquitin, suggesting that 
the LDD domain could engage the target ubiquitin to position it in a specific orientation 
that facilitates the “linear” linkage. Interestingly, we also found that the catalytic activity of 
HOIP is auto-inhibited by its own N-terminal region, which is required for the interaction 
with HOIL-1L and SHARPIN. Binding of HOIP to its regulatory subunits is required to release 
the auto-inhibition and to induce the catalytic activity of the RBR domain.
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Vitale processen die vereist zijn voor het goed functioneren van ons lichaam, zoals 
zuurstoftransport, wondgenezing en bescherming tegen pathogenen worden uitgevoerd 
door gespecialiseerde cellen die aanwezig zijn in ons bloed. Om alle functies naar behoren uit 
te voeren zijn meer dan 10 verschillende celtypes in ons bloed aanwezig. Zo zijn leukocyten 
betrokken bij aangeboren en verworven immuniteit. Megakaryocyten produceren 
bloedplaatjes voor de bloedstolling en wondgenezing, terwijl erytrocyten cruciaal zijn voor 
zuurstoftransport. Omdat veel van deze celtypen een beperkte levensduur hebben worden 
ze continu aangemaakt. Het proces van bloedcelvorming wordt hematopoëse genoemd en 
vindt plaats in het beenmerg (BM), bestaande uit een zacht sponsachtig weefsel in de holtes 
van botten. Onder invloed van het BM-micromilieu produceren hematopoëtische stamcellen 
(HSCs)  multipotente voorlopercellen, die op hun beurt weer kunnen uitrijpen tot alle soorten 
rijpe bloedcellen. De overgrote meerderheid van cellen die compleet uitgerijpt zijn komen 
in de bloedcirculatie terecht. Naast het genereren van multipotente voorlopercellen kunnen 
HSCs zichzelf vernieuwen. Hierdoor zijn deze cellen gedurende een heel leven in staat continu 
rijpere bloedcellen te produceren. De controle over de balans tussen zelfvernieuwing en 
differentiatie en de verschillende overgangen van de opeenvolgende differentiatiestadia is 
belangrijk voor een goede balans in de bloedcelontwikkeling. De regulatie van genexpressie 
speelt een essentiële rol in dit proces. Tijdens de hematopoëse worden specifieke groepen 
genen differentieel gereguleerd waardoor specifieke genexpressiepatronen gegenereerd 
worden die kenmerkend zijn voor de verschillende fasen van differentiatie van bloedcellen. 
Middels deze zogenaamde ‘transcriptieprogramma’s’ worden naast cellulaire functies 
ook het verloop van verschillende differentiatiestadia geregeld. Verworven en erfelijke 
veranderingen in de eiwitten die betrokken zijn bij gentranscriptie kunnen een breed 
spectrum aan hematologische aandoeningen veroorzaken. Deze variëren van goedaardige 
stollingsstoornissen tot kwaadaardige vormen van bloedkanker waaronder leukemie. 
Bovengenoemde veranderingen verstoren de genoombrede controle over genexpressie, 
resulterend in de vorming van transcriptieprogramma’s die bijdragen aan het ontstaan van 
bloedziekten. 
De veranderde genexpressiepatronen bepalen in belangrijke mate de ernst van de ziekte 
en de respons op therapie. Omdat afwijkende genexpressie bijdraagt  aan de pathogenese 
van hematologische aandoeningen, is een beter begrip van genexpressieregulatie tijdens 
normale en abnormale bloedcelaanmaak belangrijk voor de verbetering van de behandeling 
van de ziektes. Dit proefschrift richt zich op het verbeteren van onze kennis over verstoorde 
regulatie van genexpressie bij het ontstaan van bloedziekten. De omzetting of transcriptie 
van de genetische informatie van genen naar messenger RNA is een essentiële stap 
bij het tot expressie komen van genen. Transcriptiefactoren spelen hierbij een cruciale 
rol omdat zij bepalen of een gen wel of niet afgelezen wordt. Genetische variaties in 
transcriptiefactoren spelen vaak een belangrijke rol bij het ontstaan van bloedziekten. 
In hoofdstuk 2 beschrijven we de identificatie van een nieuwe genetische verandering 
in de transcriptiefactor GFI1B. Deze werd gevonden bij een familie met een autosomaal 
dominante vorm van het grijze bloedplaatjessyndroom (GPS). GPS wordt gekenmerkt 
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door een verhoogde bloedingsneiging veroorzaakt door een tekort aan - en niet goed 
functionerende - bloedplaatjes. De bloedplaatjes zien er grijs uit onder de microscoop 
omdat ze een tekort aan α-granules hebben. Normaliter kleuren in bloeduitstrijkanalyses 
deze granules paars aan. Bij de door de GFI1B mutatie aangedane familieleden werd verder 
een toename gevonden in de bloedplaatjes producerende megakaryocyten. Daarnaast 
vertoonden de megakaryocyten dysplastische kenmerken en vertoonden ze een afwijkende 
locatie in het beenmerg; de megakaryocyten lagen namelijk in clusters langs de bloedvaten 
in het beenmerg, een fenomeen dat niet gevonden wordt in niet aangedaan beenmerg. 
Daarnaast vonden we bij aangedane familieleden op bloedplaatjes een verlaagde expressie 
van het glycoproteïne 1bα-CD42B. Verder werd op bloedplaatjes en megakaryocyten 
een verhoogde expressie van de bloedstamcelmarker CD34 gevonden. Met genetische 
linkage- en gerichte sequentie-analyse werd een nonsens-mutatie in het GFI1B gen gevonden. 
Deze mutatie cosegregeerde met de aandoening. Met genrepressie reporter assays werd 
van het gemuteerde GFI1B eiwit aangetoond dat het de functie van het normale GFI1B eiwit 
remt op een dominant negatieve manier. Daarnaast werd aangetoond dat expressie van het 
gemuteerde GFI1B eiwit in HSCs van muizen, gevolgd door megakaryocyten-differentiatie, 
afwijkingen veroorzaakten die ook gevonden werden in de patiëntencellen. Op basis van 
bovenstaande bevindingen werd een oorzakelijk verband gelegd tussen de nonsens-
mutatie in GFI1B en de autosomaal dominante vorm van GPS. Uit deze studies blijkt dus 
dat GFI1B een belangrijke rol speelt bij de ontwikkeling en groei van megakaryocyten, 
de vorming van α-granules en de vorming van bloedplaatjes. Op basis van dit werk kan 
nu onderzocht worden welke transcriptieprogramma’s tijdens de megakaryopoëse 
door GFI1B gereguleerd worden om zodoende meer inzicht te krijgen in de vorming van 
α-granules en bloedplaatjesproductie.
Een verstoorde regulatie van genexpressie is ook een van de kenmerken van acute 
myeloïde leukemie (AML). AML is een klinisch heterogene ziekte, die wordt gekenmerkt door 
een blokkade in de differentiatie van onrijpe myeloïde cellen in het beenmerg. Daarnaast 
groeien de aangedane cellen sneller, waardoor normale onrijpe bloedcellen overgroeid 
en verdrongen worden. Door de enorme expansie in het beenmerg komen de onrijpe 
kwaadaardige bloedcellen uiteindelijk ook in de bloedbaan terecht. De 5-jaars overleving 
voor volwassen AML patiënten jonger dan 65 jaar is slechts 40% en daalt sterk met de 
leeftijd. Veel van de genetische defecten die ten grondslag liggen aan het ontstaan van AML 
zijn bekend en worden vaak gevonden in signaaltransductie-eiwitten, transcriptiefactoren 
en eiwitten die een belangrijke rol spelen bij epigenetische veranderingen. Omdat de 
gemuteerde eiwitten een belangrijke rol spelen bij de pathogenese van de ziekte zijn ze 
belangrijk voor de ontwikkeling van doelgerichte therapie waarbij de rol van het gemuteerde 
eiwit teniet wordt gedaan. Daarnaast correleren bepaalde genetische afwijkingen sterk met 
de respons op therapie. Op basis hiervan worden patiënten momenteel geclassificeerd 
met een relatief gunstige -, intermediaire -, slechte - of zeer slechte prognose. Patiënten 
met een relatief goede prognose ontvangen een minder intensieve behandeling dan 
patiënten met een slechte tot zeer slechte prognose. Ondanks de introductie van deze 
meer geïndividualiseerde therapie blijkt de overleving binnen de verschillende subgroepen 
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toch nog sterk te verschillen. De identificatie van nieuwe prognostische markers zou de 
respons op therapie mogelijk nog beter kunnen voorspellen. Hoofdstuk 3 en 4 laten zien dat 
genexpressie-analyse bij AML tot een betere voorspelling van de overleving van patiënten 
met AML kan leiden. Met behulp van genexpressie datasets die publiekelijk toegankelijk 
zijn werd in hoofdstuk 3 de correlatie tussen overleving van AML-patiënten en de mate 
van expressie van het DNA-methyl-transferase 3B (DNMT3B)-gen onderzocht. Samen met de 
paraloog DNMT3A, die vaak gemuteerd is bij AML, spelen deze genen een cruciale bij het 
onderdrukken van genexpressie door methylering van specifieke DNA-sequenties. Omdat er 
in tegenstelling tot DNMT3A geen genetische veranderingen in DNMT3B bij AML gevonden 
zijn, was een potentiële rol van DNMT3B bij deze ziekte onduidelijk. Echter, in overeenkomst 
met onafhankelijke studies, bleek uit onze studies dat verhoogde expressie van DNMT3B een 
onafhankelijke voorspellende waarde had op therapierespons. Patiënten met een verhoogde 
DNMT3B-expressie lieten namelijk een significant slechtere overleving zien, in het bijzonder 
bij patiënten met een normaal karyotype in combinatie met een NPM1 en FLT3-ITD-mutatie. 
Bij deze categorie patiënten wordt met name een slechte overleving gevonden wanneer het 
gemuteerde FLT3-ITD allel homozygoot aanwezig is. In hoofdstuk 3 wordt beschreven dat 
de subgroep met een homozygoot FLT3-ITD allel gesplitst kan worden in een groep met een 
zeer slechte overleving en een intermediaire overleving op basis van DNMT3B-genexpressie. 
Dit betekent dus dat DNMT3B-genexpressie-analyse kan bijdragen aan een verbetering 
van de classificatie van AML patiënten. Omdat het verschil tussen lage en hoge DNTM3B-
genexpressie echter klein is, is dit met standaard moleculair diagnostische methodes nog 
niet betrouwbaar te meten. Alhoewel hoge DNMT3B-genexpressie sterk correleert met 
een slechte overleving, betekent dit niet per definitie dat de hoge expressie ook een rol 
speelt bij het ontstaan van de ziekte. Om te bepalen of dat zo is dient vervolgonderzoek 
uitgevoerd te worden. 
Hoofdstuk 4 beschrijft een verbetering van de classificatie van AML-patiënten met 
een MLL-AF9 translocatie. Deze patiënten worden momenteel geclassificeerd met een 
intermediair risico, met een vijf-jaars overleving van 40%. De prognose van MLL-AF9-
positieve patiënten werd verfijnd op basis van de expressieniveaus van BRE, een gen dat 
betrokken is bij DNA-schadeherstel. Hoge expressie van BRE bleek geassocieerd te zijn met 
een betere overleving terwijl de normale expressieniveaus een zeer slechte overleving 
voorspelden van MLL-AF9-positieve patiënten. In hoofdstuk 4 hebben we aangetoond dat 
de slechte overleving van patiënten met normale BRE-expressie geassocieerd worden met 
hoge expressie van EVI1. Van de hoge EVI1-expressie was al bekend dat het een slechte 
prognostische factor is bij AML. Omdat patiënten met hoge BRE-expressie geen hoge 
EVI1-expressie vertoonden, en omgekeerd, kunnen MLL-AF9-positieve patiënten dus 
onderverdeeld worden in een groep met een zeer goede en zeer slechte overleving. Wegens 
het kleine verschil tussen normale en hoge BRE-expressie is het momenteel met routine 
moleculaire diagnostiek niet mogelijk de verschillen betrouwbaar te meten. Voor EVI1-
genexpressie bestaan wel gevalideerde moleculaire assays om de expressie betrouwbaar te 
meten. Voor een betere risico-indeling van MLL-AF9-positieve patiënten is het dus raadzaam 
te screenen op EVI1-genexpressie. Wat verder uit onze studies bleek is dat, ondanks het feit 
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dat geclaimd wordt dat EVI1-genexpressie direct door het MLL-AF9 fusie-eiwit beïnvloed 
wordt, er geen uniform genexpressieprofiel aan te wijzen is waarmee deze patiënten 
geclassificeerd kunnen worden. Een uniek genexpressieprofiel bleek wel aantoonbaar voor 
MLL-AF9-positieve patiënten met hoge BRE-expressie, maar ook voor patiënten met hoge 
BRE-expressie maar zonder de MLL-AF9 mutatie. Dit suggereert dat niet MLL-AF9, maar een 
andere, nog te identificeren, factor verantwoordelijk is voor het unieke genexpressieprofiel 
dat patiënten met hoge BRE-expressie kenmerkt. Vervolgonderzoek naar de onderliggende 
paden die samenwerken met MLL-AF9 bij maligne ontaarding is daarom belangrijk. 
Verschillende hematopoëtische aandoeningen worden gekenmerkt door een veranderde 
activiteit van NF-kB-transcriptiefactoren. Deze factoren reguleren genen die betrokken zijn 
bij celdifferentiatie, -proliferatie en apoptose. Een essentieel onderdeel van de NF-kB-route 
wordt geregeld door Lubac, een multi-domein eiwitcomplex met ubiquitineligase-activiteit. 
Lubac bestaat uit twee regulatoire subeenheden, HOIL-1L en SHARPIN en de katalytische 
subeenheid HOIP. Lubac is tot op heden het enige bekende eiwitcomplex dat de vorming 
van lineaire poly-ubiquitine-ketens vormt. Deze ketens werken als signaalmoleculen bij de 
activering van NF-kB. Omdat Lubac het enige eiwitcomplex is dat deze ketens vormt, is het 
mogelijk een belangrijk doelwit voor de ontwikkeling van therapieën voor bloedziekten 
die gekenmerkt worden door een verhoogde NF-kB-activatie. Het is daarom belangrijk op 
moleculair niveau op te helderen hoe Lubac precies lineaire ketens vormt om zodoende 
specifiek geneesmiddelen te ontwikkelen die dit proces tegengaan. Hoofdstuk 5 beschrijft 
een aantal belangrijke biochemische mechanismen die bijdragen aan de vorming van 
lineaire ubiquitineketens. In dit hoofdstuk laten we zien dat zowel de katalytische activiteit 
als de specificiteit voor de vorming van lineaire ubiquitineketens van Lubac binnen het 
ubiquitine ligase HOIP liggen. In het HOIP-eiwit ligt een domein dat verantwoordelijk 
is voor de vorming van lineaire ubiquitine ketens. Dit domein is opgebouwd uit drie 
geconserveerde subdomeinen, te weten een RING1-domein, een atypisch RING2-domein 
en een domein dat tussen RING1 en RING2 ligt. In Hoofdstuk 5 tonen we aan dat de vorming 
van lineaire ubiquitineketens in twee stappen wordt uitgevoerd waarbij RING1 en het 
tussenliggende domein verantwoordelijk zijn voor de vorming van een thioesterverbinding 
tussen ubiquitine en het RING2-domein. Vervolgens katalyseert het RING2-domein de 
binding tussen de C-terminus van een donorubiquitine met de N-terminus van een 
acceptorubiquitine. De vorming van de “lineaire” koppeling wordt bevorderd door een 
domein dat C-terminaal van RING2 ligt. Dit zogenaamde “Lineair ubiquitineketen vormend 
domein” gaat op een dusdanige manier een interactie met het acceptor-ubiquitine aan 
dat het goed gepositioneerd wordt om een lineaire ubiquitineketen te maken. Wat verder 
gevonden werd is dat de katalytische activiteit van HOIP geremd wordt door de N-terminale 
kant van het eiwit. Dit gedeelte van het eiwit gaat een interactie aan met HOIL-1L en SHARPIN. 
Juist de binding van deze eiwitten gaat de remming van dit domein op de katalytische 
activiteit van HOIP tegen. Hierdoor dragen HOIL-1L en SHARPIN bij aan de vorming 
lineaire ubiqutineketens.
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